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Executive Summary  
Background 
The opioid overdose epidemic is devastating families and communities across the United States 
(US).  Epidemiological studies from the US Centers for Disease Control and Prevention (CDC) have 
found that overall life expectancy of Americans has declined, and this decline was largely attributed 
to drug-related overdose deaths.1-3  Today in the US, overdoses are classified as the leading cause of 
injury-related death.   
The public health approach to addressing the overdose epidemic is multi-faceted, involving a 
combination of policy, education, and community interventions.  A framework developed by the 
Association of State and Territorial Health Organizations (ASTHO) describes a cross-sectoral 
response with four key strategy areas: (1) training and education; (2) monitoring and surveillance; 
(3) primary and overdose prevention; and (4) treatment, and harm reduction.   
Harm reduction strategies seek to mitigate the harms of behaviors.4  Harm reduction strategies 
include improved access to the antidote naloxone, syringe service programs (SSPs) that allow 
people who inject drugs (PWID) to obtain or exchange equipment for injections, and drug checking 
services that screen for risky drugs such as fentanyl.  These implement an alternative to the 
criminalization and disease treatment models of drug use and addiction.  Supervised injection 
facilities (SIFs) are an additional method of harm reduction.  While proponents of harm reduction 
theory recognize abstinence may be the ideal goal for some people, they accept alternatives which 
reduce the risk for death and disability even if they do not promote abstinence.5  Opponents of such 
strategies often focus on their potential to enable activities that are criminal or perceived as 
immoral.6 
Supervised Injection Facilities (or Supervised Consumption Sites) 
A SIF is a permanent or mobile place where people can inject drugs they have obtained elsewhere.7  
If it permits use of drugs by routes other than injection (such as smoking or snorting), “supervised 
consumption site” (SCS) is a more appropriate term.  SIFs typically provide equipment to allow users 
to perform safe and sterile injections while being monitored by trained medical staff who can treat 
overdoses with oxygen, naloxone, and/or other first-responder care.7  While SIF model 
implementation seems to vary based on community needs, resources, and funding, interviews with 
stakeholders suggest that there are three core features: sterile equipment, trained personnel for 
supervision, and naloxone administration (along with other first-responder medical care).  
Additional services may be added to the core features, such as health screening, treatment for 
substance use disorders (SUDs), referral coordination for social support (e.g., housing), health care 
and mental health services.7-10 
©Institute for Clinical and Economic Review, 2020 Page ES2 
Evidence Report – Supervised Injection Facilities Return toTable of Contents 
In 2003, Insite, the first legally-sanctioned SIF in North America, opened in Vancouver, British 
Columbia’s Downtown Eastside, a neighborhood with high rates of drug use, homelessness, and 
poverty.11  Vancouver has become an exemplar setting for researchers and policy advocates to 
understand the impact of the SIF model on a variety of outcomes, including the ones addressed in 
this ICER report.  
The clients of SIFs are impacted by many social determinants of health.  They are homeless, live 
alone, or have significant housing insecurity.  Mental illness and unemployment are common.  We 
spoke with a SIF client who described the people served by SIFs as “poor, homeless, marginalized…a 
beat-down people”.   
Although SIFs are considered a type of public health intervention, their population-level reach is 
measured in city blocks – not miles.12,13  The location is an important attribute that determines 
whom a SIF serves as well as its potential public health impact.  
There are no legally sanctioned SIFs operating in the United States.  Per a report in the New England 
Journal of Medicine, one unsanctioned site has been operating in the US for six years.14  There are 
news reports of elected officials or groups in New York City, Ithaca, Seattle, Denver, Washington DC, 
Chicago, Baltimore, Burlington, Oakland and San Francisco exploring feasibility, organizing 
coalitions, or preparing legislation for SIFs.15-23  
Objectives 
The purpose of this assessment is to evaluate the health and economic outcomes of a SIF.  This 
review seeks to answer the question:  What is the net health benefit of implementing a SIF (which 
includes an SSP) versus an SSP alone?  The CDC recommends SSPs as an evidence-based program 
noting they are “safe, effective, and cost saving, do not increase illegal drug use or crime, and play 
an important role in reducing the transmission of viral hepatitis, HIV, and other infections.”24 The 
ICER value framework includes both quantitative and qualitative comparisons to ensure that the full 
range of benefits and harms are considered in the judgments about the clinical and economic value.  
The assessment of effectiveness and value is made in comparison to an SSP as we believe it unlikely 
that communities without SSPs would be willing to consider a SIF.  A SIF implemented in a 
community without good SSP coverage may experience more than the incremental benefit.   
Perspective of the Client and Impact on Persons Who Use Drugs 
Section 2 of this report has an extensive description of what we heard from 48 stakeholders 
including those who are clients of SIFs/SSPs, staff members of SIFs/SSPs, researchers, clinical 
experts, legislative experts, and a law enforcement officer, and includes direct quotes from many 
stakeholders. 
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In brief, some of the major themes we heard include the following: 
• Social Isolation and Community: SIFs serve the most vulnerable and marginalized people in 
a community, with many PWUD live in social isolation due to housing insecurity, mental 
illness, and poverty.  SIFs can provide a place where PWUD will be welcomed and can build 
relationships with other clients and with staff.  In contrast to client interactions with SSPs 
that were described as “transactional and hurried”, SIFs have the potential to be more 
effective at introducing counseling interventions through a community built on 
camaraderie. 
• Integrated Services: Providing on-site access to social workers, frontline workers, or 
counselors was widely considered essential.  Their experience suggested that most clients 
could not be easily referred to external counseling as they often would not accept another 
counselling center for reasons such as distance, fears, and stigma.  
• Learning from Lived Experience: Most people commented on how the best SIFs respect the 
expertise of PWUD and include them in setting policies and operating the facility. 
• Inhalation of Drugs and Safely Testing Drugs: We heard from multiple stakeholders that 
changes in the drug supply and client preferences mean that SIFs must adapt and provide 
for the use of inhaled substances (not limited to opioids), becoming more comprehensive 
SCSs.  Several PWUD described how they use the SIF to check the potency of a new batch 
under the protection of supervision and resuscitation, if needed. 
• Health Care System Bias: PWUD noted “shaming and blaming” and “accusations of drug-
seeking” from health care system (e.g., hospitals, doctors, and EMTs).  SIFs offered a more 
compassionate way to access education, resources, and medical care.  
• Honeypot Effect:  Most PWUD and many stakeholders dismissed the possibility of a 
honeypot effect in which a SIF attracted PWUD or crime to a neighborhood, noting the long-
established poor conditions of neighborhoods where SIFs are generally located.  However, 
PWUD and stakeholders acknowledged that opposition to SIFs, SSPs, and other forms of 
harm reduction can exist in a community.  We heard from PWUD and stakeholders that 
drug use still happens just outside of SIFs and SSPs, and at least some community members 
do complain about syringe/needle debris. 
• Public Drug Use: There is a community-level trauma caused by public use as well as 
overdose.  SIFs provide the possibility of reducing this trauma to the public. 
Clinical Effectiveness 
Overview of Studies 
Our literature search identified a total of 1188 potentially relevant references for SIFs (see Appendix 
D2), and we included 48 studies that evaluated individual or community level outcomes for SIFs.  
The majority of studies evaluated SIFs from Canada (n=33), and the remaining studies evaluated 
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SIFs in Australia (n=8) and European countries (n=7, including, two from Germany, three from 
Denmark, and two from Spain).  Eighteen studies used a cohort study design, while others 
employed a pre-post ecological or time series (n=11), and cross-sectional study design (n=10).  Nine 
studies used a qualitative, exploratory, or descriptive study design.  We also included government 
sanctioned evaluation reports from MSIC in Sydney, Australia, the MSIR in North Richmond 
Australia, and the SCSs in Alberta, Canada.  To summarize the effectiveness of SSPs, we included 
one review of reviews25 that summarized results from 13 prior systematic reviews as well as three 
additional systematic reviews.26-28  These selections were drawn from a search of systematic 
reviews of SSPs which  identified a total of 72 potentially relevant references. 
We are assuming that PWID had access to SSPs during the study period, and the outcomes 
associated with SIFs are informing the added benefits of SIFs over baseline SSP access.  Much of the 
evidence regarding SIFs arises from ongoing prospective cohort studies in Vancouver, Canada, 
including studies of Insite.   
Mortality 
Published evidence and unpublished reports from stakeholders suggest that no client of a SIF has 
ever experienced death from overdose within a facility.14,29,30  However, PWUD are at high risk of  
death from overdose, and reduction of mortality inside SIFs does not necessarily demonstrate 
reduction in mortality in SIF clients.    
A Canadian prospective cohort study found that frequent use of SIFs was associated with a lower 
risk of all-cause mortality (adjusted HR[aHR]: 0.46; 95% CI: 0.26-0.80).31  However, it is hard to 
assess causality from such studies as PWUD who are frequent clients of SIFs are likely different from 
those who are not. 
Higher quality evidence on the effect of SIF on mortality probably comes from a population-based 
study in Vancouver, Canada that evaluated the effects of Insite on overdose mortality by measuring 
overdose mortality pre-and post-SIF within and beyond the 500 m area around the facility.12  The 
SIF opening was associated with a significant reduction of 35% in overdose mortality within 500 m 
of the facility, compared to a 9.3% decline in the rest of the city. Refer to Table ES1.12  
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Table ES1. Overdose Rates in the Vicinity of a SIF and Beyond (table adapted from Marshall et al. 
2011)12 
 
Overdoses within 500 m of SIF  Overdoses farther than 500 m of SIF 
Pre-SIF Post-SIF Pre-SIF Post-SIF 
Number of overdoses 56 33 113 88 
Overdose rate (95% CI)* 254 (187 to 320) 165 (108 to 221) 7.6 (6.2 to 9.0) 6.9 (5.5 to 8.4) 
Rate difference (95% 









- 35.0% (0.0 to 57.7) - 9.3% (-19.8 to 31.4) 
SIF: supervised injection facility, CI: confidence interval; Pre-SIF period= January 1, 2001 to September 20, 2003. 
Post-SIF period= September 21, 2003 to December 31, 2005 
*Expressed in units of per 100,000 person-years 
 
Non-Fatal Overdose and Health Care Utilization for Overdose 
We identified three studies that evaluated the effect of SIF use on non-fatal overdose and overdose 
requiring EMS, ambulance, or hospital care.32,33  A study from Insite from March 2004 to August 
2005 found 285 unique users who experienced 336 non-fatal overdose events.  Of these overdose 
events, 28% resulted in a transfer to hospital.32  A recent time-series analysis of SIF users at Insite 
reported that the overdose rate per 1000 visits increased from 2010 to 2017 (1.5 vs 9.5, p<0.001) 
with an increase in overdose events requiring naloxone administration (48.4% to 57.1%, p<0.001) 
but no overdose deaths were reported within the facility.33 
In a 2007 study by the New South Wales (NSW) Health Department in Sydney, Australia, opioid 
overdose-related ambulance calls were analyzed in Sydney over 36 months pre-SIF and 60 months 
post-SIF.  The SIF opening was associated with a greater reduction in ambulance calls for opioid-
related overdose events in the vicinity of the SIF compared to the rest of NSW (68% vs 61% decline, 
p=0.002).34  This effect was even higher during operating hours of the SIF (80% vs 60% decline, 
p<0.001).  
Injection Risk Behaviors  
Reducing injection risk behaviors (IRBs) is important in reducing the risk of infectious disease 
transmission.35 1101  We identified seven studies that evaluated the effect of SIFs on reducing IRBs, 
including four studies from Vancouver and three studies from European countries (Denmark, 
Germany, and Spain).  Most studies reported SIF use was associated with a reduction in IRBs.  For 
example, a cross-sectional analysis of 431 PWID in Vancouver found that SIF use was associated 
with reduced syringe sharing (adjusted OR [aOR]: 0.30; 95% CI: 0.11 to 0.82; p=0.02).36  Another 
cross-sectional study of 1082 PWID explored reasons for changes in changes in IRBs, noting 80% 
reported reductions in rushed injections, 71% reported less outdoor injections, 56% reported less 
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unsafe syringe disposal, and 37% reported using used syringes less often.13  A meta-analysis 
combined results from three European studies (Wood 2005, Kerr 2005, and Bravo 2009) and found 
SIF use was associated with a 69% reduction in the likelihood of syringe sharing (pooled effect: 0.31; 
95% CI: 0.17 to 0.55).37 
Infection Prevalence/Incidence and Health Care Utilization 
We identified studies that provided evidence on the effect of SIFs on infection incidence and 
prevalence, most of which were not designed to detect differences, specifically in rates of HIV or 
HCV.  
A cross-sectional study of 510 PWID who attended a SIF in Catalonia, Spain found that there were 
no significant differences in the prevalence of HIV or HCV among those who had frequent SIF 
attendance (i.e., daily), medium SIF attendance (i.e., > half of days), and low SIF attendance (i.e., ≤ 
half of the days).38 
More extensive evidence exists for the effects of SSPs on viral infections and the results are mixed.  
A meta-analysis pooled results from 10 studies and found a trend towards a reduced risk of HIV 
transmission with SSPs (effect size: 0.66; 95% CI: 0.43 to 1.01).39  When the analysis looked only at 
six higher-quality studies, a significant reduction was observed (effect size: 0.42; 95% CI 0.22 to 
0.81). One meta-analysis pooled results from seven studies and found an increased risk of acquiring 
HCV with SSPs (RR: 1.62; 95% CI: 1.04 to 2.52)40, but the authors noted that studies included in their 
analysis may have been affected by volunteer bias as SSPs may attract higher-risk PWID.  Other 
meta-analyses suggested SSPs may reduce the risk of acquiring HCV.28,41 
A prospective cohort of 1065 PWID attending Insite (SEOSI cohort) found the use of SIF for all 
injections versus some injections was associated with a statistically non-significant decreased 
likelihood of developing a cutaneous injection-related infection in multivariate analysis (aOR 0.58; 
95% CI: 0.29 to 1.19).42  A prospective cohort study of 129 PWID attending a DCF in Essen, Germany 
found no statistically significant reduction in injection-related abscesses.43 
Health-Related Quality of Life 
No quantitative evidence directly measuring improvements in the health-related quality of life was 
identified.  One qualitative study on people living with HIV who use drugs at Dr. Peter Center in 
Vancouver, Canada described the positive impacts on quality of life, noting the contributions of 
increased access to social, health, and broader environmental support services that led to 
improvement in their overall health.44 
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Other Outcomes 
Use and/or more frequent use of SIFs is generally associated with a higher uptake or more rapid 
entry into treatment and recovery services.45,38,46-49 
Frequent SIF use is also associated with facilitating access to health and other social services.  A 
multi-country study in Europe reported an association between frequent supervised drug 
consumption facility use and a greater likelihood of accessing counseling services, medical services, 
syringe exchange services, and education on safer use.50  A cross-sectional analysis in Denmark 
aligned with these results.51 
One study that assessed changes in drug consumption associated with the use of SIFs reported no 
substantial differences in relapse rates for injection drug use or stopping drug use pre- and post-SIF 
opening.52 
Community and Environmental Outcomes 
Among the five studies that assessed the role of SIFs in addressing public drug use and syringe and 
paraphernalia disposal was an ecological study post-SIF opening in Vancouver Canada where 
statistically significant reductions in public injection drug use were observed.  At the same facility, 
publicly discarded syringes and injection-related litter also reduced after SIF opening.53  A 
retrospective cohort study among 714 PWID attending a SIF reported that increased waiting time at 
the SIF resulted in an increased likelihood of public injecting.54  In Sydney, Australia, a time-series 
study reported that after a SIF opened there was a perceived decline in the proportion of residents 
and business owners witnessing public injections (19% vs 33%, p<0.001) and discarded syringes 
(40% vs 67%, p<0.001).55  A study of a SIF opening in Copenhagen (Denmark) reported a 56% 
reduction in public injections as well as a significant improvement in safe syringe disposal.56  In 
contrast, over a three-month period a prospective cohort study from Essen (Germany) reported no 
significant effect of a SIF on public drug use.43  In a study of DCRs in Denmark, 71% of users also 
noted that they chose the SIF for drug-use as they were conscious of public drug use bothering 
people in the neighborhood.51 
We also identified six studies that assessed the association of the SIF opening on drug-related crime 
and/or neighborhood safety.  Three studies conducted in Sydney, Australia concluded that the 
opening of the SIF did not result in a significant increase or decrease in crime (i.e., theft, drug-
related loitering, or robbery)57-59, but a slight increase in loitering around the SIF was observed.57   
Similar observations were reported from Vancouver, Canada in an ecological (pre-post) study with 
no significant changes in robbery or drug trafficking60 and a decline in vehicle break-ins post-SIF 
opening. Two studies reported that among SIF users, frequent use of SIFs was not associated with 
crime or recent incarceration.61,62  
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Uncertainty and Controversies 
The available evidence about SIFs comes from studies with cohort and cross-sectional design.  It is 
difficult to establish temporality in some cases and make inferences about the causal association 
without a reference population or control group.    
Many community factors vary considerably across cities in the world (e.g., background risk of 
bloodborne infection, community support, policing practices, access to primary medical care, 
treatment capacity and effectiveness), and the variance could impact the generalizability of 
findings.  Some of the risks to generalizability are may be lessened by a real-world experience in 
Canada and Australia where SIFs have expanded to other cities.  For example, a new SIF in North 
Richmond (Melbourne, Australia) replicated overdose mortality protection observed in Sydney.  The 
recently published review report by the Victorian Government also notes reductions in public 
injecting and ambulance calls due to overdoses, but no improvement in perceived safety and drug-
related nuisances.   
Our assessment of SIF effectiveness relies on many studies that are at least 10 years old.  It is known 
that important community factors have changed since then, including global drug supply chains and 
user preferences.  In some parts of the world, drugs typically injected are now being smoked; 
methamphetamines, for example, are replacing opioids.  The increase in fentanyl additives to 
heroin and/or cocaine has changed the mortality risk of an overdose during the past decade.  The 
estimated mortality reduction of the SIF model studied a decade ago is based on the types and 
forms of drugs consumed at that time.  Naloxone is more widespread today, with police officers, 
paramedics, community members, and PWID and their allies all having it on hand in a variety of 
settings.  It is unknown how much of a community’s overdose mortality can be reduced by a SIF 
versus expanded naloxone distribution to high-risk people and their social networks. 
Experts described the importance of local community support, including law enforcement, to open 
and maintain a SIF, noting that support for a SIF can erode when proposals and implementation 
plans with specific locations are presented to community stakeholders.   
Summary and Comment 
The review and synthesis of included evidence have been organized to demonstrate the 
contribution of a SIF to individual and population-level outcomes.  We did not identify any RCTs and 
as such, have based comparisons of SIF vs SSP on evidence from the cohort, time-series, pre-post, 
and other observational studies.  Given the available study designs from only a few communities, 
we recognize that differences between communities could impact generalizability.  Moreover, our 
rating of the effectiveness of a SIF considers its operations in the context of other harm reduction 
strategies, such as SSPs, which were available to clients in the included studies.  We believe that our 
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focus on the incremental value of a SIF is appropriate since many communities today are exploring 
if a SIF fits within a broader portfolio of harm reduction and overdose prevention framework.   
We recognize that comparisons of SIF use versus no SIF, for which we have relevant data, have 
shown incremental benefits.  Evidence from both Vancouver and Sydney found a significant 
reduction in occurrences of nonfatal overdose and mortality from overdose in the SIF neighborhood 
and beyond.  Furthermore, our research team has not uncovered any report of an overdose death 
at a SIF, bolstering our confidence in this outcome.  SIFs have demonstrated an ability to assist 
clients with accessing medical, mental health, and social support services, including the use of 
addiction treatment services.  
The contribution of a SIF to bloodborne infection control is less certain in terms of direct 
measurement of disease incidence, both due to variation in the baseline infection rates and the lack 
of incremental data compared with SSPs.  We believe that unsafe injecting behaviors are an 
important and reasonable proxy for infection control since syringe sharing is implicated as primary 
infection source of new cases of HCV in the US. 
In at least some locations, SIFs appear to reduce public injection and, sometimes, syringe and 
injection litter.  Finally, SIFs do not appear to be associated with changes in crime.    
Unlike a medication that can be manufactured reliably and administered consistently to deliver 
benefits to similar patients across the world, how a SIF is implemented can impact individual and 
community outcomes.  The intervention development, including stakeholder engagement, 
contributes to results.  Our overall assessment of the evidence does not consider the ease or 
difficulty another organization may have in setting up and running a SIF.  We assume that planning, 
stakeholder engagement, and daily management can be executed similarly to that of organizations 
in Vancouver and Sydney to produce the reported results. 
On balance, we believe we have high certainty that, compared with SSPs, SIFs prevent overdose 
deaths.  The degree to which overdose prevention translates to substantially lengthening the life of 
the individual is uncertain.  The evidence on community overdose mortality from Marshall et al. 
201112, provides moderate-quality evidence given the drop-off in effect over distance from the SIF, 
which is akin to a dose-response effect.  This, too, provides moderate certainty of a substantial 
benefit.  We do not believe that possible harms which have been reported – some communities 
report increases in needle litter near a SIF – could reduce the net benefit below incremental.  There 
is good reason to believe the net benefit is substantial. 
Thus, we have concluded that there is high certainty that SIFs, compared with SSPs provide a small, 
or substantial net health benefit , and moderate certainty that SIFs provide a substantial net health 
benefit, leading to a rating of “incremental or better” (B+).
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Cost Effectiveness 
Overview 
The primary aim of this analysis was to estimate the cost effectiveness of SIFs for IDU among PWID 
using a cost-effectiveness analysis.  The model compared SIFs to SSPs, i.e., SIF+SSP, vs. SSP-only.  
Because SIFs are not funded by the health care system or payers of health care, the base-case 
analysis was a modified societal perspective and a one-year time horizon.   
Methods and Model Structure 
We developed a decision analytic model for this evaluation, with outcome calculations adapted 
from prior relevant economic models of harm reduction for PWID63-69 and informed by interviews 
among key staff and researchers of SIFs.  
The model focused on communities of PWID, specified by parameters for individual US cities, who 
could potentially utilize SIFs in locations where SSPs already exist.  We modeled costs and outcomes 
for Boston, Philadelphia, San Francisco, Atlanta, Baltimore, and Seattle, based on the prior existence 
of an SSP,70 US geographic location, and the availability of broad city-level estimates. 
Figure ES1. Model Framework 
ED: emergency department, MAT: medication-assisted treatment, PWID: people who inject drugs, SIF: supervised 
injection facilities, SSP: syringe service program 
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Key Model Characteristics, Assumptions, and Inputs 
Table ES2. Key Model Assumptions 
Assumption Rationale 
Hypothetical legally-sanctioned SIFs in US cities are 
comparable to Insite (Vancouver, BC, Canada) in terms of 
effectiveness, services offered, and cost of living-adjusted 
operating costs.   
Insite is the first and most well-documented SIF in North 
America. 
The US cities modeled have a 0.25-mile radius area within 
the city that could have 2100 PWID clients for a SIF. 
The Insite client-service rate is the basis for the healthcare 
resource use effectiveness estimates for SIFs in all modeled 
cities. 
Rates of HIV/hepatitis C/other infections are equivalent 
between SIF+SSP and SSP-only. 
We recognize there is some evidence that SIFs may reduce 
needle sharing, leading to a reduction in infections.  
However, due to the short time horizon of our model (1 
year) and the complexity of estimating the timing of 
infections and attributing costs to these conditions, we 
chose to take a conservative approach and not include these 
additional cost off-sets. We explored a difference in 
infection rates driven by a reduction in needle sharing 
conferred by the SIF setting in a scenario analysis. 
We assumed that the rates of initiation and continuation of 
MAT are equivalent between clients using SIFs and SSPs. 
There is a lack of comparative data between these two 
services; however, stakeholders have indicated that 
increased face-to-face time spent with PWID may lead to 
increased uptake of MAT.  Therefore, we explored the 
impacts of marginal increases in MAT initiation due to SIFs in 
a scenario analysis. 
BC: British Columbia, HIV: human immunodeficiency virus, MAT: medication-assisted treatment, PWID: people 
who inject drugs, SIF: supervised injection facility, SSP: syringe service program 
 
Table ES3. Overdose Mortality Inputs 
Parameter Estimate (sensitivity analysis range) 
Fatal OD reduction within 0.25 mi of SIF12 35.0% (±20%) 
Fatal OD reduction beyond 0.25 mi of SIF12 9.3% (±20%) 
Proportion of total overdose deaths occurring within 
0.25 mi2 of SIF67 
5% (±20%) 
OD: overdose, SIF: supervised injection facility 
 
Utilizing estimates from Insite, we assumed that 0.95% of overall injections result in an overdose 
(Table ES3).33  Emergency services included both ambulance services as well as hospital ED access, 
and were conditional on the occurrence of an overdose.   
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Table ES4. Overdose and Emergency Services Inputs 
Parameter Estimate (sensitivity analysis range) 
Overdose (OD) Inputs  
Total annual injections 71 180,000 (±20%) 
Number of unique clients/month71 2,100 (±20%) 
Percent of injections resulting in OD33 0.95% (±20%) 
Emergency Services Inputs  
Proportion of ODs at SIF+SSP resulting in ambulance 
ride67,72 
0.79% (±20%) 
Proportion of ODs at SIF+SSP resulting in ED visit67,72 0.79% (±20%) 
Proportion of SSP-only ODs resulting in ambulance ride67,73 46% (±20%) 
Proportion of SSP-only ODs resulting in ED visit67,73 33% (±20%) 
Proportion of ED visits resulting in hospitalization74 48% (±20%) 
ED: emergency department, OD: overdose, SIF: supervised injection facility, SSP: syringe service program 
We assumed that SIFs provide equivalent benefit to SSPs in terms of initiation of MAT.  Therefore, 
we used the same estimate of 5.78% of PWID accessing MAT due to a referral from the SIF and/or 
SSP (Table ES5).75  We assumed 50% of PWID who begin MAT stay on treatment each year. 
Table ES5. Medication-Assisted Treatment Inputs 
Parameter Estimate (sensitivity analysis range) 
Proportion of PWID who access MAT75 5.78% (±20%) 
MAT continuation rate67 50% (±20%) 
MAT: medication-assisted treatment, PWID: people who inject drugs 
 
SIF facility and operation costs were estimated based on the Irwin et al. approach, adapting each 
community’s estimate according to their individual characteristics.66,67  Start-up and operating costs 
are shown in Table ES6.  Downstream costs of ambulance rides, ED visit and hospitalization are 
presented in Table ES7. 
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Table ES6. Operating and Facility Cost Inputs 
0BParameter 1BEstimate (sensitivity analysis range) 
2BInsite Annual Operating Cost76,77 3B$1,687,286 (±20%) 
4BTerm of Commercial Loan* 5B15 years 
6BSIF Square Footage67 7B1000 
8BAdjusted SSP Annual Operating Cost77,78 9B$1,533,279 (±20%) 
*Assumption 
SIF: supervised injection facility, SSP: syringe service program 
Table ES7. Emergency Services Cost Inputs 
Parameter Estimate (sensitivity analysis range) 
Ambulance Ride Costs79  
Boston $523.06 (±20%) 
Philadelphia $487.41 (±20%) 
San Francisco $566.34 (±20%) 
Atlanta $461.63 (±20%) 
Baltimore $492.50 (±20%) 
Seattle $516.37 (±20%) 
Overdose-related ED Visit Cost (All Cities)74 $3,451 (±20%) 
Overdose-related Hospitalization Cost80   
Boston $8,379 (±20%) 
Philadelphia $7,502 (±20%) 
San Francisco $8,683 (±20%) 
Atlanta $5,890 (±20%) 
Baltimore $7,502 (±20%) 
Seattle $8,683 (±20%) 
ED: emergency department 
Model Outcomes 
Model outcomes included total overdose deaths prevented and total costs for each intervention.  
The model outcomes also include total emergency services avoided, and total increase in MAT 
initiation.  Due to the one-year time horizon, all results are reported as undiscounted values. 
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Results 
Base-Case Results 
The annual cost of operating a SIF+SSP ranged from $1.6 million to $2.5 million, while the cost of 
operating an SSP-only ranged from $1.4 million to $1.7 million, depending on the location.  A 
hypothetical SIF+SSP was found to result in the prevention of three (Boston) to 15 (Philadelphia) 
overdose deaths per year, as well as 773 fewer overdose-related ambulance rides, 551 fewer 
overdose-related ED visits, and 264 fewer hospitalizations (all based on 180,000 
injections/year/comparator).  This resulting in cost-savings by city are shown in Table ES8, ES9 and 
ES10. 
Table ES8. Base-Case Results for Boston and Philadelphia 
Outcome Boston Philadelphia 
  SIF+SSP SSP-Only Incremental SIF+SSP SSP-Only Incremental 
Total Cost $2,261,000 $6,270,000 -$4,009,000 $1,896,000 $5,796,000 -$3,899,000 
Annual Cost of 
Facility 
$2,153,000 $1,641,000 $511,300 $1,794,000 $1,433,000 $361,500 
Ambulance Costs $7,100 $411,400 -$404,400 $6,600 $383,400 -$376,800 
ED Visit Costs $46,600 $1,947,000 -$1,901,000 $46,600 $1,947,000 -$1,901,000 
Hospitalization 
Costs 
$54,300 $2,270,000 -$2,215,000 $48,600 $2,032,000 -$1,983,000 
Overdose Deaths 9 13 -3 43 58 -15 
Ambulance Rides 14 787 -773 14 787 -773 
ED Visits 14 564 -551 14 564 -551 
Hospitalizations 6 271 -264 6 271 -264 
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Table ES9. Base-Case Results for San Francisco and Atlanta 
Outcome San Francisco Atlanta 
  SIF+SSP SSP-Only Incremental SIF+SSP SSP-Only Incremental 
Total Cost $2,624,000 $6,457,000 -$3,833,000 $1,687,000 $5,310,000 -$3,623,000 
Annual Cost of 
Facility 
$2,513,000 $1,712,000 $800,900 $1,596,000 $1,404,000 $191,500 
Ambulance Costs $7,700 $445,500 -$437,800 $6,200 $363,100 -$356,900 
ED Visit Costs $46,600 $1,947,000 -$1,901,000 $46,600 $1,947,000 -$1,901,000 
Hospitalization Costs $56,300 $2,352,000 -$2,296,000 $38,200 $1,595,000 -$1,557,000 
Overdose Deaths 12 17 -4 18 24 -6 
Ambulance Rides 14 787 -773 14 787 -773 
ED Visits 14 564 -551 14 564 -551 
Hospitalizations 6 271 -264 6 271 -264 
ED: emergency department, OD: overdose, SIF: supervised injection facility, SSP: syringe service program 
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Table ES10. Base-Case Results for Baltimore and Seattle 
Outcome Baltimore Seattle 
  SIF+SSP SSP-Only Incremental SIF+SSP SSP-Only Incremental 
Total Cost $1,727,000 $5,750,000 -$4,023,000 $2,146,000 $6,346,000 -$4,199,000 
Annual Cost of Facility $1,625,000 $1,383,000 $241,900 $2,036,000 $1,640,000 $396,100 
Ambulance Costs $6,700 $387,400 -$380,700 $7,000 $406,200 -$399,200 
ED Visit Costs $46,600 $1,947,000 -$1,901,000 $46,600 $1,947,000 -$1,901,000 
Hospitalization Costs $48,600 $2,032,000 -$1,983,000 $56,300 $2,352,000 -$2,296,000 
Overdose Deaths 26 35 -9 8 11 -3 
Ambulance Rides 14 787 -773 14 787 -773 
ED Visits 14 564 -551 14 564 -551 
Hospitalizations 6 271 -264 6 271 -264 
ED: emergency department, OD: overdose, SIF: supervised injection facility, SSP: syringe service program 
 
Sensitivity & Scenario Analysis Results 
To demonstrate effects of uncertainty on both costs and health outcomes, we varied input 
parameters using reasonable ranges to evaluate changes in costs and health services utilization.  
We also performed four scenario analyses to evaluate the base case assumptions around infection 
reduction, overdose rates, MAT uptake, and the perspective of the analysis.  The results of these 
analyses are featured on pages 52-56 of the full report. 
Summary and Comment 
The costs of operating a SIF were estimated to be higher than operating an SSP across all six cities.  
However, those costs were offset by cost savings attributed to SIFs through the avoidance of ED 
visits and subsequent hospitalizations.  Furthermore, in all six cities, SIFs were estimated to reduce 
mortality by avoiding overdose deaths. 
The model results were sensitive to several input parameters, which varied slightly across the six 
cities.  The underlying community-level risk parameters of overdose and overdose mortality, along 
with the mortality risk reduction attributed to SIFs, were the most influential model parameters.  
Additionally, parameters that determined the number of injections occurring in SIFs within each city 
also influenced the model estimates. 
Potential Other Benefits and Contextual Considerations 
For some communities, the opening of a SIF reflects a philosophical shift in addressing substance 
use disorders as a health issue, rather than a criminal issue.  SIFs serve marginalized, vulnerable 
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populations that are disadvantaged or underserved.  There are some potential other benefits 
offered by a SIF to the individual PWID, caregivers, the delivery system, other PWUD, or the public 
beyond what is described by the evidence on comparative clinical effectiveness.  A summary of 
these potential other benefits is shown in the table below.   
Table ES11. Potential Other Benefits or Contextual Considerations  
Potential Other Benefit or Contextual Consideration Relevant Information 
Assumptions made in the base-case cost-effectiveness 
estimates rendering results overly optimistic or 
pessimistic. 
Most quantitative data that informed the economic model 
are derived from SIFs operating in only two communities.  
Uncertainty exists about local factors (unmeasured or 
unmeasurable attributes unique to the people and place) 
that contributed to favorable outcomes at the time of the 
study.   
Whether the intervention differentially benefits a 
historically disadvantaged or underserved community. 
Persons served by SIFs are among the most vulnerable and 
marginalized in a community.  Given the disparities in SUD 
by socio-economic class, SIFs differentially benefit groups 
with lower life expectancy and higher disability.   
Whether the intervention will significantly reduce the 
negative impact of the condition on family and 
caregivers vs. the comparator. 
In comparison to SSPs which have been described in 
interviews as “transactional”, SIFs are more likely to engage 
clients in longer and more frequent interactions with staff 
and other clients.  A trust-based relationship can be 
instrumental in helping clients improve injection behavior 
and link to medical, mental/behavioral health and social 
services.   
Whether the intervention will have a significant impact 
on improving return to work and/or overall 
productivity vs. the comparator. 
If SIFs increase the likelihood that clients will initiate and 




Health-Benefit Price Benchmarks 
As the assessment for this non-drug topic does not include estimates of incremental quality-
adjusted life years (QALYs) or equal value life years gained (evLYG), ICER did not produce health-
benefit price benchmarks as part of this report. 
Potential Budget Impact 
As the assessment for this non-drug topic does not include price per treatment or estimates of cost-
effectiveness threshold prices, ICER did not produce potential budget impact analyses as part of this 
report. 
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1. Introduction  
1.1 Background 
National and Regional Epidemic 
The opioid overdose epidemic is devastating families and communities across the United States 
(US).  Epidemiological studies from the US Centers for Disease Control and Prevention (CDC) have 
found that overall life expectancy of Americans has declined, and this decline was largely attributed 
to drug-related overdose deaths.1-3  Today in the US, overdoses are classified as the leading cause of 
injury-related death.  Overall, drug overdose fatalities decreased 4.1% to 67,367 deaths between 
2017 and 2018, and 69.5% involved an opioid 81 and the rest from cocaine or psychostimulants with 
abuse potential.2  However, opioid-involved death rates during this period increased in a number of 
groups (those ages 65 and older, Hispanics, non-Hispanic Blacks) and regions (West, Northeast).  In 
the Northeast region, synthetic opioids other than methadone drove the annual increase, at 
17.9%.81 
The CDC viewed the epidemic of opioid fatalities as having happened in three distinct episodes.82  
The first, which began in the 1990s, involved prescription opioids.  Beginning in 2010, the second 
was marked by heroin-involved deaths.  The current drivers of the epidemic are synthetic opioids 
such as fentanyl and fentanyl analogues, which are pushing mortality even higher.  Opioid deaths 
attributable to synthetic opioids increased by 45.2% from 2016 to 2017.83  Other sources of drug 
overdose deaths may be emerging: from 2012 to 2018, the age-adjusted death rate involving 
cocaine more than tripled, and overdose deaths involving psychostimulants (e.g., 
methamphetamine, amphetamine, and methylphenidate) increased nearly 5-fold over the same 
period.2 
A Public Health Approach 
The public health approach to addressing the overdose epidemic is multi-faceted, involving a 
combination of policy, education, and community interventions.  A framework developed by the 
Association of State and Territorial Health Organizations (ASTHO) describes a cross-sectoral 
response with four key strategy areas: (1) training and education; (2) monitoring and surveillance; 
(3) primary and overdose prevention; and (4) treatment, and harm reduction.  For example, training 
and education of physicians and pharmacists can improve adherence to clinical practice guidelines 
for pain management and reduce the number of patients at risk for addiction and dependence.84 
Expanding distribution channels of naloxone, an antidote for opioid overdose, can reduce rates of 
fatal overdose.81,85,86  For people who seek treatment or want to reduce frequency of opioid use, a 
variety of medication-assisted treatments (MATs) are effective, a topic addressed by ICER 
assessments in 2014 and 2018.  The ASTHO framework recommends funding and implementing 
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supervised injection facilities — also known as safer injection facilities, supervised consumption 
sites, or overdose prevention centers—as a harm reduction strategy, noting the program is 
evidence-based for reducing fatal opioid overdose and enhancing access to primary health care.84 
Harm Reduction Theory 
Harm reduction strategies seek to mitigate the harms of behaviors.4  Injury prevention policies (e.g., 
mandating seat belts, bicycle helmets, and child safety seats) are forms of harm reduction that are 
typically widely accepted.87  When harm reduction has been applied to substance use disorders, 
controversy has sometimes arisen because such strategies do not focus on preventing the use of 
drugs but rather on reducing the risk of such use.88  Harm reduction strategies (including improved 
access to naloxone, syringe service programs, drug checking services and supervised injection 
facilities) implement an alternative to the criminalization and disease treatment models of drug use 
and addiction.  While proponents of harm reduction theory recognize abstinence may be the ideal 
goal for some people, they accept alternatives which reduce the risk for death and disability even if 
they do not promote abstinence.5  Opponents of such strategies often focus on their potential to 
enable activities that are criminal or perceived as immoral.6 
Naloxone Access  
Naloxone is an essential tool in responding to the overdose crisis as it reverses an opioid overdose 
when given intranasally or intramuscularly.  Naloxone is an opioid antagonist that is used as an 
antidote to opioids when an overdose occurs.  To be effective, it must be available at the time of 
overdose.89  When naloxone is distributed widely in a community, it safely reduces overdose deaths 
in a cost-effective manner.  We have not discovered objection to its administration in response to 
an overdose, although there have been concerns about costs90 and encouragement of riskier 
behaviors.91,92  
Syringe Service Programs 
Syringe service programs (SSPs) reduce harm by providing access to safer materials for drug 
injection (sterile syringes and needles; clean water and other equipment), and also safer disposal of 
contaminated equipment, and referrals to addiction treatment services; some also offer screening 
for bloodborne pathogens such as HIV and hepatitis C, distribution of naloxone, safer sex products, 
and access to medical, mental health, and social support services.24  As with expanded naloxone 
distribution, an SSP acknowledges injected drug use is occurring in a community and seeks to 
reduce harms associated with injecting behaviors.  Using sterile equipment for every injection 
reduces risk for acquiring and transmitting bloodborne viral infections such as HIV, hepatitis B, and 
hepatitis C.24  Because SSPs provide for disposal of contaminated equipment, they have the 
potential to enhance the safety of the public and also first responders. Historically, SSPs have raised 
concerns among those who feel that harm reduction strategies expend resources that encourage 
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immoral or illegal behaviors.93  Thirty-eight states plus the District of Columbia have laws that 
enable and/or regulate SSPs, as of August 2019.94  According to National Association of Syringe 
Exchange Network’s provider database, there are 444 SSPs operating in the United States today 
employing a variety of models, such as mobile, mail-order, and needle exchange.95  There are also 
unsanctioned SSPs that have been informally started by people who use drugs (PWUD) outside 
the restrictions imposed by some governments.93 
The CDC recommends SSPs as an evidence-based program, summarizing the effectiveness in this 
way: 
“Nearly 30 years of research has shown that comprehensive SSPs are safe, effective, 
and cost saving, do not increase illegal drug use or crime, and play an important role 
in reducing the transmission of viral hepatitis, HIV, and other infections.  Research 
shows that new users of SSPs are five times more likely to enter drug treatment and 
about three times more likely to stop using drugs than those who don’t use the 
programs.  SSPs that provide naloxone also help decrease opioid overdose deaths.  
SSPs protect the public and first responders by facilitating the safe disposal of used 
needles and syringes.”24 
Drug Checking Services 
Drug checking services are another tool used to combat the overdose crisis.  As the rate of illicit 
drugs containing highly potent opioids such as fentanyl and fentanyl analogues has increased, 
informing people about chemical composition can modify use behaviors, such as dose consumed, 
and reduce overdose risk.96  A variety of technologies exists for analyzing chemical composition, but 
little is known about optimal process and setting to impact outcomes.97  The public health impact of 
a drug checking service depends on the willingness of PWIDs to use it, and a wide range of 
willingness has been reported.98,99 
Supervised Injection Facilities 
Supervised injection facilities (SIFs) are permanent or mobile facilities where people can inject drugs 
they have obtained elsewhere.7  If they permit use of drugs by routes other than injection (such as 
smoking or snorting), the more comprehensive term is “supervised consumption sites” (SCS).  These 
facilities typically provide equipment to allow users to perform safe and sterile injections while 
being monitored by trained medical staff who can treat overdoses with oxygen, naloxone, and/or 
other first-responder care.7 The sites may also have resources and information available for 
individuals seeking addiction treatment, primary health care, or social services.  While SIF model 
implementation seems to vary based on community needs, resources, and funding, interviews with 
stakeholders suggest that there are three core features: sterile equipment, trained personnel for 
supervision, and naloxone administration (along with other first-responder medical care).   
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The following services may augment the core features: (1) self-management education for safer 
injecting practices, (2) screening for soft tissue infections, (3) hepatitis C screening/treatment, (4) 
drug toxicity screening (e.g., fentanyl), (5) on-site detoxification, (6) access to MAT, (7) referral 
coordination for social support (e.g., housing), health care and mental health services, (8) 
psychological/behavioral health counseling, (9) space for client relaxation and socialization, (10) 
personal hygiene supports (e.g., shower, laundry), (11) syringe service program (SSP) (e.g., needle 
exchange), (12) naloxone distribution, (13) space for consuming drugs by smoking, and (14) mobile 
unit to reach neighborhoods with high need.7-10  
In the 1970s, The Netherlands established the first SIF model in Europe as part of a response to 
psychosocial needs of youth and their use of illegal drugs.100  The model adapted to the needs of 
people using drugs problematically by combining a drop-in meeting space for drug consumption 
with basic health (e.g., counseling, medical care) hygiene, (e.g., shower, laundry) and food 
resources.  In the 1980s, SIFs were promoted across Europe with a goal of reducing both the harms 
of injecting drugs and the community effects of public injecting.  Around the same time, the model 
was adopted in Switzerland for similar reasons and SIFs were implemented in Germany in the 1990s 
and in Sydney, Australia in 2001.101 
In 2003, Insite, the first legally-sanctioned SIF in North America, opened in Vancouver, British 
Columbia’s Downtown Eastside, a neighborhood with high rates of drug use, homelessness, and 
poverty.11  After 17 years of continuous operation, Vancouver has become an exemplar setting for 
researchers and policy advocates to understand the impact of the SIF model on a variety of 
outcomes, including the ones addressed in this ICER report.  Currently, SIFs are available in 19 cities 
across Canada.102 
Currently in the US, there are no legally sanctioned SIFs.  Plans to open a SIF or initiate a multi-
stakeholder planning process for a SIF have been announced by some cities.  For example, the non-
profit agency Safehouse has been engaged with the development of a SIF since January 2018 in 
Philadelphia, navigating through legal, policy and community support issues.103  In 2019, the mayor 
of Somerville, a city in the Boston metropolitan area, stated plans to open a SIF in response to 
overdose deaths.104  There are news reports of elected officials or groups in New York City, Ithaca, 
Seattle, Denver, Washington DC, Chicago, Baltimore, Burlington, Oakland and San Francisco 
exploring feasibility, organizing coalitions, or preparing legislation for SIFs.15-23  A recent letter 
published in the New England Journal of Medicine described the experiences of an unsanctioned SIF 
that has been operating in the US for six years.14 
The clients of SIFs are usually homeless, live alone, or have significant housing insecurity.  
Unemployment is common.  SIF clients are impacted by many social determinants of health.  We 
spoke with a SIF client who described the people served by SIFs as “poor, homeless, marginalized…a 
beat-down people” noting that he “had given up on himself” when he found harm reduction 
services.  The prevalence of mental and behavioral health conditions is high among people who 
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inject drugs (PWID).  Although SIFs are considered a type of public health intervention, their 
population-level reach is measured in city blocks – not miles.12,13  It seems that a standalone SIF is 
generally able to address the needs of one neighborhood, as experts explained that PWIDs are 
unable or unwilling to travel far for SIF services.  Thus, location is an important attribute that 
determines whom a SIF serves as well as its potential public health impact.  
Even more than SSPs, the potential implementation of SIFs has raised objections from those who do 
not feel that facilitation (or direct observation) of drug consumption is appropriate for a health care 
or public health worker.  Even among those who support harm reduction strategies, concerns may 
be raised about the effects on a neighborhood if PWIDs are attracted and congregate.  In 2000, a 
survey of 515 residents and 209 businesses near a planned SIF location in Sydney showed that 26% 
and 37% of respondents, respectively, disagreed with the establishment of the SIF.  Disagreement 
waned two years after the SIF opened.105 
Objectives 
The purpose of this assessment is to evaluate the health and economic outcomes of a SIF.  This 
review seeks to answer the question:  What is the net health benefit of implementing a SIF (which 
includes an SSP) versus an SSP alone?  The ICER value framework includes both quantitative and 
qualitative comparisons across treatments to ensure that the full range of benefits and harms are 
considered in the judgments about the clinical and economic value.  The assessment of 
effectiveness and value is made in comparison to an SSP as we believe it unlikely that communities 
that have not been willing to implement SSPs would be willing to consider a SIF.  A SIF implemented 
in a community without good SSP coverage may experience more than the incremental benefit. 
1.2 Scope of the Assessment 
Populations 
The population of focus for the review included all PWID living in an area with access to an SSP and 
where a SIF could potentially be placed within a few blocks of where they reside. 
We also sought evidence on subpopulations suggested by the stakeholders, looking for evidence on 
the following subgroup effects: 
• Housing status, comparing effects in people living with homelessness or unstable housing 
and those with stable housing 
• Injected drug class, comparing effects in people who inject opioids with effects in people 
who inject stimulants such as cocaine or methamphetamine 
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Interventions 
The intervention of interest is the implementation of SIFs including sites that permit other forms of 
drug consumption.  We assume that SIFs will include, at a minimum, three core features: sterile 
equipment, trained personnel for supervision, and naloxone administration (along with other first-
responder medical care).  We recognize that published data come from SIFs that offer additional 
resources and services to clients which may impact some of the individual and community 
outcomes of interest. 
Comparators 
We compared SIFs to SSPs.   
Outcomes 
The outcomes of interest are described in the list below. 
• Individual outcomes 
o Overdose  
▪ Requiring EMS/ambulance or hospital care 
▪ Mortality (occurring in or out of the facility) 
o All-cause mortality 
o Infection 
▪ Chronic viral infection (hepatitis C and HIV) 
▪ Bacterial infection requiring hospitalization (e.g., antibiotics, surgery, 
endocarditis) 
▪ Skin and soft tissue infection not requiring hospitalization 
o Health-related quality of life 
o Intermediate outcomes 
▪ Use of treatment and recovery support services 
▪ Receipt of social (e.g., housing), primary medical care, dental and mental 
health services 
▪ Injection behaviors (e.g., needle and syringe sharing) 
o Drug consumption (e.g., frequency, amount)  
• Community and environmental outcomes 
o Syringe and paraphernalia disposal 
o Public drug use 
o Drug-related crime  
o Drug use prevalence 
• Health system utilization 
o Hospitalizations 
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o Emergency department visits 
o EMT/paramedic calls/responses 
Timing 
Evidence on intervention effectiveness and safety has been collected from studies of any duration. 
Settings 
The setting of interest is community SIFs, whether they are affiliated with health centers and 
hospitals, and mobile SIFs, or not.  Inpatient SIFs (i.e., located within hospital settings) are not part 
of the scope of this review. 
1.3 Definitions 
Supervised Injection Facility (SIF) – The Drug Policy Alliance defines SIFs as “Legally sanctioned 
facilities that allow people to consume pre-obtained drugs under the supervision of trained staff 
and are designed to reduce the health and public order issues often associated with public drug 
consumption. They are also called overdose prevention sites (OPS), safe or supervised consumption 
services (SCS), and drug consumption rooms (DCR).”8 
Syringe Service Programs (SSPs) – The CDC defines SSPs as “Community-based prevention programs 
that provide access to or disposal of sterile syringes and injection equipment, access to substance 
use or addiction treatments/services, health care and social services, vaccination, and testing 
services.”24 
Medication Assisted Treatments (MAT) – The Substance Abuse and Mental Health Services 
Administration defines MAT as “Use of medications, in combination with counseling and behavioral 
therapies, to provide a “whole-patient” approach to the treatment of substance use disorder.”106 
1.4 Potential Cost-Saving Measures in Opioid Use Disorder 
ICER now includes in its reports information on wasteful or lower-value services in the same clinical 
area that could be reduced or eliminated to create headroom in health care budgets for higher-
value innovative services (for more information, see https://icer-review.org/final-vaf-2017-2019/).  
These services are ones that would not be directly affected by therapies for opioid use disorder 
(OUD) (e.g., reduction in disability), as these services will be captured in the economic model.  
Rather, we are seeking services used in the current management of OUD beyond the potential 
offsets that arise from a new intervention.  During stakeholder engagement and public comment 
periods, ICER encouraged all stakeholders to suggest services (including treatments and 
mechanisms of care) currently used for patients with OUD that could be reduced, eliminated, or 
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made more efficient.  We received a suggestion that advertising (e.g., billboards) which promotes 
OUD treatment and other services for PWID may be a low value use of resources.    
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2. Perspective of People Who Use Drugs  
2.1 Methods 
During ICER’s scoping and open input periods, we received public comment submissions from 4 
stakeholders (1 SIF, 2 advocacy groups, and 1 clinical researcher) and participated in conversations 
with 37 key informants and/or organizations (4 advocacy organizations, 6 SIF/SSP staff members, 23 
researchers, 5 clinical experts, 1 law enforcement officer, 8 legislative/policy experts).  These 
comments and conversations helped us to discuss the impact on PWUD as described below.   
The ICER team also interviewed 11 clients/staff members of SIFs or SSPs that operate in Canada as 
government-approved safe consumption sites (SCS) or overdose prevention sites (OPS); they were 
also affiliated with the Canadian Association of People Who Use Drugs (CAPUD), the non-profit 
organization that assisted ICER with interviews.  The quotations that are integrated into the text 
below came directly from these interviews.  
2.2 Impact on People Who Use Drugs 
Social Isolation 
The PWUD we interviewed affirmed that SIFs serve the most vulnerable and marginalized people in 
a community, noting that many PWUD live in social isolation due to housing insecurity, mental 
illness, and poverty.  Through supervisory services, SIFs mitigate overdose risks associated with 
injecting alone, a common behavior among PWUD who do not have access to a SIF.  One 
stakeholder described the main task of a SIF 
as “provid[ing] a place where people will be 
attracted to come and feel welcomed” so 
they are not alone.  In addition to time-
critical first-responder care, SIFs serve as an 
access point for people who are socially 
isolated to learn about community 
resources and be linked to health and social services.  
“Lots of people are dead because they overdosed in public alone with no help around them…I can 
think of 13 people who are still alive today because I was there to call 911 or seek help.” – SCS Client 
“To me, a lot of drug use is very rational…very 
rationale response to a society where mental 
health care is difficult to access.” – OPS Staff 
Member and Client 
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Camaraderie and Community 
Many PWUD and stakeholders described how the SIF had enabled building of relationships with 
staff and other regular clients.  The SIF provides a comfortable, safe space for people to be their 
true selves and forge trust with others.  The SIF was one of the only judgement-free zones available 
to PWUD whose lives are filled with discrimination, criminalization, and trauma.  They felt that SIFs 
contribute to positive changes in the community that stem 
from relationship-building among clients, harm reduction 
workers (e.g., nurses, technicians), police, and even drug 
dealers.  SIFs provide an “opportunity to meet people in a 
positive way...and that is an immeasurable kind of benefit, in 
my opinion,” noted one former SIF client.   One SIF 
administrator described the purpose of a SIF as “being 
community space first, that happens to have clinical supports.”   Another one described the “living 
room effect” of a SIF – providing a comfortable environment that can help reduce stress and reduce 
the need to self-soothe with drugs.  One stakeholder pointed out that experience and research has 
demonstrated that PWIDs use SIFs when they are available. 
Health Care System Bias   
We heard from some stakeholders that SIFs provide a way for PWUD to reduce interactions with 
hospitals, doctors, and EMTs, during which they often felt there was frequent “shaming and 
blaming” and “accusations of drug-seeking”.  Many PWUD relayed stories of stigmatization that 
compromised their physical and mental health, such as refusal of primary medical care for hepatitis 
treatment follow-up.  Multiple people noted a lack of respect by the health care system for those 
who work in harm reduction (and their clients).  A participant – who was a SIF client and worked for 
an SSP – found the health care system to be “scary” and distrusted doctors because of poor 
treatment in a hospital setting.  Nurses and doctors at SCSs, however, were stated to be much more 
compassionate to the problems faced by 
clients.  
Another client noted that electronic health 
records assured PWUD are labeled “junkie” 
across the health care system, even before 
meeting a health care provider.  He and others 
felt that SIFs can offer a counterbalance to the bias of the health care system while providing 
health-related services valued by PWUD. 
“PWUD don’t have a lot of places they can go without being stigmatized, so it’s so important to have a 
place you can go and be welcomed and use safely.” – OPS Staff Member and Client 
“Needle exchange programs, yeah, 
it’s great, but it’s a momentary 
interaction; they’re not going to be 
there to save your life.” – SCS Client 
“Most interactions with pharmacists, doctors, 
lawyers…are all so stigmatizing. They make you 
feel kind of like a moral failure.” – OPS Staff 
Member and Client 
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Inhalation   
We heard from multiple stakeholders that 
changes in the drug supply and client 
preferences mean that SIFs must adapt and 
provide for the use of inhaled substances 
(not limited to opioids), becoming more 
comprehensive SCSs.  One person noted that smoking is on the rise now since people have learned 
how to get the same high with less need for the complexities of injecting.  We heard that provision 
of supplies for smoking by one harm reduction program had quadrupled over the prior 18 months.  
One interviewee believed that technology (e.g., rapid negative pressure decontamination) could 
protect the staff if government leaders allowed the spending.  Nearly every person we interviewed 
recommended that a space for smoking be included in a SIF because the strategy should focus on 
the person, not the drug.  One stakeholder highlighted the racial disparities in incarceration related 
to crack cocaine, which is primarily smoked, and recommended the provision of smoking facilities 
not only as a harm reduction practice, but also as a component of addressing structural racism in 
the United States. 
Testing New Batches or New Suppliers 
SIFs are used by some PWUD to test out new batches or drugs obtained from new suppliers.  
Several PWUD described how they use the SIF to check the potency of a new batch under the 
protection of supervision and resuscitation, if needed.  Depending on the degree of this practice in 
a community, there may be unmeasured value of a SIF related to particularly volatile periods of 
changes in the toxicity and potency of the drug supply chain. 
Pain Management   
We heard that PWUD are frequently dismissed as 
“drug seeking addicts”.  Classism, racism, sexism, and 
homophobia can add to oppression and discrimination 
that PWUD already experience.  However, one person 
noted that most people who inject or smoke drugs are 
managing significant physical and emotional pain 
caused by injury, occupation, sexual assault, or trauma.  As opioid prescribing patterns of physicians 
have changed in recent years, many people have turned to heroin or crack for pain management.  
One woman noted that “[her] doctor was more concerned about getting [her] off opiates than 
worrying about [her] pain.”  We even heard suggestions that SIFs are a safer option for people with 
“legitimate pain, legitimate anxiety” to self-manage, especially for the poor and marginalized “who 
cannot even ask a hospital for the medications they actually need.” 
“Lot of this community with lived 
experience have been through some 
hard stuff that have gone 
unaddressed.” – OPS/SCS Staff Member 
“We heard loud and clear from PWUD; they did 
not want the SIF to be just for injection.” – Public 
health agency professional 
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Access to Treatment 
Multiple stakeholders described differences in the 
time and frequency of interactions with SIFs versus 
SSPs.  In contrast to client interactions with SSPs 
that were described as “transactional and hurried”, 
SIFs have the potential to be more effective at 
introducing counseling interventions through a community built on camaraderie.  Frequency of 
engagement was noted as a good predictor for the degree to which people can transition into an 
engagement process for referral to treatment.  A setting like a SIF where people may expect to use 
it more frequently will allow for more points of contact to accelerate trust-building with the 
program.  We also heard, though, that there are many users of SSPs who have no interest in making 
use of SIF services.  Relationships and counseling enable access to a variety of services, including 
MAT, when clients are ready.  One SIF manager noted the staff are not curing people nor 
pretending to; rather, they work to motivate people to find their way into wellness, which may or 
may not be abstinence-based treatment.  A recovery specialist noted that SIFs are merely another 
interconnected pathway to recovery (among many in a community), and far “better than a shooting 
gallery in an abandoned building where there is no opportunity for recovery.”  Several stakeholders 
noted that SIFs do not address the health care system capacity constraints for treatment (e.g., new 
patients for MAT), adding that referrals must be picked up in timely manner by compassionate, 
culturally-competent professionals who respect the client’s goals.  One person called out a paradox 
in the evidence, observing that harm reduction programs must demonstrate an ability to get people 
into treatment, but treatment programs do not have to demonstrate ability to accept referrals from 
harm reduction programs.    
  
“First of all, reach people…and look at 
what their individual goals are. You cannot 
treat everyone the same.”  – SIF Manager 
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2.3 Other Considerations  
Learning from Lived Experience  
Most people commented on how the best SIFs respect the expertise of PWUD and include them in 
setting policies and operating the 
facility.  One example involved how 
client input has adjusted the use of 
naloxone.  Rapid, full-dose 
administration of naloxone eliminates 
the pain relief benefit and sends a client 
who is opioid-tolerant into withdrawal.  
While one SIF was “too trigger happy with naloxone a few years back”, it now favors oxygen and 
micro-dosing of naloxone because it respected the expertise of PWUD.   
Honeypot Effect 
PWUD dismissed the possibility of a honeypot effect in which a SIF attracted PWUD or crime to a 
neighborhood, noting the long-established poor conditions of neighborhoods where SIFs are 
generally located, and that SIFs serve people who live nearby.  Many stakeholders agreed.  One 
person from Vancouver who had feared Insite would become a drug destination for people from 
other Canadian cities noted this has not happened and that “people won’t travel more than a few 
blocks” to visit the SIF.   However, PWUD and stakeholders acknowledged that opposition to SIFs, 
SSPs, and other forms of harm reduction can exist in a community due to fear, classism, moral 
objection to drug use, and societal failures to view addiction as a health care issue.  We heard from 
PWUD and stakeholders that drug use still happens just outside of SIFs and SSPs, and at least some 
community members do complain about syringe/needle debris.   
Medical versus Community Model 
For a long time, the “nurse-centric Insite model” was the only SIF model in practice, but a variety of 
models are now available across Canada.  A few participants described how a simple first-aid model 
can be effective in preventing overdose mortality and suggest that the more expensive nurse-
centric model may not always be needed.  However, there was appreciation for the Insite model; 
one participant recommended that a city opening a SIF start with the Insite model and “then work 
your way from there”, moving toward a less medical model over time. 
Integrated Services  
Providing on-site access to social workers, frontline workers, or counselors was widely considered 
essential.  Their experience suggested that most clients could not be easily referred to external 
“I can attest that bedside care is really lacking from 
health care professionals, especially in emergency 
situations. People with lived experience are the 
experts.” – OPS Staff Member, Former Paramedic 
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counseling as they often would not accept another counselling center for reasons such as distance, 
fears, and stigma.  “A simple consumption room is better than nothing but having a little bit of 
social support on-site is fantastic,” explained a manager.  The medical director of a new SIF that 
opened in 2019 explained how it was co-designed with PWUD as a mixed service model and 
included a consulting area space (three private rooms) to offer low threshold, non-appointment-
based support for health and social services.  Experience there suggests integration boosts service 
uptake in a PWUD population where referrals to external services are less effective.   
Housing Security  
SIF clients are impacted by many social determinants of health, including housing security.  A few 
stakeholders noted the clear limitations of a SIF to impact outcomes when the basic need for 
housing remained unaddressed.  One stakeholder who worked in San Francisco described how the 
housing crisis there was linked to substance use.  Any harm reduction strategy, including a SIF, is 
affected by the housing policy and resources in the surrounding community.  As one stakeholder 
said, “mortality is important, but mortality is connected to lack of housing and other issues — and 
SIFs cannot solve for that…until housing is solved, a SIF can keep people alive and connect them to 
treatment, which has a dramatic impact on mortality.”   Another stakeholder stated that stable 
housing is required for a PWID to ever improve quality of life. 
Traumatized by Public Drug Use 
There is a community-level trauma caused by public use as well as overdose.  In many communities, 
PWUD inject in public spaces (e.g., parks, alleys) but in a location that is discreet and hidden.  They 
prefer to choose bathrooms of businesses because they have privacy (i.e., doors that close), soap, 
running water, and low chance of being caught by the police.  Both locations can lead to trauma 
among people who witness the drug use or discover an overdose.  SIFs offer a means to prevent 
this form of community-level trauma if the SIF can operate at scale.  An advocate for people with 
substance use disorder noted that harm reduction strategies are making drug use invisible in 
communities where there are enough services available by normalizing substance use and allowing 
people to access health and social services.   Quality of life increased for the community due to 
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3. Operational Guidelines  
3.1 About Insite 
Insite: Supervised Consumption Site – Vancouver Coastal Health107 
Insite was opened in 2003 in Vancouver, Canada as the first legal SIF in North America.  The facility 
was founded in response to a large number of drug-related deaths occurring in Vancouver’s 
Downtown Eastside neighborhood.  Insite is co-managed by Vancouver Coastal Health, a regional 
health authority providing health services, and the Portland Hotel Society (PHS) Community 
Services Society, a social services non-profit.  Operating on a harm-reduction model, Insite works to 
mitigate the health and socioeconomic consequences of drug use; abstinence from drugs is not 
required to be connected to care.  The model also provides care for those who use substances and 
have medical or psychological needs including Hepatitis C, HIV/AIDs, and psychiatric disorders.  
As a SIF, the site is accessible to anyone 16 years or older who injects drugs and wants a sterile and 
safe facility to do so; it is open 7 days a week, 9AM to 3AM.  Insite has a 12-booth 
injection room where PWUD can inject drugs they bring with them and where they can be 
supervised by nurses and other health care staff.  They have access to injection equipment including 
sterile syringes and clean cookers, filters, and water.  In the event of an overdose, teams are 
available to intervene immediately providing medical support including naloxone when indicated.  
After injecting, clients move to a post-injection room where they are provided with drinks such as 
juice or coffee and space to spend time with staff in a comfortable environment.   Wound care and 
immunizations are available from the medical staff which also coordinates referrals for medical, 
mental health, and social support services.  
Insite also has onsite services for withdrawal management (i.e., detoxification) on the second floor 
of the building, known as Onsite.  Onsite has twelve detoxification rooms with private bathrooms 
and has health care teams, doctors, nurses, counselors, and mental health workers.  After clients 
are stabilized, they can move to transitional recovery housing located on the third floor of the same 
building.  There they can be connected to additional resources for housing, treatment programs, 
and community support. 
According to Insite’s website, the facility sees an average of 415 visits a day and over 175,464 visits 
annually – as of 2017.  By March 2010, 7 years after their opening, there had been over 1.5 million 
visits.  Many clients visit Insite multiple times; clients average 11 visits per month.  There have been 
no fatal overdoses at Insite and, compared with non-Insite-users, Insite users are more likely to 
engage in addiction treatment.107  
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3.2 About Uniting Medically Supervised Injecting Centre 
Uniting Medically Supervised Injecting Centre108-112  
Uniting Medically Supervised Injecting Centre (MSIC) opened in Kings Cross, Sydney, Australia in 
May of 2001 and was the only SIF in Australia for 17 years before a second SIF opened in North 
Richmond, Melbourne in June 2018.  The facility was founded following suit of the opening of the 
Switzerland SIF in 1986 and was placed in Kings Cross due to the area having the highest 
concentration of people dying from drug overdose in Australia.  Uniting MSIC remains the only SIF 
in the Southern hemisphere.  Like the Insite SIF, Uniting MSIC work to minimize the harm associated 
with injecting drugs through their team of nurses, counselors, and health education professions.  In 
their mission, they emphasize that they act to prevent injury and death by being present while 
someone injects rather than supporting and/or promoting drug use to provide immediate medical 
assistance if and when needed. 
Uniting MSIC is open Mondays and Wednesdays-Fridays from 9:30 AM-9:30 PM and Tuesdays from 
9:30 AM-3:45 PM and 6:00 PM-9:30 PM.  On weekends and public holidays, they are open from 
9:30 AM to 5:30 PM.  When visiting the SIF, clients first have access to the waiting room and 
assessment area.  Once staff have a clear idea of their current situations and medical histories, they 
are invited into the injecting room that houses eight open booths fitting two people each.  Those 
who visit must be 18 years or older, not intoxicated in the moment, and they cannot be pregnant or 
accompanied by a child.  A registered nurse is always on duty and present.  
Uniting MSIC also functions as an SSP, provides advice on safer injecting practices, and also provides 
first aid and other health services.  The facility does have a resuscitation room in the event of a drug 
overdose or another health care emergency.  After injecting, clients move into an after-care area 
until they are ready to leave.  In this space, they can connect and talk with the health care team in 
an informal environment.  Coffee and tea are available as well as health promoting activities and 
the ability to connect with medical, psychosocial, housing, rehabilitation, and legal services. 
Since opening in 2001, Uniting MSIC has supported over 16,500 clients, managed over 8,500 
overdoses, and referred over 14,500 to further care and support – with 0 fatalities.  Studies have 
shown that 70% of local businesses and 78% of local residents support the center.  Uniting MSIC 
does not have an integrated detoxification program but rather refers clients who desire treatment 
for addiction, medical and mental health care, or social services support.  Around 80% of Uniting 
MSIC’s frequent clients ultimately accept referrals for these forms of treatment.  
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4. Comparative Clinical Effectiveness  
4.1 Overview 
In this review of the comparative clinical effectiveness of SIFs and other SCS, we systematically 
reviewed and synthesized existing evidence from available studies.  Full PICOTS criteria are 
described in Chapter 1.2.   
Our review focused on the effectiveness of the implementation of SIFs and other SCS in comparison 
to SSPs.  We reviewed the benefits of SIFs important to PWID and sought evidence on all outcomes 
listed in Chapter 1.  The methods and findings of our review of the evidence are described in the 
sections that follow. 
4.2 Methods 
Data Sources and Searches 
Procedures for the systematic literature review assessing the evidence on SIFs for PWID followed 
established best research methods.113,114  The review was conducted following the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.115  These 
guidelines include a checklist of 27 items, which are described further in Appendix Table A1.  
We searched MEDLINE, PsycINFO, Web of Science, and EMBASE for relevant studies of SIFs through 
July 2020.  Each search was limited to English-language studies of human subjects and excluded 
articles indexed as guidelines, letters, editorials, narrative reviews, case reports, or news items.  We 
also searched for systematic reviews of SSPs in MEDLINE and PsycINFO through July 2020.  All 
search strategies were generated utilizing the Population, Intervention, Comparator, and Study 
Design elements described previously.  The proposed search strategies included a combination of 
indexing terms (MeSH terms in MEDLINE and EMTREE terms in EMBASE) as well as free-text terms.  
To supplement the database searches, we performed manual checks of the reference lists of 
included studies and systematic reviews and invited key stakeholders to share references germane 
to the scope of this project.  We also supplemented our review with information submitted by 
stakeholders, SIF/SCS evaluations or reports, and other grey literature when the evidence met ICER 
standards (for more information, see https://icer-review.org/methodology/icers-methods/icer-
value-assessment-framework-2/grey-literature-policy/).   
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Study Selection 
After the removal of duplicate citations, references went through two levels of screening at both 
the abstract and full-text levels.  Four reviewers independently screened the titles and abstracts of 
all publications identified using DistillerSR (Evidence Partners, Ottawa, Canada) and disagreements 
were resolved through consensus.  Studies that did not meet PICOTS criteria were excluded. 
No evidence from randomized controlled trials (RCTs) was identified.  Relevant published high-
quality cohort and other observational studies of any sample size or duration were included (see 
below for details on quality assessment).  Only studies that evaluated SIF use in association with the 
relevant outcomes of interest were included in this review.  Further, we recognize that a variety of 
SIF intervention models exist.  We looked for studies of different forms of consumption (e.g., 
smoking) that expand on the SIF model.  However, we did not identify any studies that compared 
different SIF models and forms of consumption (e.g., injecting vs smoking) in terms of outcomes of 
interest.  A detailed protocol of the methods was registered on Prospero (CRD42020199977). 
Data Extraction and Quality Assessment 
Four reviewers extracted data into evidence tables.  Extracted data were verified by another 
researcher.  Elements included study name, study year, study design, location of the SIF, study 
inclusion and exclusion criteria, description of study populations, sample size, duration of follow-up, 
exposure, outcome assessments, findings, and quality assessment for each study.  The report 
utilized the 12-item and 14-item study quality assessment criteria published by NHBLI for cohort, 
cross-sectional, and before-and-after (pre-post) studies, using the categories “good,” “fair,” or 
“poor.”116  For more information on data extraction and quality assessment, refer to Appendix D. 
Assessment of Level of Certainty in Evidence 
We used the ICER Evidence Rating Matrix to evaluate the level of certainty in the available evidence 
of a net health benefit among each of the interventions of focus (see Appendix D1).117,118  
Assessment of Bias 
It is customary at ICER to assess for publication bias as part of a review.  We have no systematic way 
to conduct such an assessment on this topic.  Many published reports about SIFs are linked to those 
who provide the services.  As such, apart from the greater perceived difficulty in publishing reports 
showing negative results, there may be an additional preference to report favorable results. 
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Data Synthesis and Statistical Analyses 
Data for the available evidence on outcomes of interest are summarized in evidence tables (see 
Appendix D2) and are synthesized in the text on the following pages.  Relevant data include those 
listed in the data extraction section.  Studies that were deemed sufficiently similar in terms of 
population, intervention type, and outcome definitions were included in the synthesis.  
Due to the unavailability of RCTs among PWID to assess the implementation of SIFs, we have 
summarized the best available evidence from a comparative cohort, experimental or pre-post, and 
other observational studies.  Due to differences between the studies in terms of the study design, 
population characteristics, and outcomes (including definitions and methods of assessments), we 
were unable to conduct a quantitative assessment.  Hence, our review provides a narrative 
description of the outcomes of interest. 
4.3 Results 
Study Selection 
Our literature search identified a total of 1188 potentially relevant references for SIFs (see Appendix 
D2), and we included 48 studies that evaluated individual or community level outcomes for SIFs.  
The majority of studies evaluated SIFs from Canada (n=33), and the remaining studies evaluated 
SIFs in Australia (n=8) and European countries (n=7, including, two from Germany, three from 
Denmark, and two from Spain). Eighteen studies used a cohort study design, while others employed 
a pre-post ecological or time series (n=11), and cross-sectional study design (n=10).  Nine studies 
used a qualitative, exploratory, or descriptive study design.  We also included government 
sanctioned evaluation reports from MSIC in Sydney, Australia, the MSIR in North Richmond 
Australia, and the SCSs in Alberta, Canada.  
The primary reasons for study exclusion included outcomes that were outside the scope of this 
review, different study populations of interest, feasibility or mathematical simulation studies, or 
conference abstracts that reported duplicative data to the full publications.  In the results that 
follow, we focus on the effectiveness and implementation of SIFs on individual-level outcomes, 
community and environmental outcomes, and health system utilization outcomes.  
We also searched for systematic reviews of SSPs and identified a total of 72 potentially relevant 
references.  We included one review of reviews25 that summarized results from 13 prior systematic 
reviews as well as three recent systematic reviews not included in the review of reviews.26-28  
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Overview of Studies 
As mentioned previously, evidence for SIFs arises primarily from ongoing prospective cohort studies 
in Vancouver, Canada.  The Vancouver Injection Drug Users Study (VIDUS), AIDS Care Cohort to 
Evaluate Access to Survival Services (ACCESS), and Scientific Evaluation of Supervised Injecting 
(SEOSI) are among the longest-running community recruited prospective cohorts of PWUD 
(recruitment since May 1996).  In addition, data from cohorts enrolled from MSIC in Sydney and 
MSIR in North Richmond in Australia (SUPERMix cohort) have also been included in this assessment.  
Overall, the included studies for SIFs were comparable with respect to age (median: 30 years, range: 
25-60) and gender (males >50%).  However, there was some variation in the exposure assessment 
based of the frequency of SIF use ranging from PWID who use a SIF versus do not use a SIF, 
frequent versus rare/occasional use, PWID administering ≥75% versus <75% of their injections in 
the SIF, or used the SIF at least once versus never during the study period. PWID experiencing 
unstable housing or homelessness also varied from country to country.  Further, unstable housing 
or homelessness was not reported consistently and ranged between 17%-82% across the studies.  
Additional details of included references, their key characteristics, and main findings are 
summarized in Appendix D2. 
To determine the incremental benefit of implementing a SIF versus an SSP alone, we included 
systematic reviews of SSPs as noted above to understand the effects of SSPs.  The included 
systematic reviews evaluated the effect of SSPs on injection risk behaviors (IRBs), HIV, or HCV.  We 
did not find evidence from systematic reviews on the effects of SSPs for other outcomes included in 
our scope (e.g., access to MAT, overdose mortality); therefore, we have limited our review of the 
evidence of SSPs to infection prevention.  We acknowledge, however, SSPs have benefits beyond 
infection prevention, as noted in the CDC summary in the background section, such as increasing 
the likelihood of entering treatment.119  
However, the primary basis of our assessment of the incremental benefit of SIFs over pre-existing 
SSPs is derived from the studies evaluating the effects of SIFs as described above.  We are assuming 
that PWID had access to SSPs during the study period, and the outcomes associated with SIFs are 
informing the added benefits of SIFs over baseline SSP access.  We acknowledge, however, that the 
proportion who utilized services from SSPs is unclear, although the literature has suggested a 
considerable proportion of PWID access SSPs.120 
Quality of Individual Studies 
We used the National Heart, Blood and Lung Institute (NHBLI) criteria to rate the quality of the 
included evidence (see Appendix D).116 For the cohort, and cross-sectional study designs, we used a 
14-item NHBLI quality assessment inventory. For the pre-post and time series studies, we used the 
12-item NHBLI quality assessment inventory.  The studies were rated “good”, “fair”, or “poor.”  
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These tools included items for evaluating potential flaws in study methods or implementation, 
including sources of bias (e.g., population selection, performance, attrition, and detection), 
confounding, study power, the strength of causality in the association between interventions and 
outcomes, and other factors.  
We only rated the studies that were published in peer-reviewed journals.  We did not assign a 
quality rating to qualitative, exploratory, or descriptive studies.  In addition, we did not assign 
quality ratings to references obtained from the grey literature (e.g., evaluation reports).  Overall, 
the cohort and pre-post studies included in this review were rated good to fair; these studies had 
the least or some risk of bias but deemed not sufficient to invalidate its results.  These studies 
considered some, but not all-important outcomes and used acceptable measures that were 
generally applied equally.  On the other hand, all the cross-sectional studies were rated to be of fair 
to poor quality.  
Health-Related Quality of Life 
SIFs contribute towards a reduction in overdose-related events, infections, and other individual-
level outcomes as discussed before.  While we did not identify any quantitative evidence directly 
assessing these improvements in the health-related quality of life of PWID, these potentials for a SIF 
have been regarded to improve the quality of life of PWID.  We identified one qualitative study on 
people living with HIV who use drugs at Dr. Peter Center in Vancouver, Canada.  The study 
participants described the positive impacts of this harm reduction policy on their quality of life.  The 
participants also mentioned increased access to social, health, and broader environmental support 
services that led to an improvement in their overall health.44 
Clinical Benefits  
All-Cause Mortality 
There is an increased risk of premature mortality leading to a decrease in the life expectancy of 
PWID in the US.1,121  Beyond age 15, life expectancy in the US (1999-2016) due to drug use was 
estimated to cost men 1.4 years and women 0.7 years, on average.122  In Canada, premature 
mortality was 13 and 54 times higher among young men and women who inject drugs as compared 
to the general population.123  However, there is very limited evidence on the effect of SIFs on all-
cause mortality. One study conducted using data from two Canadian prospective cohorts reported 
that frequent use of SIFs was significantly associated with a lower risk of all-cause mortality 
(adjusted HR[aHR]: 0.46; 95% CI: 0.26-0.80, p=0.006).  The crude mortality rate of the 811 SIF clients 
in the study was 22.7 deaths per 1000 person-years, which translates to 34 years (median, IQR 27–
42) of potential life-years lost for the 13.8% who died during the study period.31 
 
©Institute for Clinical and Economic Review, 2020 Page 22 
Evidence Report – Supervised Injection Facilities Return to Table of Contents 
Overdose Mortality within SIFs 
The published evidence on overdose mortality within the SIFs suggests that no client has ever 
experienced overdose death within the facility.29,30  
In a qualitative study from Vancouver, clients reported that staff was available to rapidly respond to 
an overdose event, and injecting at a SIF in the presence of a nurse saved many lives that would 
have otherwise been lost.124 
We also heard from multiple people who work at SIFs that they know of no episodes of a client 
dying at a SIF from an overdose.  One stakeholder cited data from an unsanctioned SIF that 
operates at an undisclosed location in the United States.14  Many interviewees pointed to the 
increased risk of mortality associated with clients who live in isolation and therefore inject alone.  
Without a partner or observer, overdoses that occur when injecting alone can have fatal 
consequences.  Experts highlighted how SIFs address a specific and large group of PWUD whose risk 
for overdose mortality is elevated due to social isolation.    
Overdose Mortality within Communities 
A population-based study in Vancouver, Canada evaluated the effects of Insite on overdose 
mortality.12 Researchers assessed overdose mortality stratified by pre-and post-SIF within and 
beyond the 500 m area around the facility. The data were obtained from the British Columbia 
Coroners Service’s registry for deaths caused by overdose, before the opening of the SIF (January 
2001 to September 2003) and after the opening of the SIF (September 21, 2003, to December 
2005).  The SIF opening was associated with a significant reduction of 35% in overdose mortality 
within 500 m of the facility (absolute reduction in overdose mortality rates from 254 to 165 per 
100,000-PYs, rate difference (RD): 89 per 100,000-PYs; 95% CI: 1.6 to 175.8, p=0.048), compared to 
a 9.3% decline in the rest of the city (Table 4.1; RD: 0.7, 95% CI: -1.3 to 2.7, p=0.49). The authors 
noted that most SIF users (70%) lived within four blocks of the facility.12  
Table 4.1 Overdose Rates in the Vicinity of a SIF and Beyond (table adapted from Marshall et al. 
2011)12 
 
Overdoses within 500 m of SIF  Overdoses farther than 500 m of SIF 
Pre-SIF Post-SIF Pre-SIF Post-SIF 
Number of overdoses 56 33 113 88 
Overdose rate (95% CI)* 254 (187 to 320) 165 (108 to 221) 7.6 (6.2 to 9.0) 6.9 (5.5 to 8.4) 
Rate difference (95% 









- 35.0% (0.0 to 57.7) - 9.3% (-19.8 to 31.4) 
SIF: supervised injection facility, CI: confidence interval; Pre-SIF period= January 1, 2001 to September 20, 2003. 
Post-SIF period= September 21, 2003 to December 31, 2005 
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*Expressed in units of per 100,000 person-years 
 
Non-Fatal Overdose and Health Care Utilization for Overdose 
Non-fatal overdose events within a SIF have been captured by looking at events where SIF staff 
intervened by administering naloxone and/or oxygen or by calling EMS.32,33  We identified three 
studies that evaluated the effect of SIF use on non-fatal overdose and overdose requiring EMS, 
ambulance, or hospital care.  
A study from Insite from March 2004 to August 2005 found 285 unique users who experienced 336 
non-fatal overdose events.  Of these overdose events, 28% resulted in a transfer to hospital, and 
27% resulted in the administration of naloxone.32  A recent time-series analysis of SIF users at Insite 
reported that the overdose rate per 1000 visits increased from 2010 to 2017 (1.5 vs 9.5, p<0.001) 
with an increase in overdose events requiring naloxone administration (48.4% to 57.1%, p<0.001) 
but no overdose deaths were reported within the facility.33 
In a 2007 study by the New South Wales (NSW) Health Department in Sydney, Australia, opioid 
overdose-related ambulance calls were analyzed in Sydney over 36 months pre-SIF and 60 months 
post-SIF.  The SIF opening was associated with a greater reduction in ambulance calls for opioid-
related overdose events in the vicinity of the SIF compared to the rest of NSW (68% vs 61% decline, 
p=0.002).34  This effect was even higher during operating hours of the SIF (80% vs 60% decline, 
p<0.001).  
Changes in the Drug Supply and Injected Drug Class  
Changes in drug class and composition over time, especially a recent increase in the presence of 
fentanyl or its analogs, have caused a huge public health burden by adding to the toll of overdose 
mortality.125  The latest reports from Insite suggest that atypical overdose presentations (muscle 
rigidity, dyskinesia, or confusion) increased from 23% of overdoses in 2015 to 41% in 2017; 15% of 
atypical overdoses required transportation to a hospital via ambulance.126  The authors felt that this 
increase might be caused by fentanyl contamination in the illicit drug supply. As noted previously, a 
recent time series analysis from Insite reported that overdose rates increased significantly for all 
drug categories.  Also, the overdose rate associated with heroin increased from 2.7 per 1000 visits 
to 13 per 1000 visits over the study period.  Compared to the baseline period, SIF users in the most 
recent period had 10.4 times the risk of overdose following cocaine consumption, 4.8 times the risk 
of overdose following heroin consumption, and 2.5 times the risk of overdose following 
consumption of other opioids.33 
Likewise, in Sydney, Australia, a retrospective clinical audit of MSIC (2012-2015) reported that 
about 44 of 1000 injections contained fentanyl and with 4.4% of injections containing fentanyl 
resulted in an overdose.  Further, fentanyl users were 2.2 to 8.0 times more likely to experience an 
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overdose than heroin and other prescription opioid users (p<0.001).127  In Denmark during 2007-
2014 a prospective analysis reported that there were 12.7 heroin overdoses per 1000 injections 
compared to 4.1 oxycodone overdoses per 1000 injections.128 
A stakeholder pointed to a 5-year study of an unsanctioned SIF in the United States that 
documented a shift in types of drugs injected -- from about 85% of injections being opioid only in 
2014 to just 30% in 2019 when using a combination of opioid and stimulants (e.g., cocaine, 
methamphetamine) became common.14  Other experts described substantial variation and changes 
in the drug supply chain by region (e.g., black tar, white powder, fentanyl), polydrug use, and 
smoked products as major issues when studying harm reduction strategies.  In pursuit of identifying 
changes in drug supply that increase risk for overdose, SIFs have responded to changes in the drug 
supply chain by analyzing drug composition (e.g., fentanyl), using fentanyl testing strips and other 
devices such as mass spectrometers.   
Injection Risk Behaviors   
As noted earlier, injection drug use increases the risk of transmission of viral and bacterial 
infections.  Reducing injection risk behaviors (IRBs) is important in reducing the risk of infectious 
disease transmission.35 1101  The evidence on the effect of SIFs on the incidence of infections over 
time is limited given the methodological challenges described previously.129,130  However, the effect 
of SIFs on reducing IRBs as well as increasing uptake of safer injection education is well-established 
and serves as the primary basis of our evaluation of  the effect of SIFs on infections.   
We identified seven studies that evaluated the effect of SIFs on reducing IRBs, including four studies 
from Vancouver and three studies from European countries (Denmark, Germany, and Spain).  Most 
studies reported SIF use was associated with a reduction in IRBs.  
A cross-sectional analysis of 431 PWID in Vancouver (data derived from VIDUS cohort) found that 
use of a SIF for all, most, or some injections compared to SIF use for no or few injections was 
independently associated with reduced syringe sharing (adjusted OR [aOR]: 0.30; 95% CI: 0.11 to 
0.82; p=0.02).36  The authors found that the rates of syringe sharing were similar in the two groups 
before the SIF opened, and differences only emerged after the SIF opened; this finding suggests 
that the observed association was not confounded by an inherently lower risk of syringe sharing 
among those who used the SIF.  
 
Two cross-sectional studies among PWID attending Insite (SEOSI cohort) reported that more 
frequent SIF use was associated with reductions in IRBs.  A study of 760 PWID found consistent SIF 
use (≥25% of injections) compared to inconsistent SIF use  (<25%) was positively associated with 
reductions in many IRBs, including less reuse of syringes (aOR: 2.04; 95% CI: 1.38 to 3.01), less 
rushed injection (aOR: 2.79; 95% CI: 2.03 to 3.85), less outdoor injection (aOR: 2.70; 95% CI: 1.98 to 
3.87), using clean water (aOR: 2.99; 95% CI: 2.13 to 4.18), cooking/filtering drugs prior to injection 
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(aOR: 2.76; 95% CI: 1.84 to 4.15), safer syringe disposal (aOR: 2.13;  95% CI: 1.47-3.09), injecting in a 
clean place (aOR: 2.85; 95% CI: 1.83 to 3.86), and others.131  Another study of 582 PWID found 
exclusive SIF use (i.e., use of SIF for 100% of injections) compared to some SIF use was associated 
with reduced syringe sharing among HIV-negative individuals (OR: 0.14; 95% CI 0.00 to 0.78) but 
was not significantly associated with reduced syringe lending among HIV-positive individuals (OR: 
0.94; 95% CI 0.00 to 7.90).132  Lastly, another cross-sectional study of 1082 PWID found 75% of 
participants had perceived reductions in IRBs since the opening of the SIF. Among those who 
reported perceived changes in IRBs, 80% reported reductions in rushed injections, 71% reported 
less outdoor injections, 56% reported less unsafe syringe disposal, and 37% reported using syringes 
less often.13  Of note, these three cross-sectional studies among PWID in the SEOSI cohort had 
overlapping study periods (Stolz: March ’04 to October ’04; Wood: July ’04 to June ’05; Petrar: 
December ’03 to September ’05). 
 
We also identified three studies from European countries including Denmark, Germany, and Spain.  
A cross-sectional study of 41 PWID in Denmark found 76% of participants reported perceived 
reductions in IRBs since the opening of the SIF, including less rushed injections (63%), fewer 
outdoor injections (56%), ceasing to share syringes (54%), and cleaning injection site more often 
(44%).56  A prospective cohort study of 129 PWID in Germany found no changes in IRBs after three 
months of SIF use.43  A cross-sectional study of 249 young heroin users in Spain found SIF use was 
significantly associated with not borrowing used syringes (OR: 3.3, 95% CI: 1.4 to 7.7); of note, 96% 
of participants reported using an SSP during the reference period.133  
 
A meta-analysis combined results from three of the studies described above (Wood 2005, Kerr 
2005, and Bravo 2009) and found SIF use was associated with a 69% reduction in the likelihood of 
syringe sharing (pooled effect: 0.31; 95% CI: 0.17 to 0.55).37 
 
Stakeholders noted SIFs are effective in reducing IRBs by providing a clean, safe space to inject in a 
less rushed manner.  They described an advantage SIFs have in education and supporting safer IRBs, 
attributable to the SIF’s ability to build trust and relationships with clients over time. 
 
In our review of SSPs, six of the thirteen systematic reviews included in the review of reviews 
examined IRBs, two of which performed meta-analyses.  An earlier meta-analysis pooled results 
from 10 studies and found SSPs reduced HIV risk behaviors (weighted group mean effect size: 0.28; 
95% CI: 0.21 to 0.35).134  The other meta-analysis examined the effect of high SSP coverage plus 
opioid substitution treatment (OST) and found a reduced likelihood of syringe sharing (aOR: 0.52, 
95% CI: 0.32 to 0.83)41; of note, this review only included studies conducted in the UK and reported 
the effect of full harm reduction (i.e., high SSP coverage and OST) on IRBs as opposed to the effect 
of just SSPs.  The other reviews provided a qualitative synthesis that generally supported SSPs’ 
reduction in IRBs.   
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Safer Injection Education  
We identified three studies that reported the uptake of safer injection education (SIE) at SIFs.  All 
studies were among PWID attending Insite (SEOSI cohort).  One prospective study of 1087 PWID 
found frequent SIF use (≥75% of injections) compared to less frequent use (<75% of injections) was 
associated with an increased likelihood of receiving SIE in multivariate analyses (aOR: 1.47, 95% CI: 
1.22, 1.77),135 and one cross-sectional study of 874 PWID found daily SIF use was marginally 
associated with receiving SIE in univariate analyses (p=0.085).136  Lastly, in one qualitative study, 
narratives from 50 participants showed the SIF allows participants to identify gaps in safer injection 
knowledge by providing targeted educational messages and demonstrations of safer techniques as 
well as by promoting meaningful relationships with health care professionals.  In addition, 
participants said the environment of the SIF incites safer injecting practices over time, including 
within and outside of the SIF.137 
 
Infection Prevalence/Incidence 
We identified four studies that provided evidence on the effect of SIFs on infection incidence and 
prevalence, most of which were not designed to detect differences, specifically in rates of HIV or 
HCV.  
Viral Infections 
A cross-sectional study of 510 PWID who attended a SIF in Catalonia, Spain found that there were 
no significant differences in the prevalence of HIV or HCV among those who had frequent SIF 
attendance (i.e., daily), medium SIF attendance (i.e., > half of days), and low SIF attendance (i.e., ≤ 
half of the days).38  In a qualitative study among 22 PWID and seven staff members at the Harm 
Reduction Room in the Dr. Peter Centre in Vancouver, staff members perceived that there was a 
reduction in infections that could be potentially attributed to having a safer place to inject and safer 
injection education.138 
Much more extensive evidence exists for the effects of SSPs on viral infections.  Nine of the thirteen 
systematic reviews included in reviews of reviews examined the incidence of HIV, including one 
meta-analysis.  The meta-analysis pooled results from 10 studies and found a trend towards a 
reduced risk of HIV transmission with SSPs, although the results were not significant (effect size: 
0.66; 95% CI: 0.43 to 1.01).39  However, when pooling results from six higher-quality studies, a 
significant reduction was observed (effect size: 0.42; 95% CI 0.22 to 0.81).  Other reviews provided a 
qualitative synthesis, and their conclusions generally supported the findings of the meta-analysis.  
However, a more recent meta-analysis not included in the review of reviews found SSP use was 
associated with an increased risk of HIV seroconversion when pooling results from two studies (HR: 
1.59; 95% CI: 1.2 to 2.1).27 
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Eight of the thirteen systematic reviews included in reviews of reviews examined the incidence of 
HCV, including two meta-analyses.  One meta-analysis pooled results from seven studies and found 
an increased risk of acquiring HCV with SSPs (RR: 1.62; 95% CI: 1.04 to 2.52).40 There was substantial 
heterogeneity (I2=81%), and the authors did not conduct any sensitivity or subgroup analyses.  The 
authors noted that studies included in their analysis may have been affected by volunteer bias as 
SSPs may attract higher-risk PWID.  The other meta-analysis included three studies conducted in the 
UK and found high SSP coverage was associated with a reduced risk of HCV transmission (aOR: 0.48, 
95% CI: 0.25 to 0.93).41  The other systematic reviews provided a qualitative synthesis and results 
were mixed; these reviews also included many earlier studies that were not included in the meta-
analyses.  
We identified two meta-analyses published after the reviews of reviews that provide additional, 
recent context.  A meta-analysis by Cochrane found a trend towards reduced risk of HCV with high 
SSP coverage, although the results were not significant (RR: 0.79; 95% CI: 0.39 to 1.61); this analysis 
combined studies from North America and Europe, and there was high heterogeneity (I2=77%).28 
When stratified by region, high SSP coverage in Europe was associated with a significant reduction 
in risk of HCV acquisition (RR: 0.24; 95% CI 0.09 to 0.62). Another meta-analysis analyzed results 
from studies reporting ORs and HRs separately and found no association when analyzing ORs (OR 
0.51, 95% CI 0.05 to 5.15) but an increased risk when analyzing HRs (HR 2.05, 95% CI  1.39 to 
3.03).26  There is continued uncertainty from published research around SSPs’ effects on viral 
infections although results are likely affected by selection biases, and we urge caution when 
interpreting these results.  
Expert stakeholders we interviewed felt that the infection control benefits of SSPs are obvious and 
HIV and HCV incidence rates would rise quickly if the service were removed from a community 
given the high-risk profiles of clients of SSPs.  Experts pointed out that SIFs serve clients at even 
higher risk than SSPs.  Stakeholders believed that SIFs play an important role in reducing the 
transmission of infections, but it is difficult to measure the impact due to variable baseline rates of 
HCV and HIV among PWID in different communities.  Additionally, stakeholders noted that SIFs 
have been effective in referring clients to HCV treatment.   
Bacterial Infections 
A prospective cohort of 1065 PWID attending Insite (SEOSI cohort) found the use of SIF for all 
injections versus some injections was associated with a decreased likelihood of developing a 
cutaneous injection-related infection (CIRI) (OR: 0.47; 95% CI: 0.23 to 0.94) in univariate analyses;  
in multivariate analyses, the aOR was 0.58 and was no longer statistically significant (95% CI: 0.29 to 
1.19).42  A prospective cohort study of 129 PWID attending a DCF in Essen, Germany found no 
statistically significant reduction in injection-related abscesses.43  
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Stakeholders noted that SIFs can be effective in preventing bacterial infections such as endocarditis 
and can provide or encourage wound care.  One expert noted that SIFs have an advantage over 
other harm reduction strategies in detecting and intervening early on common soft tissue disease.  
This advantage was attributed to the frequency that clients visit SIFs and how staff build 
relationships with clients that permit discussion and intervention to prevent serious wound 
infections. 
Health Care Utilization for Infections  
We identified two studies that provided evidence on the effect of SIFs on health care utilization for 
infections among PWID attending Insite (SEOSI). 
A prospective cohort study of 1083 PWID found that over a median follow-up of 21.4 months, 9% of 
participants were admitted to the hospital of whom 49% were admitted for CIRI or complications.139 
In multivariate analysis, referral to the hospital by a SIF nurse was significantly associated with an 
increased likelihood of hospitalization for CIRI (aOR: 5.38; 95% CI: 3.39, 8.55). Participants referred 
to the hospital by a SIF nurse had shorter hospital stays compared to those who were not referred 
by a SIF nurse (4 days [IQR: 2-7] vs 12 days [IQR: 5-33], p=0.001 after adjustment). A similar analysis 
of 1083 PWID found that over a median follow-up of 18.6 months, 27% of participants visited the 
ED for a CIRI.  Referral by a SIF nurse was significantly associated with ED use for CIRI among 
females (aHR: 4.48; 95% CI: 2.76 to 7.30) and males (aHR: 2.97; 95%CI: 1.93 to 4.57).140   
Hospitalization for bacterial infections including endocarditis have not been reported directly in 
studies that assessed the effect of SIF use on health care utilization for infections.  However, a 
comment received during the public review period noted the large scale of infections and the 
burden placed on the healthcare system.  It is estimated that anywhere between 5% and 20% of 
people who inject drugs (PWID) have had infective endocarditis and related hospitalizations 
increased between 2000 and 2013, especially for young adults.141  
Intermediate Outcomes 
Uptake of Services 
SIFs may facilitate access to various services programs for PWID and in turn enable them to access 
and utilize services like treatment and recovery, health, and social services.  
Treatment and Recovery Support Services 
We identified six studies that assessed the impact of SIFs on treatment and recovery support 
services.  Across studies, the use of SIFs was associated with a higher uptake of treatment and 
recovery services. 
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A recent two-year prospective assessment of Insite reported that 11.2% of clients were enrolled in 
the co-located detoxification services at least once and frequent SIF users were more likely to enroll 
and use this service compared to non-frequent (less than once per week) users (aOR:8.15, 95% CI: 
5.38-12.34, p<0.001).45 
Three prospective studies from the SEOSI cohort reported associations between SIF use and rate of 
rapid entry into the detoxification treatment or service.  In these overlapping analyses, SIF use and 
contact with an addiction counselor led to a significant increase in detoxification uptake, resulting in 
rapid entry into methadone maintenance treatment.46-48  A prospective study found that weekly SIF 
use was positively associated with enrollment in addiction treatment and increased likelihood of 
injection cessation.47 
In Sydney Australia, a prospective study from 2001-2002 reported that frequent use of an SCS was 
positively associated with receiving a referral to a detoxification program (aOR:1.6, 95% CI: 1.2-
2.2).49  Similar findings were reported from Catalonia (Spain), with PWID who utilized a SIF having a 
significantly higher likelihood of accessing drug dependence services (aOR: 2.12, 95% CI: 1.18-
3.81).38 
Health and Social Services 
We identified seven studies that assessed the impact of SIFs on health and social services.  Broadly, 
across studies, the use of SIF was associated with increased access to health and social services.  
As described previously, PWID in Vancouver with cutaneous injection-related infections when 
referred by SIF nurse to the hospital was associated with an increased likelihood of admission 
resulting in a decrease in the average length of stay by 8 days.139  Across studies, higher use of 
ancillary services has also been reported for PWID who utilized SIF frequently compared to those 
who used them occasionally or rarely.  
A multi-country study in Europe reported an association between frequent supervised drug 
consumption facility use (compared with occasional or rare use) and a greater likelihood of 
accessing counseling services (46% vs 35% and 25%; p<0.01), medical services (37% vs 29% and 
17%, p<0.01), syringe exchange services (59% vs 54% and 44%, p<0.05), and education on safer use 
(9% vs 3% and 3%, p<0.05).50  A cross-sectional analysis in Denmark also reported that clients who 
used the facility frequently were more than twice as likely to receive treatment for an acute health 
condition compared to non-users.51 
These observations are in line with the qualitative and exploratory evidence where SIF users have 
reported greater access to care and treatment with fewer structural and social barriers as a result of 
services being provided at one accessible location.50,51,142  In a study from Dr. Peters Centre, 
Vancouver, PWID who were HIV positive highlighted that they felt comfortable discussing their drug 
use and health needs with the staff. They also noted that the harm reduction approach used at DPC 
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led to an increase in access to health care services including palliative and supportive care.44 
Likewise, qualitative evidence collected from 50 in-depth interviews indicated that SIF use facilitates 
access to care, although a minority of participants expressed otherwise. The PWID described that 
having on-site nurses at a SIF helped in providing assessment and care for injection-related 
infections as well as facilitating access to off-site health care services.143,144 
Expert stakeholders felt that access to treatment, social services, recovery services, and referrals is 
important to SIF users.  They also felt that allowing people an opportunity to enroll in treatment 
services reduces mortality.  However, agreeing to enroll in MAT or other addiction treatment 
services can take time and may depend on the client’s comfort and trust in the facility.  In cases 
where people visit SIFs frequently, the relationship can be fostered by providing more points of 
contact and a stress-free and safe environment for clients.  
Drug Consumption (e.g., frequency and amount) 
We only identified one study that assessed changes in drug consumption associated with the use of 
SIFs.  A pre-post study from Vancouver reported no substantial differences in relapse rates for 
injection drug use or stopping drug use pre- and post-SIF opening.  The authors acknowledged that 
there was an increase in smoking crack after SIF opening but it is unlikely that the facility which 
does not allow smoking could have prompted this change.52 
Community and Environmental Outcomes 
Some of the key concerns regarding the implementation of SIFs relate to community and 
environmental issues including public drug use, syringe and paraphernalia disposal, and drug-
related crime.  
Public Drug Use and Syringe or Paraphernalia Disposal 
Five studies assessed the role of SIFs in addressing public drug use and syringe and paraphernalia 
disposal associated with injection drug use.  
 
An ecological study post-SIF opening in Vancouver Canada reported statistically significant 
reductions in public injection drug use (measured by researcher counts), compared to pre-SIF 
opening (daily mean: 4.3 vs 2.4, p<0.001).  At the same facility, publicly discarded syringes (daily 
mean: 11.5 vs 5.4, p<0.05) and injection-related litter (daily mean: 601.7 vs 305.3, p=0.01) also 
reduced after SIF opening.  These declines were independent of police presence and weather 
conditions.53  A retrospective cohort study among 714 PWID attending a SIF reported that increased 




©Institute for Clinical and Economic Review, 2020 Page 31 
Evidence Report – Supervised Injection Facilities Return to Table of Contents 
In Sydney, Australia, a time-series study reported that after a SIF opened there was a perceived 
decline in the proportion of residents and business owners witnessing public injections (19% vs 
33%, p<0.001) and discarded syringes (40% vs 67%, p<0.001).55  A study of a SIF opening in 
Copenhagen (Denmark) reported a 56% reduction in public injections as well as a significant 
improvement in safe syringe disposal (59%, p <0.001).56 In contrast, over a three-month period a 
prospective cohort study from Essen (Germany) reported no significant effect of a SIF on public 
drug use.43 
 
In a study of DCRs in Denmark, 71% of users also noted that they chose the SIF for drug-use as they 
were conscious of public drug use bothering people in the neighborhood.51 
Drug-Related Crime  
An important aspect of harm reduction with SIFs is promoting (or at least not worsening) 
neighborhood safety.  We identified six studies that assessed the association of the SIF opening on 
drug-related crime and/or neighborhood safety.  
 
Three studies conducted in Sydney, Australia reported that opening of the SIF did not result in a 
significant increase or decrease in crime (i.e., theft, drug-related loitering, or robbery).57-59  After the 
opening of the SIF, a slight increase was reported for overall loitering at the front and back of the 
SIF.57  Additionally, a prospective study conducted from 1999 to 2010 reported a significant decline 
in robbery and property offenses both in the vicinity of the SIF and across the city. Of note, the 
rates of drug-related crimes declined between 1999 to 2003 and then remained constant until the 
end of the study period.  However, the authors found no association of the SIF (Sydney MSIC) with 
robbery, property crime, or drug offenses.58 In contrast, a separate pre-post study in 2013 reported 
a decline in robbery or thefts in the neighborhood after the SIF was opened.59  This study also found 
that between 2001-2008, possession of illicit substances remained stable while increases were 
reported both in the SIF neighborhood and citywide from 2009 onwards.  
 
Similar observations were reported from Vancouver, Canada in an ecological (pre-post) study with 
no significant changes in robbery or drug trafficking.60  However, compared to the pre-SIF opening, 
a decline in vehicle break-ins (302 vs 227, p<0.001) was observed post-SIF opening. Two studies—
one prospective cohort and another a time-series analysis—also reported that among SIF users, 
frequent use of SIFs was not associated with crime or recent incarceration.61,62 
 
The presence of and interactions with law enforcement may have affected the estimates but were 
not accounted for in these studies.  However, studies do not appear to show an increase in crime 
when a SIF is opened.  Furthermore, the evidence on drug-related crime is in line with observations 
shared by the experts during interviews. 
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Government Sanctioned Evaluation Reports for SIFs 
Uniting Medically Supervised Injecting Centre (MSIC) Sydney, Australia 
In May 2001, Uniting MSIC was established in Kings Cross, Sydney under a license issued by the 
government of New South Wales (NSW).  A first evaluation report was published in 2003 to cover 
the first 18 months of operation.145  In response to the evaluation results, the operation license was 
then extended.  A second set of evaluation reports was then commissioned by the NSW 
government146-149 that assessed the impact of Uniting MSIC on a range of individual outcomes (e.g., 
overdose) and community outcomes (e.g., syringe and needle disposal). A total of 9778 PWID used 
this SIF from May 2001 to April 2007, a majority of whom were male (70%) with a mean age of 33 
years.  About 40% of SIF users injected daily, and 24% were living in unstable housing.  The most 
injected drugs on-site were heroin (62%), other opioids (12%), cocaine (14%), and 
meth/amphetamines (6%).  
During these years of operation, the SIF managed 2,106 overdose-related events on-site, without a 
single death within the facility.  Between May 1998 (pre-SIF) and April 2006 (post-SIF), a significant 
decline in overdose mortality was reported both in proximity to the SIF (mean: 4 vs 1 death per 
month, p<0.001) as well as in the rest of the city (mean: 27 vs 8 deaths per month, p<0.001). A 
decline in mean monthly ambulance attendances was reported near the SIF, compared to the rest 
of the city (mean: 61% vs 68% monthly ambulance attendances, p=0.002); the percentage decline 
was reported to be higher during operational hours of the SIF. After the SIF opening, a 35% 
reduction was reported for average monthly opioid poisoning presentation at the ED compared to 
before the SIF opening (11 vs 7, p<0.01).  
In addition, there was a downward trend in reporting public injecting among SIF users between 
2001-2004 as well as in witnessing public injecting among residents and business operators 
between 2000-2005.  In addition, residents and business operators also reported seeing less 
discarded syringe in the past month between 2000-2005.  The monthly totals of discarded needles 
and syringes collected locally signaled about a 50% decrease in syringe litter following the 
establishment of the SIF; this was sustained between May 2001- April 2007.  
Medically Supervised Injection Room in North Richmond, Australia  
In October 2017, the Victorian government announced a two-year trial (June 2018 to June 2020) of 
a Medically Supervised Injection Room (MSIR) in North Richmond, Australia, with the possibility of a 
trial extension.  An independent review panel evaluated the impact of the SIF during the first 18 
months of the trial, and a report was published in June 2020.150  During the first 18 months, almost 
4,000 people visited the SIF; the average age of the clients was 41 years and 35% were living with 
homelessness or insecure accommodation. There were 116,802 supervised injections (96.6% 
involving heroin), 2,657 overdoses, and no deaths within the facility.  
 
©Institute for Clinical and Economic Review, 2020 Page 33 
Evidence Report – Supervised Injection Facilities Return to Table of Contents 
Ambulance calls involving naloxone reduced by 25% within 1 kilometer after the SIF opened; the 
decline was even greater during hours of SIF operation, with a reduction of 36%.150  
There was a decrease in the proportion of residents and business respondents reporting they had 
seen public injections since the SIF opened (p<0.05 for both groups).  There was no change in the 
proportions of residents reporting they had seen discarded syringes or needles, but there was an 
increase among business respondents).  There was an increase in the number of syringes and 
needles collected after the SIF opened, but there were also increased collection efforts during the 
last eight months of the trial.150 
The number and types of offenses within 1 kilometer of the SIF generally remained stable between 
2014 to 2019, except for drug use and drug possession offenses.  Victoria police members reported 
seeing more buying and selling of drugs and people who appeared to be under the influence.  
Victoria police also reported that crime near the facility was largely attributable to local crime 
trends that were not connected to the MSIR trial.150  
Supervised Consumptions Services in Alberta, Canada  
In 2019, the Alberta government froze the funding for new SCSs and reviewed the socioeconomic 
impacts of existing and proposed SCSs.  A review committee conducted public consultations and a 
review of qualitative and quantitative data and a report was published in March 2020.151  
There were seven established SCSs in Alberta at the time of the review– four in Edmonton, one in 
Calgary, one in Lethbridge, and one in Grande Prairie.  Most sites had been operating for more than 
12 months.  The impact of the SCSs was generally assessed within 250 to 500 meters of the SCSs in 
this review.  
The report found there was a 64% increase in all drug and alcohol poisoning deaths within 500 
meters of the SCSs compared to a 30% increase in the 501 to 2000 meter zone outside the SCSs; the 
committee noted these deaths were predominantly related to opioids. However, the review 
committee acknowledged the role of SIFs and other SCSs in saving lives.  In addition, there was a 
74% increase in total opioid-related EMS responses within 500 meters of the SCSs.  In the 
comparison zone beyond 500 meters, an average 11% decline was reported.  Additionally, police 
calls for service (a proxy for crime in their review) had generally increased in the immediate 
vicinities around the Calgary, Lethbridge, and Grande Prairie sites but not around the four 
Edmonton sites.151  
More than 16,000 Alberta residents completed an online survey about their perceptions of the SCSs 
in their communities.  The primary complaint by residents was around needle debris.  Residents 
noted an increase in seeing needles and other drug-related paraphernalia discarded in the vicinity 
of the SCSs.  In addition, residents noted concerns around public safety, seeing people who 
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appeared under the influence, and general social disorder.151  Of note, the report did not specifically 
include feedback from clients of these SCSs or the personnel who worked there. 
At least some experts and researchers have expressed serious concerns with the methods used in 
this report, including but not limited to the lack of statistical significance testing and adjustment for 
potential confounders, and have called for it to be retracted.152 
Heterogeneity and Subgroups 
Unstable Housing 
The rates of people living with homelessness or unstable housing in the included studies varies by 
region with ranges from 17% to 82%, that causes an increased public health burden.53,55  People 
living with homelessness or in unstable housing experience multiple barriers in accessing health and 
social services especially a safe place to inject.153  Although a considerable proportion of SIF users in 
studies were experiencing homelessness or living in an unstable housing, we identified few studies 
that reported results for outcomes of interest stratified by this sub-group. 
In a prospective study from Insite, SIF users experiencing homelessness had a higher likelihood of 
entry into detoxification program (aHR: 1.42, 95% CI: 1.06-1.90, p=0.019), compared to those who 
were not.48  However, another prospective study from Insite Vancouver, Canada reported that SIF 
users experiencing homelessness had a higher likelihood of not being able to access addiction 
treatment (aOR: 1.47, 95% CI: 1.09-1.98, p=0.011).154 SIF users living in unstable housing were more 
likely to receive CIRI care (aHR = 1.39, 95% CI = 1.02–1.88, compared to those with stable 
housing.155 
A study from Insite suggests that homelessness increases the likelihood of injecting in public even 
among SIF users (aOR: 3.10, 95% CI: 1.46-6.58, p<0.001).54 
Uncertainty and Controversies 
Research Methods   
The available evidence about SIFs comes from studies with cohort and cross-sectional design.  It is 
difficult to establish temporality in some cases and make inferences about the causal association 
without a reference population or control group.    
Generalizability 
Many community factors vary considerably across cities in the world (e.g., background risk of 
bloodborne infection, community support, policing practices, access to primary medical care, 
treatment capacity and effectiveness), and the variance could impact the generalizability of 
 
©Institute for Clinical and Economic Review, 2020 Page 35 
Evidence Report – Supervised Injection Facilities Return to Table of Contents 
findings.  Some of the risks to generalizability are may be lessened by a real-world experience in 
Canada and Australia where SIFs have expanded to other cities.  For example, a new SIF in North 
Richmond (Melbourne, Australia) replicated overdose mortality protection observed in Sydney.  The 
recently published review report by the Victorian Government also notes reductions in public 
injecting and ambulance calls due to overdoses, but no improvement in perceived safety and drug-
related nuisances.   
Changes in Drug Supply   
Our assessment of SIF effectiveness relies on many studies that are at least 10 years old.  It is known 
that important community factors have changed since then, including global drug supply chains and 
user preferences.  In some parts of the world, drugs typically injected are now being smoked; 
methamphetamines, for example, are replacing opioids.  The increase in fentanyl additives to 
heroin and/or cocaine has changed the mortality risk of an overdose during the past decade.  The 
estimated mortality reduction of the SIF model studied a decade ago is based on the types and 
forms of drugs consumed at that time. 
Frequency of SIF Use 
Although published studies report a range of utilization statistics (e.g., percentage of injections per 
month occurring at a SIF), uncertainty remains about the relationship between SIF visit frequency 
and effectiveness.  It is reasonable to assume that a dose-response curve exists, especially for 
overdose mortality reduction.  It is unknown what level of SIF utilization is required to achieve 
results for infection control, all-cause mortality, and overdose mortality. 
Widespread Access to Naloxone  
Naloxone is more widespread today, with police officers, paramedics, community members, and 
PWID and their allies all having it on hand in a variety of settings.  It is unknown how much of a 
community’s overdose mortality can be reduced by a SIF versus expanded naloxone distribution to 
high-risk people and their social networks. 
Community Support  
Experts described the importance of local community support, including law enforcement, to open 
and maintain a SIF, noting that support for a SIF can erode when proposals and implementation 
plans with specific locations are presented to community stakeholders.  While there is no apparent 
evidence that SIFs attract more PWID or drug-related activity to a neighborhood, uncertainty 
remains, and concerns over local health and safety might diminish support which could, in turn, 
decrease the effectiveness of a given SIF.   
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Law Enforcement 
The contribution of law enforcement to a SIF’s effectiveness is unknown.  Interviews with experts 
pointed to the importance of collaboration with local law enforcement to assure clients could enter 
and exit the SIF without being intimidated or arrested by police officers.  The data from Vancouver 
originated from a pilot study that was supported by the police department as well as city 
government officials.156  One ethnographic study described the how the increased police presence 
in the neighborhood of a SIF intimidated clients – forcing some to continuously navigate the risks of 
arrest or overdosing alone, especially clients who have outstanding warrants.157  The ability of a SIF 
to reach PWID, cultivate support from the broader community, and deliver results (individual and 
community-level outcomes) may depend on its level of collaboration with the police.  
Notwithstanding state and federal legal issues, the controversy with and for law enforcement 
involves a concern that SIFs give people the green light to use drugs illegally.  
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4.4 Summary and Comment 
Figure 4.1. ICER Evidence Rating Matrix
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  Comparative Net Health Benefit 
   A = “Superior” - High certainty of a substantial (moderate-large) net health benefit 
B = “Incremental” - High certainty of a small net health benefit 
C = “Comparable”- High certainty of a comparable net health benefit 
D= “Negative”- High certainty of an inferior net health benefit 
B+= “Incremental or Better” – Moderate certainty of a small or substantial net health benefit, with high 
certainty of at least a small net health benefit 
C+ = “Comparable or Incremental” - Moderate certainty of a comparable or small net health benefit, with 
high certainty of at least a comparable net health benefit 
C- = “Comparable or Inferior” – Moderate certainty that the net health benefit is either comparable or 
inferior with high certainty of at best a comparable net health benefit  
C++ = “Comparable or Better” - Moderate certainty of a comparable, small, or substantial net health 
benefit, with high certainty of at least a comparable net health benefit 
P/I = “Promising but Inconclusive” - Moderate certainty of a small or substantial net health benefit, small 
likelihood of a negative net health benefit 
I = “Insufficient” – Any situation in which the level of certainty in the evidence is low 
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The review and synthesis of included evidence have been organized to demonstrate the 
contribution of a SIF to individual and population-level outcomes.  We did not identify any RCTs and 
as such, have based comparisons of SIF vs SSP on evidence from the cohort, time-series, pre-post, 
and other observational studies.  Our research process also included interviews with 37 experts, 
including 11 PWID, who provided anecdotes and helped build the framework of outcomes to 
investigate.  Given the available study designs from only a few communities, we recognize that 
differences between communities could impact generalizability.  Moreover, our rating of the 
effectiveness of a SIF considers its operations in the context of other harm reduction strategies, 
such as SSPs, which were available to clients in the included studies.  We believe that our focus on 
the incremental value of a SIF is appropriate since many communities today are exploring if a SIF fits 
within a broader portfolio of harm reduction and overdose prevention framework.   
We produced a single evidence rating using the ICER Evidence Rating Matrix (Figure 4.1), 
considering the effectiveness of a SIF in addressing the public health challenges of injection drug 
use.  We recognize that comparisons of SIF use versus no SIF, for which we have relevant data, have 
shown incremental benefits.  Evidence from both Vancouver and Sydney found a significant 
reduction in occurrences of nonfatal overdose and mortality from overdose in the SIF neighborhood 
and beyond.  Furthermore, our research team has not uncovered any report of an overdose death 
at a SIF, bolstering our confidence in this outcome.  SIFs have demonstrated an ability to assist 
clients with accessing medical, mental health, and social support services, including the use of 
addiction treatment services.  
The contribution of a SIF to bloodborne infection control is less certain in terms of direct 
measurement of disease incidence, both due to variation in the baseline infection rates and the lack 
of incremental data compared with SSPs.  SIFs do reach a population that is known to be at high risk 
for transmission of serious infectious diseases such as HIV and HCV, and the available evidence 
demonstrates improvements in injection behaviors; these improvements would be expected to 
reduce disease transmission.  We believe that unsafe injecting behaviors are an important and 
reasonable proxy for infection control since syringe sharing is implicated as primary infection source 
of new cases of HCV in the US.  In at least some locations, SIFs appear to reduce public injection 
and, sometimes, syringe and injection litter.  Finally, SIFs do not appear to be associated with 
changes in crime.    
Unlike a medication that can be manufactured reliably and administered consistently to deliver 
benefits to similar patients across the world, how a SIF is implemented can impact individual and 
community outcomes.  The intervention development, including stakeholder engagement, 
contributes to results.  Our overall assessment of the evidence does not consider the ease or 
difficulty another organization may have in setting up and running a SIF.  We assume that planning, 
stakeholder engagement, and daily management can be executed similarly to that of organizations 
in Vancouver and Sydney to produce the reported results. 
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On balance, we believe we have high certainty that, compared with SSPs, SIFs prevent overdose 
deaths.  The degree to which overdose prevention translates to substantially lengthening the life of 
the individual is uncertain.  The evidence on community overdose mortality from Marshall et al. 
201112, provides moderate-quality evidence given the drop-off in effect over distance from the SIF, 
which is akin to a dose-response effect.  This, too, provides moderate certainty of a substantial 
benefit.  We do not believe that possible harms which have been reported – some communities 
report increases in needle litter near a SIF – could reduce the net benefit below incremental.  There 
is good reason to believe the net benefit is substantial. 
Thus, we have concluded that there is high certainty that SIFs, compared with SSPs provide a small, 
or substantial net health benefit , and moderate certainty that SIFs provide a substantial net health 
benefit, leading to a rating of “incremental or better” (B+).  
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5. Cost Effectiveness  
5.1 Overview 
The primary aim of this analysis was to estimate the cost effectiveness of SIFs for IDU among PWID 
using a cost-effectiveness analysis.  The model compared SIFs to SSPs, which may provide a multi-
day or multi-week supply of clean needles and syringes to PWID or provide one-to-one exchanges 
for contaminated products.158  Because SIFs are not funded by the health care system or payers of 
health care, the base-case analysis was a modified societal perspective and a one-year time horizon.  
We also considered a health care payer perspective as a scenario analysis.  The model was 
developed in Microsoft® Excel® for Office 365 (Version 2005).  
5.2 Methods 
We developed a decision analytic model for this evaluation, with outcome calculations adapted 
from prior relevant economic models of harm reduction for PWID63-69 and informed by interviews 
among key staff and researchers of SIFs.  
The model focused on communities of PWID, specified by parameters for individual US cities, who 
could potentially utilize SIFs in locations where SSPs already exist, i.e., SIF+SSP, vs. SSP-only.  We 
calculated each setting’s outcomes over one year, based on published data and observations in 
prior published economic models.  The model did not track a single PWID cohort over time; rather, 
a population of PWID within a given community was estimated based on available data for each 
location and then outcomes for each community were calculated per year.  The costs and outcomes 
were then summed over the one-year time horizon.  We modeled six different US cities, based on 
local parameters, in order to develop a tool that may be customized to provide cost-effectiveness 
estimates for any US city given the appropriate data. 
Model Structure 
PWID within a given community entered the model in either the SIF+SSP (i.e., post-SIF) or SSP-only 
(i.e., pre-SIF) arm (Figure 5.1).  Among the total population of PWID, the number of post-SIF 
injections/month was calculated (A); all pre-SIF injections were assumed to occur without 
availability of a SIF (B).  For PWID who overdose (A1), we calculated the proportions that require 
ambulance utilization and emergency department (ED) visits.  We also calculated PWID who are on 
(A2) or not on (A3) medication-assisted treatment (MAT); among PWID who are already on MAT, we 
calculated the proportion per year who successfully stay on treatment.  Among PWID who are not 
on MAT, we calculated the proportion per year who start it.  MAT uptake and success rates were 
assumed to be equivalent between comparators in the base case, but increased MAT uptake and 
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success rates due to a SIF were explored in a scenario analysis.  These same outcomes were 
calculated for B1-3 and totals for a given community were estimated and compared.  Community 
overdose mortality (C) was estimated based on the proportion of injections in the SIF, applying a 
risk reduction estimate described below. 
Figure 5.1. Model Framework 
ED: emergency department, MAT: medication-assisted treatment, PWID: people who inject drugs, SIF: supervised 
injection facilities, SSP: syringe service program 
 
Locations 
The populations of focus for the economic evaluation included PWID at various locations in the US.  
We modeled costs and outcomes for Boston, Philadelphia, San Francisco, Atlanta, Baltimore, and 
Seattle, based on the prior existence of an SSP,70 US geographic location, and the availability of 
broad city-level estimates (Table 5.1).   
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Table 5.1. Baseline Community Characteristics 
City Characteristics Boston Philadelphia 
San 
Francisco 
Atlanta Baltimore Seattle 
Population Density 
(people/square mile)159,160 
13,943 11,692 18,581 3,858 7,594 8,391 
Commercial Property 
Value(Cost per square 
foot)161-163 
$550 $207 $300 $244 $202 $414 
Commercial Mortgage Loan 
Rates164,165 
7% 7% 7% 7% 7% 7% 
Cost of Living Ratio vs. 
Vancouver, BC166 
1.24 1.05 1.47 0.93 0.95 1.18 
Number of PWID within city 
limits167-172 
29,500* 68,800* 22,500 23,100* 42,200 26,000 
Number of Overdose 
Deaths per Year173-178 
250 1,150 330 482 692 227 
*Estimated based on city population size and average proportion of known PWID in San Francisco, Baltimore, and 
Seattle 
BC: British Columbia, PWID: people who inject drugs 
Interventions 
The list of interventions was developed with input from community organizations, clinicians, 
researchers, and government agencies on which interventions to include.  The full list of 
interventions is as follows: 
• Intervention of interest: SIF+SSP (i.e., Post-SIF) 
• Comparator intervention: SSP-Only (i.e., Pre-SIF) 
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Key Model Characteristics and Assumptions 
Table 5.2. Key Model Assumptions 
Assumption Rationale 
Hypothetical legally-sanctioned SIFs in US cities are 
comparable to Insite (Vancouver, BC, Canada) in terms of 
effectiveness, services offered, and cost of living-adjusted 
operating costs.   
Insite is the first and most well-documented SIF in North 
America. 
The US cities modeled have a 0.25-mile radius area within 
the city that could have 2100 PWID clients for a SIF. 
The Insite client-service rate is the basis for the healthcare 
resource use effectiveness estimates for SIFs in all modeled 
cities. 
Rates of HIV/hepatitis C/other infections are equivalent 
between SIF+SSP and SSP-only. 
We recognize there is some evidence that SIFs may reduce 
needle sharing, leading to a reduction in infections.  
However, due to the short time horizon of our model (1 
year) and the complexity of estimating the timing of 
infections and attributing costs to these conditions, we 
chose to take a conservative approach and not include these 
additional cost off-sets. We explored a difference in 
infection rates driven by a reduction in needle sharing 
conferred by the SIF setting in a scenario analysis. 
We assumed that the rates of initiation and continuation of 
MAT are equivalent between clients using SIFs and SSPs. 
There is a lack of comparative data between these two 
services; however, stakeholders have indicated that 
increased face-to-face time spent with PWID may lead to 
increased uptake of MAT.  Therefore, we explored the 
impacts of marginal increases in MAT initiation due to SIFs in 
a scenario analysis. 
BC: British Columbia, HIV: human immunodeficiency virus, MAT: medication-assisted treatment, PWID: people 




We utilized estimates from Marshall et al.12 to calculate the overdose mortality risk reduction 
associated with SIFs (Table 5.3).  We calculated the mortality reduction attributable to the SIF as the 
absolute difference between: (a) fatal overdose reduction within a 0.25 mile radius around the SIF 
and (b) fatal overdose reduction beyond a 0.25 mile radius around the SIF; this was then applied to 
pre-SIF overdose fatalities per city to derive expected fatalities within and outside the effective 
range of the SIF.  Of note, the Marshall et al. estimate for overdose reduction near the SIF is a 
weighted average of two Vancouver, BC census tracts within a 500-meter radius of the SIF.  As these 
two census tract distances were within 0.25 mile, we employed this distance instead of 500 meters 
in this US-based analysis.  As in Irwin et al.,66,67 we assumed that 5% of overall overdose deaths in 
each city occurred within the 0.25 mi radius of the SIF.  Thus, the equation for calculating post-SIF 
OD deaths was: 
Pre-SIF_OD_deaths_(City)–(OD_reduction_<0.25_mi – OD_reduction_>0.25_mi)*ppn_OD_death_<0.25_mi*OD_deaths_(City)  
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Table 5.3. Overdose Mortality Inputs 
Parameter Estimate (sensitivity analysis range) 
Fatal OD reduction within 0.25 mi of SIF12 35.0% (±20%) 
Fatal OD reduction beyond 0.25 mi of SIF12 9.3% (±20%) 
Proportion of total overdose deaths occurring within 
0.25 mi2 of SIF67 
5% (±20%) 
OD: overdose, SIF: supervised injection facility 
 
Overdoses and Emergency Services 
Utilizing estimates from Insite, we assumed that 0.95% of overall injections result in an overdose 
(Table 5.4).33  Emergency services included both ambulance services as well as hospital ED access, 
and were conditional on the occurrence of an overdose.  We utilized estimates from Irwin et al. to 
parameterize these services, with 0.79% of overdoses at a SIF versus 46% of overdoses outside a SIF 
resulting in an ambulance call, and 0.79% of overdoses at a SIF versus 33% of overdoses outside a 
SIF resulting in an ED visit.67  We note that the estimates for emergency services utilization for 
overdoses at a SIF are lower than some published estimates,32-33 but are in line with current 
protocols based on stakeholder feedback.  Based on an analysis of the Agency for Healthcare 
Research and Quality’s Healthcare Cost and Utilization Project (HCUP) National Emergency 
Department Sample, we assumed that 48% of ED visits for overdoses resulted in an inpatient 
admission.74  
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Table 5.4. Overdose and Emergency Services Inputs 
Parameter Estimate (sensitivity analysis range) 
Overdose (OD) Inputs  
Total annual injections 71 180,000 (±20%) 
Number of unique clients/month71 2,100 (±20%) 
Percent of injections resulting in OD33 0.95% (±20%) 
Emergency Services Inputs  
Proportion of ODs at SIF+SSP resulting in ambulance 
ride67,72 
0.79% (±20%) 
Proportion of ODs at SIF+SSP resulting in ED visit67,72 0.79% (±20%) 
Proportion of SSP-only ODs resulting in ambulance ride67,73 46% (±20%) 
Proportion of SSP-only ODs resulting in ED visit67,73 33% (±20%) 
Proportion of ED visits resulting in hospitalization74 48% (±20%) 
ED: emergency department, OD: overdose, SIF: supervised injection facility, SSP: syringe service program 
Medication-Assisted Treatment 
We assumed that SIFs provide equivalent benefit to SSPs in terms of initiation of MAT.  Therefore, 
we used the same estimate of 5.78% of PWID accessing MAT due to a referral from the SIF and/or 
SSP (Table 5.5).75  We explored differences in uptake in MAT in a scenario analysis.  We assumed 
50% of PWID who begin MAT stay on treatment each year. 
Table 5.5. Medication-Assisted Treatment Inputs 
Parameter Estimate (sensitivity analysis range) 
Proportion of PWID who access MAT75 5.78% (±20%) 
MAT continuation rate67 50% (±20%) 
MAT: medication-assisted treatment, PWID: people who inject drugs 
 
SIF and SSP Operations and Facilities Costs 
SIF facility and operation costs were estimated based on the Irwin et al. approach, adapting each 
community’s estimate according to their individual characteristics.66,67  We applied start-up costs as 
well as marginal operating costs, adjusting prior 2013 estimates to 2020 US dollars using the 
Consumer Price Index (Table 5.6, below).77  Start-up costs were calculated by multiplying the size of 
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the Insite SIF (1000 ft2) by the commercial real estate cost per ft2 per city (Table 5.1, above); this 
cost was then amortized over the length of the loan period to calculate an annual loan payment.  
The Insite annual operating cost was multiplied by the cost-of-living ratio per city compared to 
Vancouver, BC (Table 5.1, above).  Each city’s annual SIF cost thus equaled the annual loan payment 
plus the annual operating cost.  We assumed that the SIF’s service offerings match those of Insite, 
as that site is also the source for the effectiveness parameters. 
SSP facility and operation costs were estimated from Teshale et al., who reported on the costs of 
operating these facilities in a variety of settings in the US.78  We adopted the large (serving 2500 
clients), urban SSP setting from Teshale, and then adjusted the budget items based on the SSP 
offerings that were available at the time of the launch of Insite, in order to align the differences in 
costs with the services that were added with Insite and the measured mortality impact.  This 
included removing naloxone distribution and medical/testing services, and their associated 
personnel costs (including benefits).  We then adjusted the costs to 2020 US dollars using the 
Consumer Price Index from 2016 to 2020 dollars.77  In order to estimate SSP operation and facility 
costs in each modeled city, we applied US cost-of-living city-level weights, with Teshale’s estimate 
assumed to be the overall mean. 
Table 5.6. Operating and Facility Cost Inputs 
Parameter Estimate (sensitivity analysis range) 
Insite Annual Operating Cost76,77 $1,687,286 (±20%) 
Term of Commercial Loan* 15 years 
SIF Square Footage67 1000 
Adjusted SSP Annual Operating Cost77,78 $1,533,279 (±20%) 
*Assumption 
SIF: supervised injection facility, SSP: syringe service program 
Emergency Services Costs 
We used Centers for Medicare and Medicaid Services (CMS) fee schedules with location-specific 
adjustments to calculate the costs of ambulance rides (Table 5.7).79  Overdose-related ED visit costs 
were estimated from the Nationwide Emergency Department Sample, assuming a 30% cost-to-
charge ratio.74 Overdose-related hospitalization costs were adapted from an analysis of Vizient 
hospital data that were summarized at the regional level, using the average amount that the 
hospital was paid for opioid-related admissions.80 
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Table 5.7. Emergency Services Cost Inputs 
Parameter Estimate (sensitivity analysis range) 
Ambulance Ride Costs79  
Boston $523.06 (±20%) 
Philadelphia $487.41 (±20%) 
San Francisco $566.34 (±20%) 
Atlanta $461.63 (±20%) 
Baltimore $492.50 (±20%) 
Seattle $516.37 (±20%) 
Overdose-related ED Visit Cost (All Cities)74 $3,451 (±20%) 
Overdose-related Hospitalization Cost80   
Boston $8,379 (±20%) 
Philadelphia $7,502 (±20%) 
San Francisco $8,683 (±20%) 
Atlanta $5,890 (±20%) 
Baltimore $7,502 (±20%) 
Seattle $8,683 (±20%) 
ED: emergency department 
Model Outcomes 
Model outcomes included total overdose deaths prevented and total costs for each intervention.  
The model outcomes will also include total emergency services avoided, and total increase in MAT 
initiation.  Due to the one-year time horizon, all results are reported as undiscounted values. 
Base-Case Analysis 
Costs and cost effectiveness were estimated using the incremental cost-effectiveness ratios, with 
incremental analyses comparing SIF+SSP to SSP-only.  Because the health care system does not hold 
financial responsibility for funding SIFs, the base-case analysis used a modified societal perspective.   
Sensitivity Analyses 
We performed one-way sensitivity analyses to identify the key drivers of model outcomes, using 
available measures of parameter uncertainty (i.e., confidence intervals) or reasonable ranges for 
each input described in the model inputs section above.   
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Scenario Analyses 
In addition, we also performed the following scenario analyses to test the impacts of our model 
assumptions: 
• SIF-associated reduction in HIV and HCV infections.  We employed the approach used by 
Irwin et al. to estimate the reduction in infections among PWID.  This approach was driven 
by a 70% reduction in needle sharing among SIF clients compared to the non-SIF PWID 
(Table 5.8).  Given the 1-year time horizon and the decision to exclude health benefits in 
terms of utility weights, we did not include costs associated with HIV/HCV treatment in this 
scenario. 
Table 5.8. SIF-Associated HIV and HCV Reduction Inputs for Scenario Analysis66,67 
Parameter Estimate (sensitivity analysis range) 
Odds Ratio: SIF reduction in needle sharing 0.30 (95% CI: 0.11 to 0.82) 
Probability of HIV infection from single injection 0.0067 (±20%) 
Probability of HCV infection from single injection 0.030 (±20%) 
Needle sharing rate among PWID 0.011 (±20%) 
Proportion of unbleached needles 100% (±20%) 
Number of needle sharing partners among PWID 1.69 (±20%) 
Proportion of PWID who are HIV Positive (all cities) 0.17 (±20%) 
Proportion of PWID who are HCV Positive (all cities) 0.25 (±20%) 
HCV: hepatitis C virus, HIV: human immunodeficiency virus, PWID: people who inject drugs, SIF: supervised 
injection facilities 
 
• Threshold analysis of overdose rate needed for cost parity.  We lowered the overdose rate 
per city until the overall costs of a SIF+SSP and an SSP-only were equivalent. 
 
• SIF-associated increase in MAT uptake and MAT retention.  Assuming that MAT uptake at an 
SSP-only would be lower than the proportion of SIF+SSP clients who access MAT (5.78%), we 
estimated the incremental number of MAT clients at a SIF+SSP by decreasing (over a range 
of 0%-100%) the relative proportion of SSP-only clients who access it.  In addition, we did a 
two-way sensitivity analysis of the differences in (a) MAT uptake and (b) MAT retention 
rates between SIF+SSP and SSP-only.  Given the 1-year time horizon and the decision to 
exclude health benefits in terms of utility weights, we did not include costs associated with 
MAT in this scenario. 
• Health care payer perspective analysis.  In this scenario we focused on direct health care 
costs by excluding SIF and SSP costs and utilizing health care reimbursements instead of 
 
©Institute for Clinical and Economic Review, 2020 Page 49 
Evidence Report – Supervised Injection Facilities Return to Table of Contents 
total cost for hospitalizations.  Reimbursements represent what the health care payer paid 
to the hospital for the provision of care rather than the net cost of care to the hospital. 
Table 5.9. Hospitalization Costs for Health Care Payer Scenario Analysis 
City Health Care Payer Reimbursement80 
Boston $5,290 
Philadelphia $6,318 





We used several approaches to validate the model.  First, we provided preliminary methods and 
results to multiple SIF stakeholders, including researchers and SIF staff from various locations.  
Based on feedback from these groups, we refined data inputs used in the model.  Second, we varied 
model input parameters to evaluate face validity of changes in results.  We performed model 
verification for model calculations using internal reviewers.  Finally, we compared results to other 
cost-effectiveness models in this therapy area. 
5.3 Results 
Base-Case Results 
The annual cost of operating a SIF+SSP ranged from $1.6 million to $2.5 million, while the cost of 
operating an SSP-only ranged from $1.4 million to $1.7 million, depending on the location.  A 
hypothetical SIF+SSP was found to result in the prevention of three (Boston) to 15 (Philadelphia) 
overdose deaths per year, as well as 773 fewer overdose-related ambulance rides, 551 fewer 
overdose-related ED visits, and 264 fewer hospitalizations (all based on 180,000 
injections/year/comparator).  This resulted in cost-savings for: (a) ambulance rides avoided, from -
$437,800 (San Francisco) to -$356,900 (Atlanta); (b) ED visits avoided (-$1.9 million); and (c) 
hospitalizations avoided, from -$2.3 million (San Francisco and Seattle) to -$1.6 million (Atlanta).  
For each of the six cities, a SIF+SSP saved money compared to an SSP-only, driven primarily by 
reductions in ED visit and hospitalization costs (of note, OD deaths avoided is not included in the 
costs per comparator).  The overall cost-savings for a SIF+SSP versus SSP-only ranged from -$4.2 
million (Seattle) to -$3.6 million (Atlanta). 
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Table 5.10. Base-Case Results for Boston and Philadelphia 
Outcome Boston Philadelphia 
  SIF+SSP SSP-Only Incremental SIF+SSP SSP-Only Incremental 
Total Cost $2,261,000 $6,270,000 -$4,009,000 $1,896,000 $5,796,000 -$3,899,000 
Annual Cost of 
Facility 
$2,153,000 $1,641,000 $511,300 $1,794,000 $1,433,000 $361,500 
Ambulance Costs $7,100 $411,400 -$404,400 $6,600 $383,400 -$376,800 
ED Visit Costs $46,600 $1,947,000 -$1,901,000 $46,600 $1,947,000 -$1,901,000 
Hospitalization 
Costs 
$54,300 $2,270,000 -$2,215,000 $48,600 $2,032,000 -$1,983,000 
Overdose Deaths 9 13 -3 43 58 -15 
Ambulance Rides 14 787 -773 14 787 -773 
ED Visits 14 564 -551 14 564 -551 
Hospitalizations 6 271 -264 6 271 -264 
ED: emergency department, SIF: supervised injection facility, SSP: syringe service program  
 
©Institute for Clinical and Economic Review, 2020 Page 51 
Evidence Report – Supervised Injection Facilities Return to Table of Contents 
Table 5.11. Base-Case Results for San Francisco and Atlanta 
Outcome San Francisco Atlanta 
  SIF+SSP SSP-Only Incremental SIF+SSP SSP-Only Incremental 
Total Cost $2,624,000 $6,457,000 -$3,833,000 $1,687,000 $5,310,000 -$3,623,000 
Annual Cost of 
Facility 
$2,513,000 $1,712,000 $800,900 $1,596,000 $1,404,000 $191,500 
Ambulance Costs $7,700 $445,500 -$437,800 $6,200 $363,100 -$356,900 
ED Visit Costs $46,600 $1,947,000 -$1,901,000 $46,600 $1,947,000 -$1,901,000 
Hospitalization Costs $56,300 $2,352,000 -$2,296,000 $38,200 $1,595,000 -$1,557,000 
Overdose Deaths 12 17 -4 18 24 -6 
Ambulance Rides 14 787 -773 14 787 -773 
ED Visits 14 564 -551 14 564 -551 
Hospitalizations 6 271 -264 6 271 -264 
ED: emergency department, SIF: supervised injection facility, SSP: syringe service program 
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Table 5.12. Base-Case Results for Baltimore and Seattle 
Outcome Baltimore Seattle 
  SIF+SSP SSP-Only Incremental SIF+SSP SSP-Only Incremental 
Total Cost $1,727,000 $5,750,000 -$4,023,000 $2,146,000 $6,346,000 -$4,199,000 
Annual Cost of Facility $1,625,000 $1,383,000 $241,900 $2,036,000 $1,640,000 $396,100 
Ambulance Costs $6,700 $387,400 -$380,700 $7,000 $406,200 -$399,200 
ED Visit Costs $46,600 $1,947,000 -$1,901,000 $46,600 $1,947,000 -$1,901,000 
Hospitalization Costs $48,600 $2,032,000 -$1,983,000 $56,300 $2,352,000 -$2,296,000 
Overdose Deaths 26 35 -9 8 11 -3 
Ambulance Rides 14 787 -773 14 787 -773 
ED Visits 14 564 -551 14 564 -551 
Hospitalizations 6 271 -264 6 271 -264 
ED: emergency department, SIF: supervised injection facility, SSP: syringe service program 
Sensitivity Analysis Results 
To demonstrate effects of uncertainty on both costs and health outcomes, we varied input 
parameters using reasonable ranges to evaluate changes in costs saved per overdose death avoided 
(Figure 5.2), cost per ambulance ride avoided (Appendix Figure E1), cost per ED visit avoided 
(Appendix Figure E2), and cost per hospitalization avoided (Appendix Figure E3).  The parameter 
with the largest impact on the cost per OD death avoided was the overdose mortality reduction 
within 0.25 mi2 of the SIF.12  Other parameters with notable impact included the number of 
injections/year/clientele, the proportion of injections that result in overdoses, the proportion of 
overall overdose deaths/year/city that occur within 0.25 mi2 of a SIF, and overdose deaths per city. 
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Figure 5.2. One-Way Sensitivity Analysis Results 
Costs Saved per OD Death Avoided, Boston 
 
Costs Saved per OD Death Avoided, Philadelphia 
Costs Saved per OD Death Avoided, San Francisco 
 
  
Parameter Low Value High Value Low Result High Result Spread
1 Overdose Mortality: Reduction Within 0.25 mi of SIF 0.280 0.420 -$1,715,144 -$980,831 $734,312
# Total annual injections in the SIF 144,000 216,000 -$966,552 -$1,529,415 $562,863
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$966,552 -$1,529,415 $562,863
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$985,442 -$1,510,526 $525,083
3 Overdose Mortality: Ppn. of City OD Deaths Within 0.25 mi of SIF 0.040 0.060 -$1,559,980 -$1,039,987 $519,993
4 Overdose Deaths/Year: Boston 200 300 -$1,559,980 -$1,039,987 $519,993
# Hospitalization Cost: Boston $6,704 $10,055 -$1,110,064 -$1,385,904 $275,840
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$1,110,064 -$1,385,904 $275,840
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$1,378,240 -$1,117,728 $260,512
# Cost of Living Ratio vs. Vancouver: Boston 0.99 1.49 -$1,378,240 -$1,117,728 $260,512
# Cost of ED VIsit: Boston $2,761 $4,141 -$1,129,647 -$1,366,320 $236,673
# First Year SSP Cost $1,226,623 $1,839,934 -$1,145,803 -$1,350,165 $204,361
2 Overdose Mortality: Reduction Outside 0.25 mi of SIF 0.074 0.112 -$1,163,759 -$1,345,352 $181,593
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$1,222,369 -$1,273,599 $51,230
# Cost of Ambulance Ride: Boston $418 $628 -$1,222,809 -$1,273,159 $50,350
# Number of Unique SIF Clients/Month 1,680 2,520 -$1,259,937 -$1,236,031 $23,907
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$1,254,269 -$1,241,699 $12,570
# Cost/sqft Commercial Property: Boston $440 $660 -$1,251,743 -$1,244,224 $7,519
# Commercial Mortgage Loan Interest: Boston 5% 9% -$1,250,287 -$1,245,542 $4,745
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$1,248,424 -$1,247,544 $880
-$1.8M -$1.6M -$1.4M -$1.2M -$1.0M
Parameter Low Value High Value Low Result High Result Spread
1 Overdose Mortality: Reduction Within 0.25 mi of SIF 0.280 0.420 -$362,657 -$207,391 $155,266
# Total annual injections in the SIF 144,000 216,000 -$206,211 -$321,547 $115,336
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$206,211 -$321,547 $115,336
3 Overdose Mortality: Ppn. of City OD Deaths Within 0.25 mi of SIF 0.040 0.060 -$329,849 -$219,899 $109,950
5 Overdose Deaths/Year: Philadelphia 920 1380 -$329,849 -$219,899 $109,950
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$210,022 -$317,736 $107,715
# Hospitalization Cost: Philadelphia $6,001 $9,002 -$237,036 -$290,722 $53,685
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$237,036 -$290,722 $53,685
# Cost of ED VIsit: Philadelphia $2,761 $4,141 -$238,154 -$289,604 $51,451
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$287,857 -$239,901 $47,955
# Cost of Living Ratio vs. Vancouver: Philadelphia 0.84 1.26 -$287,857 -$239,901 $47,955
# First Year SSP Cost $1,226,623 $1,839,934 -$244,486 -$283,272 $38,786
2 Overdose Mortality: Reduction Outside 0.25 mi of SIF 0.074 0.112 -$246,070 -$284,467 $38,397
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$258,690 -$269,068 $10,378
# Cost of Ambulance Ride: Philadelphia $390 $585 -$258,779 -$268,979 $10,200
# Number of Unique SIF Clients/Month 1,680 2,520 -$266,148 -$261,610 $4,537
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$265,168 -$262,590 $2,579
# Cost/sqft Commercial Property: Philadelphia $166 $248 -$264,186 -$263,571 $615
# Commercial Mortgage Loan Interest: Philadelphia 5% 9% -$264,067 -$263,679 $388
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$263,968 -$263,790 $178
-$400,000 -$350,000 -$300,000 -$250,000 -$200,000
Parameter Low Value High Value Low Result High Result Spread
1 Overdose Mortality: Reduction Within 0.25 mi of SIF 0.280 0.420 -$1,242,355 -$710,460 $531,895
# Total annual injections in the SIF 144,000 216,000 -$685,403 -$1,122,538 $437,136
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$685,403 -$1,122,538 $437,136
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$701,199 -$1,106,743 $405,544
3 Overdose Mortality: Ppn. of City OD Deaths Within 0.25 mi of SIF 0.040 0.060 -$1,129,963 -$753,309 $376,654
6 Overdose Deaths/Year: San Francisco` 264 396 -$1,129,963 -$753,309 $376,654
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$1,020,953 -$786,989 $233,964
# Cost of Living Ratio vs. Vancouver: San Francisco 1.18 1.76 -$1,020,953 -$786,989 $233,964
# Hospitalization Cost: San Francisco $6,946 $10,419 -$795,702 -$1,012,239 $216,538
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$795,702 -$1,012,239 $216,538
# Cost of ED VIsit: San Francisco $2,761 $4,141 -$814,322 -$993,619 $179,298
# First Year SSP Cost $1,226,623 $1,839,934 -$823,209 -$984,732 $161,524
2 Overdose Mortality: Reduction Outside 0.25 mi of SIF 0.074 0.112 -$842,962 -$974,498 $131,536
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$882,960 -$924,981 $42,022
# Cost of Ambulance Ride: San Francisco $453 $680 -$883,321 -$924,621 $41,300
# Number of Unique SIF Clients/Month 1,680 2,520 -$913,418 -$894,523 $18,895
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$908,825 -$899,116 $9,708
# Cost/sqft Commercial Property: San Francisco $240 $360 -$905,524 -$902,417 $3,107
# Commercial Mortgage Loan Interest: San Francisco 5% 9% -$904,922 -$902,961 $1,961
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$904,331 -$903,610 $722
-$1.3M -$1.2M -$1.1M -$1.0M -$0.9M -$0.8M -$0.7M -$0.6M
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Costs Saved per OD Death Avoided, Atlanta 
 
Costs Saved per OD Death Avoided, Baltimore  
 
Costs Saved per OD Death Avoided, Seattle 
 
Parameter Low Value High Value Low Result High Result Spread
1 Overdose Mortality: Reduction Within 0.25 mi of SIF 0.280 0.420 -$803,995 -$459,777 $344,218
# Total annual injections in the SIF 144,000 216,000 -$461,822 -$708,194 $246,372
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$461,822 -$708,194 $246,372
7 Overdose Deaths/Year: Atlanta 386 578 -$731,260 -$487,507 $243,753
3 Overdose Mortality: Ppn. of City OD Deaths Within 0.25 mi of SIF 0.040 0.060 -$731,260 -$487,507 $243,753
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$470,608 -$699,409 $228,801
# Cost of ED VIsit: Atlanta $2,761 $4,141 -$523,630 -$646,386 $122,756
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$635,678 -$534,338 $101,340
# Cost of Living Ratio vs. Vancouver: Atlanta 0.74 1.12 -$635,678 -$534,338 $101,340
# Hospitalization Cost: Atlanta $4,712 $7,068 -$534,724 -$635,292 $100,568
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$534,724 -$635,292 $100,568
# First Year SSP Cost $1,226,623 $1,839,934 -$539,656 -$630,360 $90,704
2 Overdose Mortality: Reduction Outside 0.25 mi of SIF 0.074 0.112 -$545,526 -$630,650 $85,124
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$573,283 -$596,733 $23,451
# Cost of Ambulance Ride: Atlanta $369 $554 -$573,484 -$596,532 $23,048
# Number of Unique SIF Clients/Month 1,680 2,520 -$590,313 -$579,703 $10,611
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$587,747 -$582,269 $5,477
# Cost/sqft Commercial Property: Atlanta $195 $293 -$585,874 -$584,142 $1,732
# Commercial Mortgage Loan Interest: Atlanta 5% 9% -$585,539 -$584,445 $1,093
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$585,209 -$584,807 $403
-$900,000 -$800,000 -$700,000 -$600,000 -$500,000 -$400,000
Parameter Low Value High Value Low Result High Result Spread
1 Overdose Mortality: Reduction Within 0.25 mi of SIF 0.280 0.420 -$621,763 -$355,565 $266,198
# Total annual injections in the SIF 144,000 216,000 -$356,487 -$548,335 $191,848
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$356,487 -$548,335 $191,848
8 Overdose Deaths/Year: Baltimore 554 830 -$565,514 -$377,009 $188,505
3 Overdose Mortality: Ppn. of City OD Deaths Within 0.25 mi of SIF 0.040 0.060 -$565,514 -$377,009 $188,505
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$362,908 -$541,914 $179,006
# Hospitalization Cost: Baltimore $6,001 $9,002 -$407,803 -$497,020 $89,217
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$407,803 -$497,020 $89,217
# Cost of ED VIsit: Baltimore $2,761 $4,141 -$409,660 -$495,163 $85,503
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$488,463 -$416,359 $72,105
# Cost of Living Ratio vs. Vancouver: Baltimore 0.76 1.14 -$488,463 -$416,359 $72,105
2 Overdose Mortality: Reduction Outside 0.25 mi of SIF 0.074 0.112 -$421,878 -$487,708 $65,830
# First Year SSP Cost $1,226,623 $1,839,934 -$421,302 -$483,521 $62,219
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$443,698 -$461,124 $17,427
# Cost of Ambulance Ride: Baltimore $394 $591 -$443,848 -$460,975 $17,127
# Number of Unique SIF Clients/Month 1,680 2,520 -$456,050 -$448,772 $7,278
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$454,554 -$450,269 $4,285
# Cost/sqft Commercial Property: Baltimore $162 $242 -$452,910 -$451,912 $998
# Commercial Mortgage Loan Interest: Baltimore 5% 9% -$452,717 -$452,087 $630
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$452,561 -$452,262 $299
-$700,000 -$600,000 -$500,000 -$400,000 -$300,000
Parameter Low Value High Value Low Result High Result Spread
1 Overdose Mortality: Reduction Within 0.25 mi of SIF 0.280 0.420 -$1,980,327 -$1,132,481 $847,846
# Total annual injections in the SIF 144,000 216,000 -$1,125,567 -$1,756,309 $630,742
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$1,125,567 -$1,756,309 $630,742
3 Overdose Mortality: Ppn. of City OD Deaths Within 0.25 mi of SIF 0.040 0.060 -$1,801,173 -$1,200,782 $600,391
9 Overdose Deaths/Year: Seattle 181 272 -$1,801,173 -$1,200,782 $600,391
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$1,145,900 -$1,735,977 $590,077
# Hospitalization Cost: Seattle $6,946 $10,419 -$1,283,404 -$1,598,472 $315,068
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$1,283,404 -$1,598,472 $315,068
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$1,577,571 -$1,304,306 $273,265
# Cost of Living Ratio vs. Vancouver: Seattle 0.94 1.42 -$1,577,571 -$1,304,306 $273,265
# Cost of ED VIsit: Seattle $2,761 $4,141 -$1,310,497 -$1,571,380 $260,883
# First Year SSP Cost $1,226,623 $1,839,934 -$1,328,369 -$1,553,507 $225,138
2 Overdose Mortality: Reduction Outside 0.25 mi of SIF 0.074 0.112 -$1,343,691 -$1,553,360 $209,670
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$1,413,064 -$1,468,812 $55,748
# Cost of Ambulance Ride: Seattle $413 $620 -$1,413,543 -$1,468,334 $54,791
# Number of Unique SIF Clients/Month 1,680 2,520 -$1,454,107 -$1,427,770 $26,337
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$1,448,001 -$1,433,875 $14,126
# Cost/sqft Commercial Property: Seattle $331 $497 -$1,444,058 -$1,437,819 $6,239
# Commercial Mortgage Loan Interest: Seattle 5% 9% -$1,442,849 -$1,438,912 $3,937
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$1,441,417 -$1,440,460 $957
-$2.0M -$1.8M -$1.6M -$1.4M -$1.2M
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Scenario Analyses Results 
SIF-Associated Reduction in HIV and HCV Infections 
In a model assuming that SIFs reduce needle sharing, and that this reduction in needle sharing 
reduces transmission of viral infection, a single SIF was found to decrease the number of new cases 
of HIV by between 1 (Baltimore) and 4 (San Francisco) cases per year, and to decrease the number 
of HCV infections per year by between 6 (Baltimore) and 23 (San Francisco) cases per year 
(Appendix Table E1). 
Threshold Analysis of Overdose Rate Needed for Cost Parity Between SIF+SSP and SSP-Only 
We performed a threshold analysis that estimated how low the OD rate would need to be in each 
city to reach parity between the costs of a SIF+SSP and SSP-only.  These ranged between 0.05% 
(Atlanta and Baltimore) and 0.16% (San Francisco), all representing significantly lower OD rates than 
the base case (Table 5.13). 
Table 5.13. Threshold Analysis of Overdose Rate 
 Base Case OD Rate Incremental Cost Threshold OD Rate Incremental Cost 
Boston 0.95% -$4,009,000 0.11% $0 
Philadelphia 0.95% -$3,899,000 0.08% $0 
San Francisco 0.95% -$3,833,000 0.16% $0 
Atlanta 0.95% -$3,623,000 0.05% $0 
Baltimore 0.95% -$4,023,000 0.05% $0 
Seattle 0.95% -$4,199,000 0.08% $0 
OD: overdose 
SIF-Associated Increase in MAT Uptake and MAT Retention 
In the base-case analysis, the proportion of clients who accessed MAT was 5.78% in both 
comparator arms.  This estimate was based on data collected from a SIF in Australia.  If MAT uptake 
at an SSP-only is instead assumed to be 0% of the SIF+SSP, the SIF+SSP would result in 121 
additional clients who access treatment.  We modeled this increase in MAT uptake in increments of 
10% in order to demonstrate the impact of these assumptions (Table 5.14).  The two-way sensitivity 
analysis of MAT uptake and MAT retention is available in Appendix Table E2. 
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121 109 97 85 73 61 49 36 24 12 0 
*Base case 
MAT: medication-assisted treatment, SIF: Supervised Injection Facilities, SSP: Syringe Service Program 
Health Care Payer Perspective Analysis Focused on Direct Health Care Costs and the Potential 
Differences in Those Costs between the Interventions 
When we focused on health care payer costs only by excluding SIF and SSP operating and facility 
costs, and by utilizing payer reimbursement costs instead of total (societal) cost, SIF+SSP was still 
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Table 5.15. Scenario Analysis of Health Care Payer Perspective 
 Boston Philadelphia 
 SIF+SSP SSP-Only Incremental SIF+SSP SSP-Only Incremental 
Total Cost $88,000 $3,792,000 -$3,704,000 $94,200 $4,042,000 -$3,948,000 
Annual Cost of Facility $0 $0 $0 $0 $0 $0 
Ambulance Costs $7,100 $411,400 -$404,400 $6,600 $383,400 -$376,800 
ED Visit Costs $46,600 $1,947,000 -$1,901,000 $46,600 $1,947,000 -$1,901,000 
Hospitalization Costs $34,300 $1,433,000 -$1,398,000 $41,000 $1,711,000 -$1,670,000 
 San Francisco Atlanta 
 SIF+SSP SSP-Only Incremental SIF+SSP SSP-Only Incremental 
Total Cost $101,100 $4,350,000 -$4,248,000 $80,800 $3,478,000 -$3,397,000 
Annual Cost of Facility $0 $0 $0 $0 $0 $0 
Ambulance Costs $7,700 $445,500 -$437,800 $6,200 $363,100 -$356,900 
ED Visit Costs $46,600 $1,947,000 -$1,901,000 $46,600 $1,947,000 -$1,901,000 
Hospitalization Costs $46,800 $1,957,000 -$1,910,000 $27,900 $1,167,000 -$1,139,000 
 Baltimore Seattle 
 SIF+SSP SSP-Only Incremental SIF+SSP SSP-Only Incremental 
Total Cost $94,200 $4,046,000 -$3,952,000 $100,400 $4,310,000 -$4,210,000 
Annual Cost of Facility $0 $0 $0 $0 $0 $0 
Ambulance Costs $6,700 $387,400 -$380,700 $7,000 $406,200 -$399,200 
ED Visit Costs $46,600 $1,947,000 -$1,901,000 $46,600 $1,947,000 -$1,901,000 
Hospitalization Costs $41,000 $1,711,000 -$1,670,000 $46,800 $1,957,000 -$1,910,000 
ED: emergency department, SIF: supervised injection facility, SSP: syringe service program 
Model Validation 
Model validation followed standard practices in the field.  We tested all mathematical functions in 
the model to ensure they were consistent with the report (and supplemental Appendix materials).  
We also conducted sensitivity analyses with null input values to ensure the model was producing 
findings consistent with expectations.  Further, independent modelers tested the mathematical 
functions in the model as well as the specific inputs and corresponding outputs. 
Model validation was also conducted in terms of comparisons to other model findings.  We 
searched the literature to identify models that were similar to our analysis, with comparable 
populations, settings, perspective, and treatments. 
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Prior Economic Models 
We identified four prior published economic evaluations of SIFs in the US, along with published 
analyses of the Insite facility in Vancouver, BC.  Our model was informed in large part by these 
models, though with some different assumptions.  Unlike prior models, our approach focused on 
explicitly comparing SIF+SSP to an SSP operating alone in a city.  Because of this decision, many of 
the outcomes highlighted by prior models, such as infection rates and MAT initiation, were assumed 
to be equivalent in our base case. 
Our model also utilized the distance-based OD death risk reduction from Marshall et al. in a slightly 
different way than most previous models, by attributing the 25.7% incremental mortality risk 
reduction associated with the SIF to one quarter mile radius around the SIF.12  Behrends et al. 
attributed this risk reduction more broadly to a half-mile radius, while other prior models have used 
a variety of other methods to attribute lives saved to SIFs.63  Therefore, it is difficult to exactly 
reconcile the estimated mortality impact from our model with others, though they are all consistent 
in estimating that SIFs reduce mortality. 
In terms of SIF operating costs, our model estimates aligned fairly closely with those taking the 
same costing approach but diverged slightly from those that used city- or county-specific wage 
estimates or different financing approaches.  For example, our estimated cost of running the SIF in 
Seattle for one year was $2,036,000, compared to the Hood et al. estimate of $1,222,332 using 
wage rates for actual staff employed by the county to run their hypothetical SIF.64  In that regard, 
our results for Seattle may be conservative, assuming their SIF operating model was to be executed. 
Limitations 
There are a number of important limitations to consider when evaluating our model estimates.  
First, the costs of operating a SIF in cities around the US are extrapolations from a single North 
American SIF in Vancouver, BC.  The actual costs of operating a SIF in any of the cities we modeled 
will depend on many local factors and the actual funding mechanisms used.  Furthermore, the 
operations of both SIFs and SSPs may vary widely from city to city.  Second, the mortality risk 
reduction estimates we used also come from the estimated impact of that same single North 
American SIF at a single point in time.  The long-term OD mortality risk reduction associated with 
SIFs is unknown.  Lastly, we cannot account for rapidly evolving pandemic-associated factors. 
5.4 Summary and Comment 
We developed a decision analytic model to estimate the costs and outcomes associated with 
operating a SIF compared to an SSP only in six cities in the US over a one-year time horizon.  The 
costs of operating a SIF were estimated to be higher than operating an SSP across all six cities.  
However, those costs were offset by cost savings attributed to SIFs through the avoidance of ED 
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visits and subsequent hospitalizations.  Furthermore, in all six cities, SIFs were estimated to reduce 
mortality by avoiding overdose deaths. 
The model results were sensitive to several input parameters, which varied slightly across the six 
cities.  The underlying community-level risk parameters of overdose and overdose mortality, along 
with the mortality risk reduction attributed to SIFs, were the most influential model parameters.  
Additionally, parameters that determined the number of injections occurring in SIFs within each city 
also influenced the model estimates. 
Conclusions 
Operating a SIF was estimated to save lives and additionally to reduce medical care associated with 
overdoses in all six US cities modeled.  We estimated that operating a SIF results in fewer lives lost 
to overdoses and lower costs overall after accounting for the incremental costs associated with 
operating a SIF compared to an SSP alone. 
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6. Potential Other Benefits and Contextual 
Considerations  
Our reviews seek to provide information on potential other benefits offered by the intervention to 
the individual PWID, caregivers, the delivery system, other PWUD, or the public that would not have 
been considered as part of the evidence on comparative clinical effectiveness.  We also recognize 
that there may be broader contextual issues related to the severity of the condition, whether other 
treatments are available, and ethical, legal, or other societal priorities that influence the relative 
value of illnesses and interventions.  These general elements are listed in the table below, and the 
subsequent text provides detail about the elements that are applicable.  We sought input from 
stakeholders, including individual clients, advocacy organizations, policy makers, clinicians, law 
enforcement agencies, researchers, and SIF managers, to inform the contents of this section.  
Each ICER review culminates in a public meeting of an independent voting Council of clinicians, 
patients, and health services researchers.  As part of their deliberations, Council members will judge 
whether a treatment may substantially impact the considerations listed in Table 6.1.  The presence 
of substantial other benefits or contextual considerations may shift a council member’s vote on an 
intervention’s long-term value for money to a different category than would be indicated by the 
clinical evidence and economic modeling alone.  A Council member may also determine that there 
are no other benefits or contextual considerations substantial enough to shift their vote.  All factors 
that are considered in the voting process are outlined in ICER’s value assessment framework.  The 
content of these deliberations is described in the last chapter of ICER’s Final Evidence Report, which 
is released after the public meeting.  
This section, as well as the Council’s deliberation, provides stakeholders with information to inform 
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Table 6.1. Potential Other Benefits or Contextual Considerations  
Likert Scale of Potential Other Benefits and Contextual Considerations 
1 (Suggests Lower Value) 2 (Intermediate) 3 (Suggests Higher Value) 
Uncertainty or overly favorable model 
assumptions creates significant risk that 
base-case cost-effectiveness estimates are 
too optimistic. 
 Uncertainty or overly unfavorable model 
assumptions creates significant risk that 
base-case cost-effectiveness estimates are 
too pessimistic. 
This intervention will not differentially 
benefit a historically disadvantaged or 
underserved community. 
 This intervention will differentially benefit a 
historically disadvantaged or underserved 
community. 
Will not significantly reduce the negative 
impact of the condition on family and 
caregivers vs. the comparator. 
 Will significantly reduce the negative impact 
of the condition on family and caregivers vs. 
the comparator. 
Will not have a significant impact on 
improving return to work and/or overall 
productivity vs. the comparator. 
 Will have a significant impact on improving 
return to work and/or overall productivity 
vs. the comparator. 
Other  Other 
  
6.1 Potential Other Benefits and Contextual Considerations 
Impact on PWID Care 
The opening of a SIF represents a community’s commitment to treat substance use disorders as a 
health issue, rather than a criminal issue.  Its availability allows law enforcement and medical 
professionals to guide PWID to a SIF for immediate and long-term support of a substance use 
disorder, including screening and prevention of related health issues (e.g., HIV, hepatitis, soft tissue 
infections).  It provides another access point for health and social support services, and referral 
coordination, especially for people with housing insecurity and mental illness.  It is possible that a 
SIF makes a significant impact on the entire infrastructure of care for substance use disorders in the 
neighborhoods where it operates and/or for the clients it serves. 
Serving the Marginalized 
Persons served by SIFs are among the most vulnerable and marginalized in a community.  Well-
established social norms and public opinions regarding substance use disorders place PWID at a 
disadvantage for health and social support resources in many communities. 
Addressing Health Disparities 
Given the disparities in SUD by socio-economic class, SIFs differentially benefit groups with lower 
life expectancy and higher disability.  For example, the average annual rate of heroin use was 5.5% 
for people in the lowest household income group (<$20,000), which was 3.4 times higher than the 
>$50,000 household income group.179  The relationship between race-ethnicity and SUD is 
confounded by income with larger percentages of minority populations living in poverty.  A SIF that 
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is able to engage clients and successfully refer them to treatment can contribute to improving 
health equity for recovery as well as overdose-related deaths. 
Relationship-Building with Clients 
Due to the personal histories of mental illness and substance abuse, some SIF clients have difficulty 
building and maintaining trust with others, especially health care professionals.  In comparison to 
SSPs which have been described in interviews as “transactional”, SIFs are more likely to engage 
clients in longer and more frequent interactions with staff and other clients.  A trust-based 
relationship can be instrumental in helping clients improve injection behavior and link to medical, 
mental/behavioral health and social services.   
Screening of Street Drug Toxicity 
It was reported that some SIF clients use the facility when obtaining drugs from a new or different 
source.  The SIF can provide direct protection for PWID in this case.  Toxicity screening of drugs 
before injection and/or analysis of remnants allows for a SIF to be part of a community’s 
surveillance system of the drug supply and contribute to timely public warnings about lethal 
substances in circulation.   
Attribution of Benefits to the SIF versus Other Factors 
Most quantitative data that informed the economic model are derived from SIFs operating in only 
two communities.  Uncertainty exists about local factors (unmeasured or unmeasurable attributes 
unique to the people and place) that contributed to favorable outcomes at the time of the study.  It 
is not possible to separate features of the intervention from local community factors, such as 
infection rates, resources for persons with housing insecurity, access to primary medical care, etc. 
that vary across communities that may be considering implementing a SIF.  In communities where 
SIFs are introduced, they represent a new form of harm reduction that augments other strategies 
already in place, notably medication-assisted treatment, naloxone distribution, and syringe service 
programs.   
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7. Health-Benefit Price Benchmarks 
As the assessment for this non-drug topic does not include estimates of incremental quality-
adjusted life years (QALYs) or equal value life years gained (evLYG), ICER did not produce health-
benefit price benchmarks as part of this report. 
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8. Potential Budget Impact  
As the assessment for this non-drug topic does not include price per treatment or estimates of cost-



















This is the first ICER review of supervised injection facilities.  
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Appendix A. Search Strategic Results 
Table A1. PRISMA 2009 Checklist 
  Checklist Items 
TITLE 
Title 1 Identify the report as a systematic review, meta-analysis, or both. 
ABSTRACT 
Structured summary  2 
Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
INTRODUCTION 
Rationale  3 Describe the rationale for the review in the context of what is already known.  
Objectives  4 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 





Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
Eligibility criteria  6 
Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
Information sources  7 
Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.   
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.   
Study selection  9 
State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included 
in the meta-analysis).   
Data collection process  10 
Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.   
Data items  11 
List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.   
Risk of bias in 
individual studies  
12 
Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at 
the study or outcome level), and how this information is to be used in any data synthesis.   
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  Checklist Items 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).   
Synthesis of results  14 
Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., 
I2) for each meta-analysis.   
Risk of bias across 
studies  
15 
Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting 
within studies).   
Additional analyses  16 
Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which 
were pre-specified.   
RESULTS 
Study selection  17 
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each 
stage, ideally with a flow diagram.   
Study characteristics  18 
For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide 
the citations.   
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   
Results of individual 
studies  
20 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention 
group (b) effect estimates and confidence intervals, ideally with a forest plot.   
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.   
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
DISCUSSION 
Summary of evidence  24 
Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key 
groups (e.g., healthcare providers, users, and policy makers).   
Limitations  25 
Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).   
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.   
FUNDING 
Funding  27 
Describe sources of funding for the systematic review and other support (e.g., supply of data), role of funders for the 
systematic review.   
From:  Moher D, Liberati A, Tetzlaff J, Altman DG.  The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The 
PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
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Table A2. Search Strategies for Supervised Injection Facilities: Ovid MEDLINE(R) Epub Ahead of 
Print, In-Process & Other NonIndexed Citations, Ovid MEDLINE(R) Daily, Ovid MEDLINE and 
Versions(R) 1946 to Present + PsycInfo 
# Search Term 
1 
((Supervised or safe* or drug) adj2 (inject* or shooting or consumption or smok* or inhal*) adj3 
(facilit* or room* or galler* or cent* or site* or service*)).ti,ab. 
2 (overdose adj3 prevention adj3 (site* or service*)).ti,ab 
3 1 or 2  
4 
(addresses OR autobiography OR bibliography OR biography OR clinical trial, phase I OR comment OR 
congresses OR consensus development conference OR dictionary OR directory OR duplicate publication 
OR editorial OR encyclopedia OR guideline OR interactive tutorial OR newspaper OR commentaries).pt 
5 3 not 4 
6 (animals not (humans and animals)).sh. 
7 5 not 6 
8 limit 7 to English language 
9 remove duplicates from 8 
 
Table A3. Search Strategies for Supervised Injection Facilities: EMBASE 
# Search Term 
1 
((supervised OR safe* OR drug) NEAR/3 (inject* OR shooting OR consumption OR smok* OR inhal*) 
NEAR/3 (facilit* OR room* OR galler* OR cent* OR site* OR service*)):ti,ab 
2 (overdose NEAR/3 prevention NEAR/3 (site* OR service*)):ti,ab 
3 #1 OR #2 
4 #3 NOT (('animal'/exp OR 'nonhuman'/exp OR 'animal experiment'/exp) NOT 'human'/exp) 
5 #4 NOT [medline]/lim 
6 #5 AND [english]/lim 
 
Table A4. Search Strategy for Supervised Injection Facilities: Web of Science (Limited to English 
language; Year: 1900-2020); Database: Excluding Medline and refined by WOS 
# Search Term 
1 
TS=  (("SUPERVISED" OR "SAFE*" OR "DRUG")  NEAR/2  ("SMOK*" OR "INHAL*" OR "INJECT*" OR 
"CONSUMPTION" OR "SHOOT*")  NEAR/2  ("FACILIT*" OR "SERVICE*" OR "ROOM*" OR "GALLER*" OR 
"CENT*" OR "SITE*")  ) 
2 TS= “OVERDOSE PREVENTION SITES” OR TS="OVERDOSE PREVENTION SERVICE*" 
3 #1 OR #2 
4 #3 Refined by: [excluding] Databases: ( MEDLINE ) AND Databases: ( WOS ) 
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Table A5.  Search Strategy for Syringe Service Programs: Ovid MEDLINE(R) Epub Ahead of Print, 
In-Process & Other NonIndexed Citations, Ovid MEDLINE(R) Daily, Ovid MEDLINE and Versions(R) 
1946 to Present + PsycInfo 
# Search Term 
1 Needle-Exchange Programs/ 
2 
((needle* or syringe* or inject*) adj3 (program* or service* or exchange* or distribut* or 
dispens*)).ti,ab. 
3 1 or 2  
4 (systematic review or meta-analysis).pt. 
5 ((systematic* adj2 review*) or meta-analys* or ((evidence or quantitative) adj2 synthes*)).ti,ab. 
6 4 or 5 
7 3 and 6 
8 (animals not (humans and animals)).sh. 
9 7 not 8 
10 limit 9 to english language 
11 remove duplicates from 10 
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Figure A1. PRISMA flow Chart Showing Results of Literature Search for Supervised Injection 
Facilities 
 
6 references identified 
through other sources 
1030 references after 
duplicate removal 
312 references assessed 
for eligibility in full text 
1188 references identified 
through literature search 
718 citations excluded 1030 references screened 
267 citations excluded for 
outcomes  
 
48 total references 
18 cohort studies 
11 pre-post or time-series 
10 cross-sectional 
9 qualitative studies 
48 references included in 
synthesis 
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Appendix B. Previous Systematic Reviews and 
Technology Assessments  
Potier, C., Laprévote, V. et al. (2014) “Supervised Injection Services: What Has Been 
Demonstrated? A Systematic Literature Review”.30 
A systematic review was identified on the data available on supervised injection services (SISs) to 
determine whether they have achieved their desired objectives.  The review included 75 articles in 
the final analysis including descriptive, cross-sectional, and analytical assessments.  Of these, 68% 
(n= 51) were related to a SIS in Vancouver, 17% (n= 13) from Sydney, and 3% (N=2) from Europe.   
Fourteen studies described the characteristics of the most frequent SIS users.  Most SIS users were 
described as male, aged 30-35 years, experiencing housing and employment insecurity and with a 
previous history of incarceration.  The most frequently used drugs were heroin, cocaine, opiates, 
and amphetamines.  Seven studies concluded that no death by overdose had been reported at a 
SIS; in Vancouver, the SIS led to a 35% decrease in fatal overdoses.  In Vancouver and Sydney, 
regular SIS use was associated with reduced syringe sharing (aOR = 0.30, 95%CI = [0.11–0.82]), 
syringe reuse (aOR = 2.04, 95%CI = [1.38–3.01]), and public-space injection (aOR = 2.79, 95%CI = 
[1.93–3.87]); a meta-analysis determined that the SIS was associated with a 69% reduction in 
syringe sharing. According to six studies, SIS users received care for injection-related problems and 
five studies reported that SIS use resulted in an increase referral to addiction treatment (OR= 1.32, 
95%CI = [1.11-1.58]: P=0.002).  Seven surveys evaluated perceptions of local residents, police, and 
professionals.  In Sydney, 70% of residents and 58% of business owners favored the SIS and saw a 
decrease in drug use and syringe waste.  However, most business owners and residents still related 
SIS use to a negative image of the district and the “honey-pot” effect.  
McNeil, R., Small, W. (2014) “Safer Environment Interventions: A Qualitative Synthesis of the 
Experiences and Perceptions of People Who inject Drugs”.180  
McNeil and Small conducted a systematic review to evaluate the influence of social, structural, and 
environmental factors on access and engagement with Safe Environment Interventions (SEIs) 
among people who inject drugs (PWID).  The review included 29 references referring to 21 studies 
in the final evaluation.  The included articles were published in Canada (n=16), the USA (n=6), Russia 
(n=4), and other settings (n=4).  The four themes described in the analysis were- SEIs as a refuge, 
increased use of social services, SEIs impact on survival, and the social-structural impact on the SEIs.  
Multiple studies emphasized on the importance of the SEIs as a refuge from violence on the streets.  
SEIs promoted safer injecting by redefining the social and environmental contexts of injection drug 
use.  In addition to being a refuge from violence, SEIs also enabled safer drug use practices by 
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enabling harm reduction.  The use of these facilities allowed clients to access safer injection 
equipment which in turn allowed them to practice safer habits and access to a safer space to 
contributing to reductions in risky injection behavior.  Rushed injections and syringe sharing was 
reduced and enabled more autonomy for the clients.  These facilities mediated access to social and 
healthcare services.  Trust was identified as a critical component; trust between clients and staff 
was associated with increased acceptance of drug treatment referrals and other services.  
Kennedy, M C., Karamouzian, M., Kerr, Thomas.  (2017) “Public Health and Public Order 
Outcomes Associated with Supervised Drug Consumption Facilities: A Systematic Literature 
Review”181 
Kennedy et al, conducted a systematic review to assess health and community outcomes related to 
use of supervised drug consumption facility (SCF) use.  A total of 47 studies were included in the 
final analysis including cohort, pre-post, cross-sectional, or time-series analyses.  28 studies were 
conducted in Vancouver, Canada, 10 in Sydney and the remaining in Europe (n=9).  
Overall, the review found that the use of SCFs was associated with a decrease in overdose deaths, 
an increase in PWID receiving addiction and medical treatment, and a decrease in substance use in 
public.  Eight studies examined overdose-related outcomes, of which six studies found an 
association between the establishment of a SIF and reduction in overdose-related deaths.  For 
example, the establishment of Insite, Vancouver was correlated with a 35% decline in overdose 
related deaths near the vicinity of the SIF, compared to a 9% decline outside of this vicinity.  In 
Sydney, Australia opening of SIF was associated with a reduction in ambulance calls as well as 
opioid related poisoning presentations near the SIF.  Four studies reported that frequent SIF use 
was associated with a decrease in injection risk behaviors including syringe sharing.  A cross-
sectional study based in Vancouver reported that SIF users are 70% less likely to borrow or lend a 
used syringe and two additional studies from Denmark and Vancouver found an association 
between SIF use and a reduction in other unsafe injection behaviors including injecting outdoors, 
rushed injections, and reusing syringes. SIF use was also reported to be positively associated with 
an increase in safer injection practices.  Further, four studies reported that frequent SIF use was 
associated with an increased likelihood of entry into and uptake of addiction treatment.  At Insite, 
Vancouver, use of detox services increased by more than 30% in the year after the SIF was opened, 
compared to the year before; rapid entry into detox services was also associated with contact with 
an addiction counselor at a SIF. Three other studies report similar data.  Five studies reported that 
implementation a SIF in Vancouver and Sydney was associated with a reduction in the number of 
people injecting publicly, publicly discarded syringes, and injection-related litter.  Besides, four 
studies conducted in Sydney found no changes in drug-related crime, and similar results were 
reported in two studies from Vancouver.  
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Lange, B. Bach-Mortensen, A M. (2019) “A Systematic Review of Stakeholder Perceptions of 
Supervised Injection Facilities”.182  
Stakeholder perceptions of supervised injection facilities (SIFs) were evaluated in this systematic 
review.  Of the 47 included articles, the majority were conducted in Canada (n=26) and Australia (n= 
8).  The mean sample size of the included studies was 55.8 (SD: 64).  Patients who use drugs 
(PWUD), including women, reported that the largest benefit to SIFs (sanctioned or unsanctioned) 
was their ability to provide a safe space from violence, theft, and police harassment.  The increased 
safety of PWUD at a SIF was attributed to several factors such as education on drug use, a hygienic 
environment, availability of necessary supplies, and supervision especially in the case of an 
overdose.  Business sector, community workers, and health professionals also reported a reduction 
in publicly discarded syringes.  On the other hand, the most highlighted concerns with sanctioned 
SIFs were associated with current restrictions, age, and pregnancy.  Across four studies, PWUD 
expressed concerns that SIFs did not allow assisted injections, whereas staff described disruptive 
client behavior and personnel safety as their main concern.  For sanctioned SIFs, stakeholders 
suggested revising restrictions and regulations, to allow drug sharing and injecting drugs other than 
heroin.  These stakeholders also suggested to increase the operating hours of a SIF. 
Rand Report.  (2018) “Assessing the Evidence on Supervised Drug Consumption Sites”. 183  
Researchers conducted a systematic review to assess the existing evidence on supervised 
consumption sites (SCSs) using PubMed, Embase, Scopus, Web of Science, and WorldCat.  
Seventeen reviews were identified as quasi-experiments and simulation studies, while five 
systematic reviews were identified, and one piece of grey literature.  
Overall, the authors concluded that the scientific evidence on the effectiveness of SCSs is limited.  
The authors note that not many scientific studies exist and of those that do, they were limited to 
only a few locations such as Vancouver and Sydney; in addition, there are no randomized controlled 
trials (RCTs) evaluating individual or population-level outcomes. According to the research 
evaluated, clients who attend an SCS and overdose in the presence of staff are much more likely to 
live thanks to the staff being equipped with naloxone.  According to a study conducted in 
Vancouver, there is a significant reduction in fatal drug overdoses in the area surrounding the SCS 
compared to outside of the area, and studies conducted in Vancouver and Sydney identified a 
significant decrease in opioid-related emergency service calls.  Several cross-sectional studies 
concluded that frequent SCS uses adopt better safer injection practices than those who use the SCS 
less frequently.  
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Appendix C. Ongoing Studies  
Table C1. On-going Studies for Supervised Injection Facilities  
Title/Trial Sponsor Study Design Comparators Patient Population Primary Outcomes 
Estimated Completion 
Date 
The Vancouver Injection Drug 
Users Study (VIDUS) 
 
Canadian Institutes of Health 
Research (CIHR) 
Prospective cohort  
N= 2,700 PWID 
n/a 
People who inject 
drugs 
Impact of prescription opioid 
misuse, risk behaviors for HIV, non-
fatal and fatal overdose 
Unclear 
The AIDS Care Cohort to 
Evaluate Exposure to Survival 
Services (ACCESS) 
 





Individuals living with 
HIV who use illicit 
drugs 
Estimate the effects of social, 
policy, physical and economic 
aspects of the HIV risk 
environments on the individual and 
community 
Unclear 
At-Risk Youth Study (ARYS) 
 
Canadian Institutes of Health 
Research (CIHR) 






n/a Street-involved youth 
Demographic data as well as 
information about drug use 
patterns, HIV and sexually 
transmitted infection (STI), risk 
behavior including sexual practices 
and risks related to drug use, access 
to health and social services, and 
engagement in the criminal justice 
system 
Unclear 
SuperMIX: The Melbourne 







People who inject 
drugs in Melbourne, 
Australia 
Information on how injecting drug 
use evolves, focused on periods 
during which cohort members 
cease injecting drug use and if they 
subsequently relapse and the 
drivers of this cessation and 
relapse. 
2021 
Source: bccsu.ca, Burnet Institute
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Appendix D. Comparative Clinical Effectiveness 
Supplemental Information  
We performed screening at both the abstract and full-text level.  Four investigators screened all 
abstracts identified through electronic searches according to the inclusion and exclusion criteria 
described earlier.  We did not exclude any study at abstract-level screening due to insufficient 
information.  For example, an abstract that did not report an outcome of interest would be 
accepted for further review in full text.  We retrieved the citations that were accepted during 
abstract-level screening for full text appraisal.  One investigator reviewed full papers and provided 
justification for exclusion of each excluded study. 
Further, we will use 12-item National Heart Lung and Blood Institute (NHLBI) Quality Assessment 
Tool to assess the quality of the pre-post studies with no control group and 14- item NHBLI Quality 
Assessment Tool for observational cohort and cross-sectional studies, using the categories as 
“good,” “fair,” or “poor” quality. 116 
Good: A study has the least risk of bias, and results are valid.  
Fair: A study susceptible to some bias deemed not sufficient to invalidate its results.  The fair-quality 
category is likely to be broad, so studies with this rating will vary in their strengths and weaknesses.  
Poor: A study that has a significant risk of bias.  Studies rated poor are excluded from the body of 
evidence.  
ICER Evidence Rating 
We used the ICER Evidence Rating Matrix (see Figure D1) to evaluate the evidence for a variety of 
outcomes.  The evidence rating reflects a joint judgment of two critical components: 
1. The magnitude of the difference between a therapeutic agent and its comparator in “net 
health benefit” – the balance between clinical benefits and risks and/or adverse effects; and 
2. The level of certainty in the best point estimate of net health benefit.117,118 
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Figure D1. ICER Evidence Rating Matrix 
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Table D2. Evidence Tables 











Wood et al 2004† 53 
 









Mean number of visits in 
first week of SIF opening= 
184; after 2 months of SIF 






SIF opening was associated with reductions in 
number of people injecting in public (daily 
mean: 2.4, 95% CI: 1.9 – 3.0) after vs. 4.3, 95% 
CI: 3.5 – 5.4) before SIF opening, publicly 
discarded syringes (daily mean: 5.4, 95% CI: 4.7 
– 6.3) after vs. (11.5, 95% CI: 10.0 – 13.2) 
before SIF opening, and injection-related litter 
(daily mean: 310, 95% CI: 305 – 317) after vs. 
(601, 95% CI: 590 – 613) before SIF opening. 
Wood et al 2005_a† 
132 
 









Exclusive SIF use (i.e., use of SIF for 100% of 
injections) compared to some SIF use was 
associated with reductions in syringe sharing 
among HIV-negative individuals (OR: 0.14; 95% 
CI 0.00 to 0.78) but was not associated with 
reductions in syringe lending among HIV-
positive individuals (OR: 0.94; 95% CI 0.00 to 
7.90). 
Wood et al 2005_b† 
136 
 
Study quality: Fair 
Cross-sectional 
May 2003 to 
October 
2004 
874 PWID from the SEOSI 
cohort; 293 (33.5%) 




Daily SIF use was marginally associated with 
reporting safer injecting education (p=0.085) in 
univariate analyses.  
Kerr 2005† 36 
 
Study quality: Fair 
Cross-sectional  
December 
2003 to June 
2004 
431 active PWIDs from the 
VIDUS cohort 
SIF use (most, all, or some 
of the injections): 20.9% 
Syringe sharing: 11.4% 
Syringe sharing 
 
Use of SIF was associated with reduced syringe 
sharing (aOR: 0.30, 95% CI: 0.11-0.82, p=0.02).  
Between SIF users versus non-users, the rates 
of syringe sharing were similar prior to the SIF 
opening (X2= 0.46, p = 0.50), suggesting that the 
observed reduction was not due to the SIF 
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selecting PWIDs at inherently lower risk of 
syringe sharing. 
Kerr and Stoltz 2006† 
52 
 





Pre-SIF IDUs: 674 
Post-SIF IDUs: 700 
Use injected drug pre-SIF: 
17% 
Use injected drug post-SIF: 
15% 
Injection behaviors 
No substantial differences in the relapse rate in 
the community (17% vs. 20%), stopping 
injections (17% vs. 15%), introduction and 
discontinuation of methadone (11% vs. 7% and 
13 vs. 11%, respectively). 
The only difference that exceeded 5% cut-off 
was increase in number who started smoking 
crack cocaine (21% v 29%). 
Kerr and Tyndall 
200632 
 









285 unique participants 
from the SEOSI cohort 
accounted for overdoses  
Non-fatal overdose 
There were 336 overdose events at the SIF 
corresponding to a rate of 1.33 (95% CI: 0.0-
3.6) overdoses per 1000 injections. Of these 
events, 28% required transport to the hospital 
and 27% resulted in the administration of 
naloxone.  
Wood et al 2006†46  
 





1031 PWID who used the 
SIF 
Males: 71% 
Regular SIF use: 58% 
Attendance at SIF, 
Use of services 
At least weekly SIF use (aHR = 1.72; 95% CI: 
1.25 – 2.38, p=0.001) and contact with a SIF 
addictions counsellor (aHR = 1.98; 95% CI: 1.26 
– 3.10, p=0.003) were associated with more 
rapid time to entry into a detoxification 
program. 
Wood et al 2006 60 
 















Post SIF opening, no significant increase was 
observed in drug trafficking: (124 vs 116, 
MD=7.9, p=0.803), assaults/robbery: (174 vs 
180, MD=-6.2, p=0.565). Significant declines 
were observed in vehicle break-ins/theft: (302 
vs 227, MD=75.7, p=0.001), post SIF opening. 
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Kerr and Small 2007† 
124 
 







50 PWID from the SEOSI 
cohort 







Ability to rapidly respond to an overdose and 
ability to provide naloxone, made the SIF stand 
out compared to other settings where it takes 
longer for people to respond or they receive no 
care at all. 
Reduced risk when injecting at INSITE versus 
alone or in an alley and an increased sense of 
security 
Stoltz et al 2007† 131 
 
Study quality: Fair 
Cross-sectional 
July 2004 to 
June 2005 
760 PWID from the SEOSI 
cohort 
Age, median: 39.3 years 
Male: 70% 
Consistent vs 
inconsistent SIF use 
stratified by 
characteristics + 
changes in injection 
practices 
associated w/ 
consistent SIF use 
Consistent SIF use (≥25% of injections) was 
positively associated with decreased public 
injections (aOR = 2.70, 95%CI: 1.98-3.87, 
p<0.001); safer syringe or paraphernalia 
disposal (aOR = 2.13, 95%CI: 1.47-3.09, 
p<0.001); decreased reuse of syringes less 
often (aOR: 2.04, 95% CI: 1.38-3.01, p<0.001); 
less rushed injection (aOR: 2.79 95% CI: 2.03-
3.85, p<0.001); using clean water for injecting 
(aOR = 2.99; 95% CI: 2.13 – 4.18, p<0.001); 
cooking or filtering drugs prior to injecting (aOR 
= 2.76; 95% CI: 1.84 – 4.15, p<0.001); tie off 
prior to injection (aOR = 2.63; 95% CI: 1.58 – 
4.37, p<0.001) and it promoted injecting in a 
clean location (aOR = 2.85, 95%CI: 2.09-3.89, 
p<0.001). 
Wood et al 2007†48 
 
Study quality: Good 






1031 PWID from the SEOSI 
cohort  








There was a significant increase in uptake of 
detoxification services post-SIF opening, 
compared to pre-SIF opening (aOR: 1.32, 95% 
CI: 1.11-1.57, p=0.002).  
Use of detoxification service was positively 
associated with a more rapid entry into the 
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Regular SIF use (weekly): 
58%  
MMT (aHR: 3.73, 95% CI: 2.57-5.39). 
Of those enrolled in the detoxification program, 
a significant decline in monthly SIF use was 
observed after discharge from detoxification, 
compared to 1-month period before 
enrollment (19 vs 24 visits, p=0.002) 
McKnight et al 
2007†54 
 




June 6, 2004 
– July 31, 
2005 
714 PWID from the SEOSI  
Age, median (range): 39 
(33-45) years 
Male: 71% 
History of incarceration: 
30% 
Unstable housing or 
homelessness: 7% 
HIV seropositive: 21% 




Waiting time at SIF affected SIF use that was 
associated with increased likelihood of public 
injecting (aOR: 3.26, 95% CI: 2.11-5.6, p<0.001) 
Homelessness also increased the likelihood of 










1082 PWID from the SEOSI 
cohort 
Age, median (IQR): 38.4 
(32.7–44.3) years 
Female: 28% 
HIV positive: 16.5% 
Daily heroin use: 50.5% 
Injection behaviors 
Of the 1,082 PWID who utilized Insite that were 
surveyed, 74.8% (n=809) reported changing 
their injection behaviors since using a SIF. 
Among these clients who changed their 
injection behaviors, 71% indicated that utilizing 
the SIF has led to less outdoor injections, and 
56% reported less unsafe syringe disposal. 
Milloy et al 2008† 184 
 






1090 PWIDs from SEOSI 
cohort 
Age, median (IQR): 38.42 
(32.7-44.3) years 
Female: 29% 
History of non-fatal 
overdose: 58.53% 
Non-fatal overdose 
Frequent SIF use (≥75% of injections) was not 
associated with recent non-fatal overdose 
(aOR: 1.01, 95% CI: 0.77-1.32, p=0.96) 
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Fast et al 2008137 
 







50 PWID from the SEOSI 
cohort 






Participants indicated that there have been 
substantial gaps in knowledge about safer 
injecting practices among local PWIDs. These 
gaps lead to unsafe injecting behaviors and 
negative health outcomes. Based on users’ 
perspectives, the SCS was found to help clients 
identify and address these gaps in knowledge 
through a range of mechanisms that are unique 
to this facility (e.g., targeted educational 
messaging). 
Small et al 2008† 144 
 
Study quality: Not 
assessed 
Qualitative NR 
50 PWID from the SEOSI 
cohort 
Age, range: 25-60 years 
Males: 56% 
Barriers to care, 
Access to care 
Referrals 
SIF facilitated access to on-site nursing 
attention and care for injection-related 
infection and facilitated uptake of health 
services. SIFs have potential to overcome many 
of the social and structural barriers to care. 
Wood et al 2008† 135 
 





1,087 PWID from the SEOSI 
cohort 









Frequent use of SIF (≥75% of injections) was 
associated with an increased likelihood of 
receiving safer injection education (aOR: 1.47, 
95% CI: 1.22-1.77, p<0.001). 
Lloyd-Smith et al 
2008† 42 
 





1,065 PWID from the SEOSI 
cohort 
Age, median (IQR) of those 
with CIRI at BL: 36 (31-43) 
years; those without CIRI at 




SIF use was not significantly associated with 
development of a CIRI (aOR = 0.58; 95% CI: 
0.29-1.19). 
Lloyd-Smith 2009† 155 
 





1083 PWIDs from SEOSI 
cohort 
Provision of care at 
the SIF (CIRI) 
About 27% received care, 65% of whom 
attended the SIF for this purpose. Among SIF 
clients, factors associated with receiving care 
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included, unstable housing (aHR = 1.39, 95%CI 
= 1.02–1.88), and daily heroin injection (aHR = 
1.52, 95%CI = 1.13–2.4). 
Milloy et al 2009† 61 
 
Study quality: Good 
 
Prospective cohort 
July 2004 to 
November 
2005 
902 PWID from the SEOSI 
cohort 




Frequent SIF use (all/most injections vs 
few/some/none) was not associated with 
recent incarceration (aOR = 0.99; 95% CI: 0.79 – 
1.23, p=0.92). 
Small et al 2009† 143 
 







50 PWID from SEOSI cohort 
Age, range: 25-60 years 
Males: 56% 
Stigma, Integrated 
care, Access to 
social services 
SIF provided assessment and care for injection-
related infections, as well as enhanced access 
to off-site medical services. Presence of 
professional nursing staff aided clients to 




Study quality: not 
assessed  
Qualitative 
May 2007 to 
June 2007 
22 PWID attending a harm 
reduction room in 
Vancouver 
Age, mean (range): 43.8 
(28-54) years 
Male: 68% 
HIV Seropositive: 100% 
 




Receipt of services, 
Skin and soft tissue 
infection, HIV, 
Hepatitis C 
The Harm Reduction Room (HRR) influenced 
access to care by building trusting relationships 
and encouraging use of other services, such as 
SEI and care for infections. The most common 
reasons for using the HRR were hygiene, 
overdose risk, and physical safety especially 
among female participants. Participants and 
staff noted that reduction in infections could be 
due to SEI and having a safer place to inject. 
Milloy et al 2010† 154 
 
Study quality: Good 
Prospective cohort  
July 2004 to 
June 2006 
889 PWID from the SEOSI 
cohort 




20% of SIF users were unable to access any 
type of drug or alcohol treatment in the 
previous 6 months. Frequent use of SIF (≥75% 
of injections) was not associated with trying but 
being unable to access addiction treatment 
(aOR = 1.08; 95% CI: 0.84 – 1.40, p=0.54). 
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Lloyd-Smith et al 
2010† 139 
 
Study quality: Good  




1083 PWID from the SEOSI 
cohort 
Age, median (IQR): 38.4 
(32.7-44.3) years 





Referral to the hospital by a SIF nurse was 
associated with an increased likelihood of 
hospitalization for CIRI in multivariate analyses 
(aHR: 5.38; 95% CI: 3.39, 8.55). Referral by SIF 
nurse was associated with shorter hospital 
stays (4 days [IQR: 2-7] vs 12 days [IQR: 5-33], 
p=0.001 after adjustment 
Marshall 2011 12 
 





(Jan 2001 to 
Sep 2003) 
Post-SIF  
(Sep 2003 to 
Dec 2005) 
Pre-SIF (<500 m) = 56 
Post SIF (<500 m) = 33 
Pre-SIF (>500 m) =113 
Post-SIF (>500 m) =88 
Overdose mortality 
In two years, post-SIF opening, fatal overdose 
decreased by 35% within 500m from SIF (253.8 
to 165.1 deaths per 100,000 PYs, p=0.048), 
compared to two-years pre-SIF opening. During 
the same period, fatal overdose decreased by 
9.3% in the rest of the city (7.6 to 6.9 deaths 
per 100,000 PYs, p=0.49). The rate difference 
between these two periods was significant 
(1·6–175·8 per 100 000 PYs, p=0·048). 
DeBeck et al 2011†47 
 
Study quality: Good 
Prospective cohort  
December 
2003 to June 
2006  
1090 PWID from SEOSI 
cohort 




Regular SIF use (in past 6-
months): 37%  
Current MMT: 23% 
 
Drug use; 
Use of services 
Regular use of SIF use at baseline (aHR = 1.33, 
95% CI:1.04–1.72) and having contact with the 
addiction counselor in the SIF (aHR = 1.54, 95% 
CI: 1.13–2.08) were independently and 
positively associated with initiation of addiction 
treatment. 
Enrolment in MMT (aHR: 1.57, 95% CI: 1.02-
2.40) and other addiction treatment program 
(aHR: 1.85, 95% CI: 1.06-3.24) were positively 
associated with injection drug use cessation. 
Lloyd-Smith et al 
2012† 140 
 






1,083 PWID from the SEOSI 
cohort 
Age, median (IQR): 39.7 
(33.7-45.3) years 
Infections  
During the study period, 289 (27%) participants 
used the ED for a CIRI. Referral to hospital by 
SIF nurses was independently and positively 
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 Male: 70% associated with ED use for CIRI among (aOR= 
4.69, 95% CI: 2.76 – 7.97). 
McNeil et al 2014 44 
 






13 Dr. Peter Center 
residents (DPC) 







Participants highlighted that DPC aided in 
providing better access to healthcare services. 
It provided clients with a comfortable space to 
have discussions about their drug use and 
decreased stigmatization. Environmental 
support by facility decreased drug-related risks 
and improved health outcomes, including 
HAART adherence and survival. 
Gaddis et al 2017† 45 
 







1316 PWIDs from VIDUS & 
ACCESS cohort 
Age, median (IQR): 46.2 
(40.2 - 52.1) years 
Males: 67% 
Unstable housing: 80% 





11.2% of clients reported enrolling in 
detoxification services co-located with the SIF 
at least once during the study period. Frequent 
use of SIF was associated with enrollment into 
the detoxification program (aOR: 8.15, 95% CI: 
5.38-12.34, p<0.001) 
Myer and Belisle 
2018†62 
 









Compared to the 89 weeks pre-Insite, 
Vancouver, the police district that contains 
Insite observed a significant (per-week) 
reduction with 6.0 less violent crimes, 34.5 
fewer property crimes, and 42.3 less all crimes 
post-Insite opening; three other police districts 
observed no significant changes in crime post-
Insite opening. 






2016 to April 
2017 
1581 overdose events  





Of 1581 overdose events at Insite, Vancouver, 
31.4% were atypical overdose presentations 
(dyskinesia, confusion, and muscle rigidity). Of 
497 atypical overdose presentations, 84.5% 
were treated with oxygen, 69% with naloxone, 
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Study quality: Not 
assessed 
and 15.1% were transferred to hospital by 
ambulance. 
Notta et al 2019† 33 
 
Study quality: Good 
Time series 
January 2010 
to June 2017 
N/R Overdose 
Overdose rate per 100 visits increased from 
2010-2017 (1.5 vs 9.5, p<0.001) with an 
increase in overdose events requiring naloxone 
administration (48.4% to 57.1%, p<0.001). No 
overdose deaths reported within the facility.  
In the recent period clients were more likely to 
experience an overdose events as compared to 
baseline if they consumed cocaine (RR: 10.4, 
95% CI: 6.7-16.1, p<0.001) or  heroin (RR: 4.8, 
95% CI: 4.3-5.3, p<0.001) 
Kennedy et al 2019† 31 
 




2006 to June 
2017 
811 PWIDs 
Age, median (IQR): 39(33-
46) years 
Males: 65.7% 
Unstable housing: 81.9% 
HIV seropositive: 30.3% 
Hep C: 85.3% 
All-cause mortality 
13.8% participants died during the study period 
with a CRM of 22.7 per 1000-PY (95% CI: 18.7-
27.4). Frequent use of SIF was inversely 
associated with a risk of all-cause mortality 
(aHR: 0.46; 95% CI: 0.26-0.80, p=0.006). 
Sydney, Australia 
Freeman et al 2005† 57 
 











loitering or dealing 
Theft, robbery, or drug-related loitering in front 
of SIF was not associated with the opening of 
SIF (p>0.05). 
Increase in drug-related loitering at the back of 
the SIF were reported post-SIF opening 
(p<0.05) 
Salmon et al 2007† 55 
 
 




Year 2000: Residents 





From 2000 to 2005, a significant decline in 
witnessing public injecting drug use was 
reported by both, residents (33%, 28%, and 
19%, p<0.001) and business owners (38%, 32%, 
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Year 2002: Residents 
(n=540), Business owners 
(n=207)       
Year 2005: Residents 
(n=316), Business owners 
(n=210) 
drugs offered for 
purchase in the last 
month 
and 28%, p=0.03). Business owners located 
beyond 500m of SIF were less likely to see this 
change (p<0.001) 
Similarly, a significant decline in witnessing 
publicly discarded syringes was reported by 
both, residents (67%, 58%, and 40%, p<0.001) 
and business owners (72%, 64%, and 57%, 
p=0.01). Business owners located beyond 500m 
of SIF were less likely to see this change 
(p<0.001) 
Variable change was observed in drugs been 
offered for purchase was reported by both, 
residents (28%, 29%, and 26%, p=0.80) and 
business owners (33%, 34%, and 28%, p=0.26) 
over time. 
Kimber, Mattick et al 
2008† 49 
 
Study quality: Good 
Prospective cohort 
May 2001 to 
Oct 2002 
3715 PWIDs who used 
MSIC 
1385 referrals to 577 
clients 
Overall referral uptake: 
35% 
Number of referrals  
drug characteristics 
16% SIF clients with drug treatment referrals 
had confirmed drug treatment uptake. 
Frequent SIF use was associated with receiving 
written referral to drug treatment (aHR: 1.6, 
95% CI: 1.2-2.2, p<0.01) 
Salmon et al 2010†34 
 
Study quality: Good 
Ecological Pre-post 
May 1998 to 
April 2006 





Significant decrease in average monthly 
ambulance attendances in MSIC vicinity, 
compared to rest of the city (61% vs 68%, 
p=0.002) 
Significant decline in average monthly 
ambulance attendances was observed during 
SIF operating hours, compared to rest of the 
city (80% vs 60%, p<0.001) 
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Fitzgerald et al 2010 58 
 
 
Study quality: Good 
Time series 
May 2001 to 
March 2010 
N/A – Crime statistics 
Police recorded 
incidents related to 
robbery, property, 
illicit drug offenses 
Incidence of robbery and property related 
crimes declined in both the vicinity of SIF 
(MSIC) and the rest of Sydney between 1999 
and 2010 
Illicit drug related offense incidents declined 
vicinity of SIF (MSIC) between 1999 and 2003 
and then remained stable until 2009  
A similar trend was reported in the rest of 
Sydney. Illicit drug related arrests declined from 
1999 to 2003, with a slightly upward trend from 














In 2002, a significant decline in robbery rates 
was reported near Kings Cross (281 to 112 
incidents). Between 2002-2012, a decline in 
robbery rates per 100,000-persons was 
reported (1,646 to 563). Significant reduction 
was reported in thefts in Kings Cross (36,174 to 
16,724 incidents per 100,000-persons) and rest 
of NSW (6,399 vs 3,359 incidents per 100,000 
persons). Total illicit drug offences increased in 
both the Kings Cross LAC and the rest of 
Sydney. (p < 0.001 for all comparisons) 
Latimer 2016† 127 
 
 







undertaken by 4,177 
unique individuals 
Current drug use: Heroin 
(25%), Other opioids (58%), 
Crystal meth (13%), 
Cocaine (4%) 
Fentanyl overdose 
Overdose events were highest among users of 
fentanyl (4.4%) with a significantly higher 
overdose risk (crude RR: 2.21, 95% CI: 1.8-2.6), 
p<0.0001), as compared to heroin users 
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Roxburgh et al 2017 
128 
 
Study quality: Good 
Prospective cohort 
Jan 2007 to 
April 2014 
909 PWIDs who used the 
SIF experiencing 2860 
overdose 







During the period 2007–2014, there were 12.7 
heroin overdoses per 1000 injections compared 
to 4.1 oxycodone overdoses per 1000 
injections. 
Heroin overdoses appeared to be more severe 
than oxycodone overdoses and risk of 
experiencing overdose with heroin was 
significantly higher than with oxycodone (OR: 
3.1, 95% CI: 3.0-3.2). 
Denmark 
Van der Poel et al 
2003# 142 
 
Study quality: Not 
assessed 
Exploratory 2000 67 PWUD Use of services 
Average SIF visits for four facilities (prior to the 
interview) was six days (median: 7 days) and 
two-times (median: 2.5) in last 24hrs. DCR use 
led to 30% reporting more attention to 
hygiene, while 59% reported seeing no effect of 
visiting a DCR on their drug use. 
Kinnard 2014# 56 
 
 





41 PWIDs who use the DCR 
Age, median (IQR): 37 (30-
43) years 
Males: 90.2% 
Unstable housing: 26.8% 
Daily DCR use: 29.3% 
Disposal of syringes 
Behavior change 
Injection frequency 
After SIF opening, 59% reported safer disposal 
of syringes; 76% reduction in injection risk 
behaviors [including decline in rushed injection 
(63%), public injecting (56%) and ceasing 
syringe sharing (54%)]; p<0.001).  
Toth et al 2016# 51 
 
 





154 PWID who use at least 
one of 5 SCFs 
Injection behaviors,  
Use of treatment 
and recovery 
support services 
SIF users receiving SEI were more likely to have 
access to sterile equipment (68.8% vs 25.9%, 
p=0.02). SIF users who were advised to seek 
medical help were more likely to receive 
treatment for disease, compared to those who 
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were not advised to seek medical help (51.3% 
vs 25.7%, p<0.05). 
Spain 
Bravo 2009# 133 
 
Study quality: Fair 
Cross-sectional  2002 to 2005  
249 PWID 
Age ≤25 years: 37.3% 
Males: 44.3% 
SIF users: 39% 
Unstable housing: 48.5% 
NEP use: 96% 
Injection practices 
Among 249 PWID in two cities with SIFs, clients 
had significantly higher likelihood of not 
borrowing used syringes (aOR: 3.30, 95% CI: 
1.4-7.7), compared to non-SIF clients. 
Obtaining sterile syringes for free at the NEP 
was associated with not borrowing (aOR: 2.6, 
95% CI: 1.0-6.8) and not sharing injection 
equipment (aOR: 3.2, 95% CI: 1.4-7.3), 
compared to not accessing NEP. 
Folch 2018#38 
 
Study quality: Fair 
Cross-sectional 2014 to 2015  
520 PWID who used a DCR 




Regular SIF use (frequent): 
21.2% 
In prison (ever): 73.1% 
Injection behaviors, 
Use of treatment 
support services 
SIF use in Catalonia, Spain was associated with 
significantly lower odds of public injection 
(aOR: 0.27, 95% CI: 0.12-0.62), and sharing 
syringes (aOR: 0.39, 95% CI: 0.20-0.78) and 
significantly higher odds of safe disposal of 
syringes (aOR: 5.77, 95% CI: 3.41-9.77) and 
accessing drug dependence services (aOR: 2.12, 
95% CI: 1.18-3.81). 
Germany 
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Zurhold et al 2003#50 
Germany 
 
Study quality: Poor  
Cross-sectional 2000 
616 PWID using 
consumption rooms in 
Germany 
Age, mean: 32.6 years 
Male: 80% 
Years of drug use, mean: 11 
Regular SIF use: 33% 
Heroin use at baseline: 84% 
Use of treatment 
and recovery 
support services, 
Receipt of services 
Frequent use of SCS was significantly associated 
with use of syringe exchange services (59% vs 
54% and 44%, p<0.05); counselling services 
(46% vs 35% and 25%; p<0.01) ; medical 
services (37% vs 29% and 17%, p<0.01); and 
education on safer use (9% vs 3% and 3%, 










129 PWID using DCFs in 
Germany 
Age, mean: 31 years 
Male: 75% 
History of incarceration: 
37% 
Length of attendance 
(median): 5 weeks 
Years of drug use, mean 
(SD): 11 (6) years 
Injection behaviors, 




Regular and consistent DCF attendance [n (%)]: 
9 (7%) of clients. SIF attendance for >3 months: 
29 (22%); Left DCR by week 4: 26 (20%); 
attended the facility for less than a week: 29 
(22%).  
3months prior to DCF: 83% of clients were in 
contact at least once with low-threshold 
ancillary services (e.g., emergency shelter, 
canteen/cafeteria facility located within the 
DCF building, and mobile medical unit.  
After attending DCF: 46% Clients reported 
regular use of available services and facilities 
(46%); did not use any service (40%). Reasons 
for stopping DCF use included transfer to health 
insurance treatment system facilities (37%), 
enrollment in methadone maintenance, and 
imprisonment (17%). Clients stopped attending 
without providing a reason (21%) and two 
clients died (one from suicide, one from 
unknown reasons). 
Insite, Vancouver and MSIC, Australia - fixed stand-alone or specialized model (†) 
Dr. Peter Centre, Vancouver – Integrated model (‡) 
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Some centers in Spain, Germany, and Denmark - Mobile model (#) 
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c. San Francisco 
 
  
Parameter Low Value High Value Low Result High Result Spread
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$4,095 -$6,277 $2,182
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$6,377 -$4,397 $1,980
# Hospitalization Cost: Boston $6,704 $10,055 -$4,613 -$5,759 $1,146
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$4,613 -$5,759 $1,146
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$5,727 -$4,645 $1,083
# Cost of Living Ratio vs. Vancouver: Boston 0.99 1.49 -$5,727 -$4,645 $1,083
# Cost of ED VIsit: Boston $2,761 $4,141 -$4,694 -$5,678 $983
# First Year SSP Cost $1,226,623 $1,839,934 -$4,761 -$5,610 $849
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$5,021 -$5,296 $276
# Total annual injections in the SIF 144,000 216,000 -$5,021 -$5,296 $276
# Cost of Ambulance Ride: Boston $418 $628 -$5,081 -$5,290 $209
# Number of Unique SIF Clients/Month 1,680 2,520 -$5,236 -$5,136 $99
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$5,212 -$5,160 $52
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$5,170 -$5,202 $33
# Cost/sqft Commercial Property: Boston $440 $660 -$5,201 -$5,170 $31
# Commercial Mortgage Loan Interest: Boston 5% 9% -$5,195 -$5,176 $20
-$7,000 -$6,000 -$5,000 -$4,000 -$3,000 -$2,000 -$1,000 $0
Parameter Low Value High Value Low Result High Result Spread
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$4,015 -$6,073 $2,059
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$6,208 -$4,274 $1,935
# Hospitalization Cost: Philadelphia $6,001 $9,002 -$4,531 -$5,557 $1,026
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$4,531 -$5,557 $1,026
# Cost of ED VIsit: Philadelphia $2,761 $4,141 -$4,552 -$5,536 $983
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$5,502 -$4,586 $917
# Cost of Living Ratio vs. Vancouver: Philadelphia 0.84 1.26 -$5,502 -$4,586 $917
# First Year SSP Cost $1,226,623 $1,839,934 -$4,673 -$5,415 $741
# Cost of Ambulance Ride: Philadelphia $390 $585 -$4,947 -$5,141 $195
# Total annual injections in the SIF 144,000 216,000 -$4,927 -$5,122 $195
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$4,927 -$5,122 $195
# Number of Unique SIF Clients/Month 1,680 2,520 -$5,087 -$5,001 $87
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$5,069 -$5,019 $49
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$5,028 -$5,060 $32
# Cost/sqft Commercial Property: Philadelphia $166 $248 -$5,050 -$5,038 $12
# Commercial Mortgage Loan Interest: Philadelphia 5% 9% -$5,048 -$5,040 $7
-$7,000 -$6,000 -$5,000 -$4,000 -$3,000 -$2,000 -$1,000 $0
Parameter Low Value High Value Low Result High Result Spread
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$3,846 -$6,071 $2,224
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$6,080 -$4,216 $1,865
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$5,600 -$4,317 $1,283
# Cost of Living Ratio vs. Vancouver: San Francisco 1.18 1.76 -$5,600 -$4,317 $1,283
# Hospitalization Cost: San Francisco $6,946 $10,419 -$4,365 -$5,552 $1,188
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$4,365 -$5,552 $1,188
# Cost of ED VIsit: San Francisco $2,761 $4,141 -$4,467 -$5,450 $983
# First Year SSP Cost $1,226,623 $1,839,934 -$4,515 -$5,401 $886
# Total annual injections in the SIF 144,000 216,000 -$4,699 -$5,131 $432
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$4,699 -$5,131 $432
# Cost of Ambulance Ride: San Francisco $453 $680 -$4,845 -$5,072 $227
# Number of Unique SIF Clients/Month 1,680 2,520 -$5,010 -$4,907 $104
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$4,985 -$4,932 $53
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$4,943 -$4,974 $31
# Cost/sqft Commercial Property: San Francisco $240 $360 -$4,967 -$4,950 $17
# Commercial Mortgage Loan Interest: San Francisco 5% 9% -$4,964 -$4,953 $11
-$7,000 -$6,000 -$5,000 -$4,000 -$3,000 -$2,000 -$1,000 $0
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Parameter Low Value High Value Low Result High Result Spread
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$3,770 -$5,603 $1,833
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$5,766 -$3,972 $1,794
# Cost of ED VIsit: Atlanta $2,761 $4,141 -$4,195 -$5,179 $983
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$5,093 -$4,281 $812
# Cost of Living Ratio vs. Vancouver: Atlanta 0.74 1.12 -$5,093 -$4,281 $812
# Hospitalization Cost: Atlanta $4,712 $7,068 -$4,284 -$5,090 $806
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$4,284 -$5,090 $806
# First Year SSP Cost $1,226,623 $1,839,934 -$4,324 -$5,050 $727
# Cost of Ambulance Ride: Atlanta $369 $554 -$4,595 -$4,779 $185
# Total annual injections in the SIF 144,000 216,000 -$4,625 -$4,728 $103
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$4,625 -$4,728 $103
# Number of Unique SIF Clients/Month 1,680 2,520 -$4,729 -$4,644 $85
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$4,709 -$4,665 $44
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$4,672 -$4,702 $30
# Cost/sqft Commercial Property: Atlanta $195 $293 -$4,694 -$4,680 $14
# Commercial Mortgage Loan Interest: Atlanta 5% 9% -$4,691 -$4,682 $9
-$7,000 -$6,000 -$5,000 -$4,000 -$3,000 -$2,000 -$1,000 $0
Parameter Low Value High Value Low Result High Result Spread
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$4,174 -$6,233 $2,059
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$6,407 -$4,407 $2,000
# Hospitalization Cost: Baltimore $6,001 $9,002 -$4,691 -$5,717 $1,026
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$4,691 -$5,717 $1,026
# Cost of ED VIsit: Baltimore $2,761 $4,141 -$4,712 -$5,695 $983
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$5,618 -$4,789 $829
# Cost of Living Ratio vs. Vancouver: Baltimore 0.76 1.14 -$5,618 -$4,789 $829
# First Year SSP Cost $1,226,623 $1,839,934 -$4,846 -$5,562 $716
# Cost of Ambulance Ride: Baltimore $394 $591 -$5,105 -$5,302 $197
# Total annual injections in the SIF 144,000 216,000 -$5,125 -$5,256 $130
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$5,125 -$5,256 $130
# Number of Unique SIF Clients/Month 1,680 2,520 -$5,246 -$5,162 $84
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$5,228 -$5,179 $49
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$5,187 -$5,220 $33
# Cost/sqft Commercial Property: Baltimore $162 $242 -$5,209 -$5,198 $11
# Commercial Mortgage Loan Interest: Baltimore 5% 9% -$5,207 -$5,200 $7
-$7,000 -$6,000 -$5,000 -$4,000 -$3,000 -$2,000 -$1,000 $0
Parameter Low Value High Value Low Result High Result Spread
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$4,320 -$6,544 $2,224
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$6,688 -$4,601 $2,087
# Hospitalization Cost: Seattle $6,946 $10,419 -$4,838 -$6,026 $1,188
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$4,838 -$6,026 $1,188
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$5,947 -$4,917 $1,030
# Cost of Living Ratio vs. Vancouver: Seattle 0.94 1.42 -$5,947 -$4,917 $1,030
# Cost of ED VIsit: Seattle $2,761 $4,141 -$4,940 -$5,924 $983
# First Year SSP Cost $1,226,623 $1,839,934 -$5,008 -$5,856 $849
# Total annual injections in the SIF 144,000 216,000 -$5,304 -$5,517 $213
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$5,304 -$5,517 $213
# Cost of Ambulance Ride: Seattle $413 $620 -$5,329 -$5,535 $207
# Number of Unique SIF Clients/Month 1,680 2,520 -$5,482 -$5,382 $99
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$5,459 -$5,405 $53
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$5,415 -$5,449 $34
# Cost/sqft Commercial Property: Seattle $331 $497 -$5,444 -$5,420 $24
# Commercial Mortgage Loan Interest: Seattle 5% 9% -$5,439 -$5,424 $15
-$8,000 -$7,000 -$6,000 -$5,000 -$4,000 -$3,000 -$2,000 -$1,000 $0
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c. San Francisco 
 
  
Parameter Low Value High Value Low Result High Result Spread
# Hospitalization Cost: Boston $6,704 $10,055 -$6,474 -$8,083 $1,609
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$6,474 -$8,083 $1,609
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$8,039 -$6,519 $1,519
# Cost of Living Ratio vs. Vancouver: Boston 0.99 1.49 -$8,039 -$6,519 $1,519
# Cost of ED VIsit: Boston $2,761 $4,141 -$6,589 -$7,969 $1,380
# First Year SSP Cost $1,226,623 $1,839,934 -$6,683 -$7,875 $1,192
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$7,047 -$7,434 $387
# Total annual injections in the SIF 144,000 216,000 -$7,047 -$7,434 $387
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$7,129 -$7,428 $299
# Cost of Ambulance Ride: Boston $418 $628 -$7,132 -$7,426 $294
# Number of Unique SIF Clients/Month 1,680 2,520 -$7,349 -$7,209 $139
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$7,229 -$7,312 $83
# Cost/sqft Commercial Property: Boston $440 $660 -$7,301 -$7,257 $44
# Commercial Mortgage Loan Interest: Boston 5% 9% -$7,292 -$7,265 $28
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$7,281 -$7,276 $5
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$7,280 -$7,278 $2
-$10,000 -$8,000 -$6,000 -$4,000 -$2,000 $0
Parameter Low Value High Value Low Result High Result Spread
# Hospitalization Cost: Philadelphia $6,001 $9,002 -$6,360 -$7,800 $1,440
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$6,360 -$7,800 $1,440
# Cost of ED VIsit: Philadelphia $2,761 $4,141 -$6,390 -$7,770 $1,380
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$7,723 -$6,436 $1,287
# Cost of Living Ratio vs. Vancouver: Philadelphia 0.84 1.26 -$7,723 -$6,436 $1,287
# First Year SSP Cost $1,226,623 $1,839,934 -$6,559 -$7,600 $1,041
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$6,941 -$7,219 $278
# Cost of Ambulance Ride: Philadelphia $390 $585 -$6,943 -$7,217 $274
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$6,916 -$7,189 $273
# Total annual injections in the SIF 144,000 216,000 -$6,916 -$7,189 $273
# Number of Unique SIF Clients/Month 1,680 2,520 -$7,141 -$7,019 $122
# Cost/sqft Commercial Property: Philadelphia $166 $248 -$7,088 -$7,072 $17
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$7,087 -$7,075 $12
# Commercial Mortgage Loan Interest: Philadelphia 5% 9% -$7,085 -$7,074 $10
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$7,082 -$7,077 $5
-$10,000 -$8,000 -$6,000 -$4,000 -$2,000 $0
Parameter Low Value High Value Low Result High Result Spread
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$7,860 -$6,059 $1,801
# Cost of Living Ratio vs. Vancouver: San Francisco 1.18 1.76 -$7,860 -$6,059 $1,801
# Hospitalization Cost: San Francisco $6,946 $10,419 -$6,126 -$7,793 $1,667
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$6,126 -$7,793 $1,667
# Cost of ED VIsit: San Francisco $2,761 $4,141 -$6,269 -$7,650 $1,380
# First Year SSP Cost $1,226,623 $1,839,934 -$6,338 -$7,581 $1,244
# Total annual injections in the SIF 144,000 216,000 -$6,596 -$7,202 $606
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$6,596 -$7,202 $606
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$6,798 -$7,121 $324
# Cost of Ambulance Ride: San Francisco $453 $680 -$6,801 -$7,119 $318
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$6,790 -$7,072 $282
# Number of Unique SIF Clients/Month 1,680 2,520 -$7,032 -$6,887 $145
# Cost/sqft Commercial Property: San Francisco $240 $360 -$6,972 -$6,948 $24
# Commercial Mortgage Loan Interest: San Francisco 5% 9% -$6,967 -$6,952 $15
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$6,963 -$6,956 $6
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$6,962 -$6,957 $6
-$10,000 -$8,000 -$6,000 -$4,000 -$2,000 $0
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Parameter Low Value High Value Low Result High Result Spread
# Cost of ED VIsit: Atlanta $2,761 $4,141 -$5,888 -$7,269 $1,380
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$7,148 -$6,009 $1,140
# Cost of Living Ratio vs. Vancouver: Atlanta 0.74 1.12 -$7,148 -$6,009 $1,140
# Hospitalization Cost: Atlanta $4,712 $7,068 -$6,013 -$7,144 $1,131
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$6,013 -$7,144 $1,131
# First Year SSP Cost $1,226,623 $1,839,934 -$6,068 -$7,088 $1,020
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$6,447 -$6,710 $264
# Cost of Ambulance Ride: Atlanta $369 $554 -$6,449 -$6,708 $259
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$6,492 -$6,636 $145
# Total annual injections in the SIF 144,000 216,000 -$6,492 -$6,636 $145
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$6,656 -$6,527 $128
# Number of Unique SIF Clients/Month 1,680 2,520 -$6,638 -$6,519 $119
# Cost/sqft Commercial Property: Atlanta $195 $293 -$6,588 -$6,569 $19
# Commercial Mortgage Loan Interest: Atlanta 5% 9% -$6,584 -$6,572 $12
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$6,581 -$6,576 $5
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$6,577 -$6,580 $3
-$8,000 -$7,000 -$6,000 -$5,000 -$4,000 -$3,000 -$2,000 -$1,000 $0
Parameter Low Value High Value Low Result High Result Spread
# Hospitalization Cost: Baltimore $6,001 $9,002 -$6,584 -$8,024 $1,440
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$6,584 -$8,024 $1,440
# Cost of ED VIsit: Baltimore $2,761 $4,141 -$6,614 -$7,994 $1,380
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$7,886 -$6,722 $1,164
# Cost of Living Ratio vs. Vancouver: Baltimore 0.76 1.14 -$7,886 -$6,722 $1,164
# First Year SSP Cost $1,226,623 $1,839,934 -$6,802 -$7,806 $1,004
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$7,163 -$7,445 $281
# Cost of Ambulance Ride: Baltimore $394 $591 -$7,166 -$7,442 $277
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$7,194 -$7,377 $183
# Total annual injections in the SIF 144,000 216,000 -$7,194 -$7,377 $183
# Number of Unique SIF Clients/Month 1,680 2,520 -$7,363 -$7,245 $118
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$7,369 -$7,261 $108
# Cost/sqft Commercial Property: Baltimore $162 $242 -$7,312 -$7,296 $16
# Commercial Mortgage Loan Interest: Baltimore 5% 9% -$7,309 -$7,299 $10
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$7,306 -$7,301 $5
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$7,303 -$7,305 $2
-$9,000-$8,000-$7,000-$6,000-$5,000-$4,000-$3,000-$2,000-$1,000 $0
Parameter Low Value High Value Low Result High Result Spread
# Hospitalization Cost: Seattle $6,946 $10,419 -$6,791 -$8,458 $1,667
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$6,791 -$8,458 $1,667
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$8,347 -$6,901 $1,446
# Cost of Living Ratio vs. Vancouver: Seattle 0.94 1.42 -$8,347 -$6,901 $1,446
# Cost of ED VIsit: Seattle $2,761 $4,141 -$6,934 -$8,315 $1,380
# First Year SSP Cost $1,226,623 $1,839,934 -$7,029 -$8,220 $1,191
# Total annual injections in the SIF 144,000 216,000 -$7,445 -$7,744 $300
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$7,445 -$7,744 $300
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$7,477 -$7,772 $295
# Cost of Ambulance Ride: Seattle $413 $620 -$7,479 -$7,769 $290
# Number of Unique SIF Clients/Month 1,680 2,520 -$7,694 -$7,555 $139
# Cost/sqft Commercial Property: Seattle $331 $497 -$7,641 -$7,608 $33
# Commercial Mortgage Loan Interest: Seattle 5% 9% -$7,634 -$7,614 $21
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$7,627 -$7,622 $5
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$7,626 -$7,623 $2
-$10,000 -$8,000 -$6,000 -$4,000 -$2,000 $0
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c. San Francisco 
 
  
Parameter Low Value High Value Low Result High Result Spread
# Hospitalization Cost: Boston $6,704 $10,055 -$13,488 -$16,840 $3,352
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$16,747 -$13,582 $3,165
# Cost of Living Ratio vs. Vancouver: Boston 0.99 1.49 -$16,747 -$13,582 $3,165
# Cost of ED VIsit: Boston $2,761 $4,141 -$13,726 -$16,602 $2,876
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$16,861 -$14,034 $2,827
# First Year SSP Cost $1,226,623 $1,839,934 -$13,923 -$16,406 $2,483
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$14,681 -$15,487 $806
# Total annual injections in the SIF 144,000 216,000 -$14,681 -$15,487 $806
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$14,853 -$15,476 $622
# Cost of Ambulance Ride: Boston $418 $628 -$14,858 -$15,470 $612
# Number of Unique SIF Clients/Month 1,680 2,520 -$15,310 -$15,019 $290
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$15,060 -$15,233 $173
# Cost/sqft Commercial Property: Boston $440 $660 -$15,210 -$15,119 $91
# Commercial Mortgage Loan Interest: Boston 5% 9% -$15,192 -$15,135 $58
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$15,170 -$15,159 $11
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$15,166 -$15,162 $4
-$20,000 -$15,000 -$10,000 -$5,000 $0
Parameter Low Value High Value Low Result High Result Spread
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$16,561 -$13,542 $3,020
# Hospitalization Cost: Philadelphia $6,001 $9,002 -$13,249 -$16,250 $3,001
# Cost of ED VIsit: Philadelphia $2,761 $4,141 -$13,312 -$16,187 $2,876
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$16,090 -$13,409 $2,680
# Cost of Living Ratio vs. Vancouver: Philadelphia 0.84 1.26 -$16,090 -$13,409 $2,680
# First Year SSP Cost $1,226,623 $1,839,934 -$13,666 -$15,833 $2,168
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$14,459 -$15,040 $580
# Cost of Ambulance Ride: Philadelphia $390 $585 -$14,464 -$15,035 $570
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$14,408 -$14,977 $570
# Total annual injections in the SIF 144,000 216,000 -$14,408 -$14,977 $570
# Number of Unique SIF Clients/Month 1,680 2,520 -$14,876 -$14,623 $254
# Cost/sqft Commercial Property: Philadelphia $166 $248 -$14,767 -$14,732 $34
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$14,764 -$14,740 $25
# Commercial Mortgage Loan Interest: Philadelphia 5% 9% -$14,760 -$14,738 $22
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$14,754 -$14,745 $10
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$14,749 -$14,750 $1
-$20,000 -$15,000 -$10,000 -$5,000 $0
Parameter Low Value High Value Low Result High Result Spread
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$16,375 -$12,623 $3,753
# Cost of Living Ratio vs. Vancouver: San Francisco 1.18 1.76 -$16,375 -$12,623 $3,753
# Hospitalization Cost: San Francisco $6,946 $10,419 -$12,763 -$16,236 $3,473
# Cost of ED VIsit: San Francisco $2,761 $4,141 -$13,061 -$15,937 $2,876
# First Year SSP Cost $1,226,623 $1,839,934 -$13,204 -$15,795 $2,591
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$15,953 -$13,530 $2,423
# Total annual injections in the SIF 144,000 216,000 -$13,742 -$15,004 $1,262
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$13,742 -$15,004 $1,262
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$14,162 -$14,836 $674
# Cost of Ambulance Ride: San Francisco $453 $680 -$14,168 -$14,830 $662
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$14,145 -$14,733 $587
# Number of Unique SIF Clients/Month 1,680 2,520 -$14,651 -$14,348 $303
# Cost/sqft Commercial Property: San Francisco $240 $360 -$14,524 -$14,474 $50
# Commercial Mortgage Loan Interest: San Francisco 5% 9% -$14,514 -$14,483 $31
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$14,506 -$14,492 $13
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$14,505 -$14,493 $12
-$20,000 -$15,000 -$10,000 -$5,000 $0
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Parameter Low Value High Value Low Result High Result Spread
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$15,659 -$12,403 $3,256
# Cost of ED VIsit: Atlanta $2,761 $4,141 -$12,267 -$15,143 $2,876
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$14,892 -$12,518 $2,374
# Cost of Living Ratio vs. Vancouver: Atlanta 0.74 1.12 -$14,892 -$12,518 $2,374
# Hospitalization Cost: Atlanta $4,712 $7,068 -$12,527 -$14,883 $2,356
# First Year SSP Cost $1,226,623 $1,839,934 -$12,643 -$14,768 $2,125
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$13,430 -$13,980 $549
# Cost of Ambulance Ride: Atlanta $369 $554 -$13,435 -$13,975 $540
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$13,524 -$13,826 $302
# Total annual injections in the SIF 144,000 216,000 -$13,524 -$13,826 $302
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$13,866 -$13,599 $268
# Number of Unique SIF Clients/Month 1,680 2,520 -$13,829 -$13,581 $249
# Cost/sqft Commercial Property: Atlanta $195 $293 -$13,725 -$13,685 $41
# Commercial Mortgage Loan Interest: Atlanta 5% 9% -$13,718 -$13,692 $26
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$13,710 -$13,700 $9
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$13,702 -$13,708 $6
-$20,000 -$15,000 -$10,000 -$5,000 $0
Parameter Low Value High Value Low Result High Result Spread
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$17,145 -$13,931 $3,214
# Hospitalization Cost: Baltimore $6,001 $9,002 -$13,716 -$16,717 $3,001
# Cost of ED VIsit: Baltimore $2,761 $4,141 -$13,779 -$16,654 $2,876
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$16,429 -$14,004 $2,425
# Cost of Living Ratio vs. Vancouver: Baltimore 0.76 1.14 -$16,429 -$14,004 $2,425
# First Year SSP Cost $1,226,623 $1,839,934 -$14,170 -$16,263 $2,093
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$14,923 -$15,510 $586
# Cost of Ambulance Ride: Baltimore $394 $591 -$14,928 -$15,505 $576
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$14,988 -$15,369 $381
# Total annual injections in the SIF 144,000 216,000 -$14,988 -$15,369 $381
# Number of Unique SIF Clients/Month 1,680 2,520 -$15,339 -$15,094 $245
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$15,352 -$15,127 $225
# Cost/sqft Commercial Property: Baltimore $162 $242 -$15,233 -$15,200 $34
# Commercial Mortgage Loan Interest: Baltimore 5% 9% -$15,227 -$15,206 $21
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$15,222 -$15,211 $10
# Ppn. of SIF ODs resulting in ED visit 0.0063 0.0095 -$15,214 -$15,219 $5
-$20,000 -$15,000 -$10,000 -$5,000 $0
Parameter Low Value High Value Low Result High Result Spread
# Hospitalization Cost: Seattle $6,946 $10,419 -$14,148 -$17,621 $3,473
# Insite Annual Operating Cost $1,349,829 $2,024,743 -$17,390 -$14,378 $3,012
# Cost of Living Ratio vs. Vancouver: Seattle 0.94 1.42 -$17,390 -$14,378 $3,012
# Ppn. of ED visits resulting in hospitalization 38.4% 57.6% -$17,684 -$14,684 $3,001
# Cost of ED VIsit: Seattle $2,761 $4,141 -$14,446 -$17,322 $2,876
# First Year SSP Cost $1,226,623 $1,839,934 -$14,643 -$17,125 $2,482
# Total annual injections in the SIF 144,000 216,000 -$15,510 -$16,134 $624
# Percent of injections at SIF resulting in OD 0.760% 1.140% -$15,510 -$16,134 $624
# Ppn. of No SIF ODs resulting in ambulance 0.368 0.552 -$15,577 -$16,191 $615
# Cost of Ambulance Ride: Seattle $413 $620 -$15,582 -$16,186 $604
# Number of Unique SIF Clients/Month 1,680 2,520 -$16,029 -$15,739 $290
# Cost/sqft Commercial Property: Seattle $331 $497 -$15,919 -$15,850 $69
# Commercial Mortgage Loan Interest: Seattle 5% 9% -$15,905 -$15,862 $43
# Ppn. of SIF ODs resulting in ambulance 0.0063 0.0095 -$15,889 -$15,879 $11
# Ppn. of No SIF ODs resulting in ED visit 0.264 0.396 -$15,887 -$15,882 $5
-$20,000 -$15,000 -$10,000 -$5,000 $0
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Table E1. Scenario Analysis of SIF-Associated Reduction in HIV and HCV Infections 









Difference SIF+SSP SSP Only Difference 
HIV 
Cases 
47 49 -2 113 115 -2 56 60 -4 
HCV 
Cases 
278 293 -15 668 683 -15 334 357 -23 









Difference SIF+SSP SSP Only Difference 
HIV 
Cases 
36 39 -2 27 28 -1 41 43 -2 
HCV 
Cases 
215 229 -15 161 167 -6 243 258 -15 
 




Relative Difference in SSP-Only Clients who Access MAT Compared to SIF+SSP 







































0% 61 61 61 61 61 61 61 61 61 61 61 
10% 61 60 59 59 58 58 57 56 56 55 55 
20% 61 59 58 57 56 55 53 52 51 50 49 
30% 61 59 57 55 53 52 50 48 46 44 42 
40% 61 58 56 53 51 49 46 44 41 39 36 
50% 61 58 55 52 49 46 42 39 36 33 30 
60% 61 57 53 50 46 42 39 35 32 28 24 
70% 61 56 52 48 44 39 35 31 27 22 18 
80% 61 56 51 46 41 36 32 27 22 17 12 
90% 61 55 50 44 39 33 28 22 17 12 6 
100%* 61 55 49 42 36 30 24 18 12 6 0* 
*Base case  
